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Alzheimer‟s disease is a devastating neurodegenerative disorder and the leading cause of 
dementia.  The disease manifests via a multitude of pathologies including neuroinflammation, 
oxidative stress, metal ion dyshomeostasis, and naturally, cell death.  To date, no cure is 
available for Alzheimer‟s disease, and FDA approved treatments only offer symptomatic relief.  
To address the multifaceted nature of this disorder, the design of several diverse compounds, 
targeting a variety of pathological effects, was generated.  First, a series of ligands based on 
curcumin and diosgenin were synthesized following the bivalent design strategy. These 
  
 
 
multifunctional ligands were evaluated for their neuroprotective abilities in MC65 cells.  From 
this series, two compounds were discovered to have neuroprotective ability, antioxidative 
function, and anti-Aß oligomerization (AßO) properties.  A second set of molecules was also 
designed, wherein a hybrid compound strategy was utilized.  These ligands combined 
pharmacophore features from two natural products known to have neuroprotective properties, 
curcumin and melatonin.  A representative hybrid was to shown to protect MC65 cells from Aß-
induced toxicity and to have significant anti-oxidative activity.  Additionally, two analogs retain 
the same beneficial features as the representative hybrid, but are active in the low nanomolar 
range.   Mechanistic studies propose that the primary function conferring protection is through 
disruption of interactions between AßOs and partner proteins associated with the mitochondria.  
Furthermore, one potent hybrid was also shown to be able to pass the BBB.  Lastly, studies of 
glyburide, a common antidiabetic medication, have previously noted its off-target anti-
inflammatory effects.  These effects were found to be specific for the NLRP3 inflammasome, 
which has been implicated as an effector in AD development.  Therefore, syntheses of a series of 
glyburide analogs were performed.  From biological characterization, the initial analog 
synthesized was able to successfully inhibit the NLRP3 inflammasome and reduce IL-1ß 
expression without affecting blood glucose.  Further in vivo studies demonstrated an ability to 
prevent or ameliorate adverse inflammation-related outcomes in inflammatory models of 
peritonitis and acute myocardial infarction.  Two other analogs were also found to prevent IL-1ß 
release at concentrations similar to that of the initial analog.  Altogether, these investigations 
have yielded three novel series of compounds, all capable of modifying Alzheimer‟s disease 
pathology.  Results from biological assays warrant future investigations into the development, 
  
 
 
optimization, and characterization of these analogs as potential treatments for Alzheimer‟s 
disease.
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1 Introduction 
1.1 Alzheimer’s Disease  
1.1.1 General Pathology and Statistics 
 Alzheimer‟s disease (AD) is a progressive neurodegenerative disorder, affecting an 
estimated 5.2 million people in the United States and up to 30 million people worldwide in 
2014.
1
  The National Institute of Aging defines AD as “an irreversible, progressive brain disease 
that slowly destroys memory and thinking skills, and eventually even the ability to carry out the 
simplest tasks.”2  First described in 1901 by Dr. Alois Alzheimer, for whom the disease is 
named, he called it the “disease of forgetfulness.”3  This is a very accurate description, as AD is 
typified by an accelerated decline in memory and cognitive function.  As the disease progresses 
from mild to moderate to severe, patients diagnosed with AD will slowly lose their ability to 
reason properly and show increasingly poor judgment and deterioration of memory.  Eventually, 
there may even be a complete loss of coherent communication.  As motor skills decline, simple 
tasks become more difficult, and ultimately, daily personal assistance will become required.  
Minor personality changes will also become more pronounced, manifesting as irritation, 
agitation, anger, and paranoia.  Often times, these mood swings occur in the evenings and have 
therefore become known as “sundowning” syndrome.4  Over time, these effects will culminate 
and effectively incapacitate the patient, leaving them susceptible to secondary infections and 
illnesses, such as pneumonia, bladder infections, bedsores, cardiovascular disease, and 
complications associated with falls.  Although patients with AD could eventually experience 
enough brain degeneration to shut down vital bodily functions, mortality is almost always caused 
by one of these co-morbidities.
5, 6 
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Statistically, AD is the leading cause of dementia, accounting for more than 50% of all 
cases, and is the 6
th
 leading cause of death in the United States.  Furthermore, the number of 
deaths associated with AD rose 68% between 2000 and 2010, while other diseases with 
traditionally high mortality rates actually decreased, i.e. breast cancer, prostate cancer, heart 
disease, stroke, and HIV.
1
  The estimated economic burden of AD for the United States for 2014 
alone is $214 billion, and approximately 1 in 5 Medicare dollars is spent on caring for an 
individual with AD.  These costs are projected to rise to $1.2 trillion by 2050.
1
   
 
Figure 1.  Facts and figures describing AD 2013.  Adapted from the Alzheimer‟s Association.1 
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1.1.2 Molecular Etiology 
 Despite significant advances in the understanding of AD and its pathology, the exact 
etiology of the illness remains elusive.  However, AD does exhibit two pathological hallmarks 
that are specific to the disease and are used for postmortem confirmation.  These hallmarks are 
amyloid-ß (Aß) plaques and neurofibrillary tangles (NFT) comprised of hyperphosphorylated tau 
proteins.
7-9
   
 
Figure 2. Cartoon and silverstain depicting Aß plaques and NFTs.  Adapted from BrightFocus
®
 
Foundation.
10 
 
1.1.2.1 Amyloid-ß protein 
 Amyloid-ß are a collection of proteins around 40 amino acid residues that are the main 
constituents of the histological plaques found in the brains of patients with AD.  While lengths 
can vary from 36 to 43, Aß40 and Aß42 are by far the two most common forms of the protein and 
are of the highest concentrations in vivo.
11-13
  Notably, Aß42 has been suggested to be the more 
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toxic of the two species, due to its higher degree of hydrophobicity and increased tendency to 
oligomerize.
14
  Aß is formed by the sequential cleavage of the Amyloid precursor protein (APP), 
first by ß-secretase and then γ-secretase, as shown in Figure 1.  
 
Figure 3. Proteolytic formation of Aß from APP.  Abbreviations: C-terminal fragment ß (CTFß); 
C-terminal fragment γ (CTFγ); soluble amyloid precursor protein ß (sAPPß). Adapted from 
Shaw et al.
15 
 
Under normal physiological conditions, Aß peptides are properly metabolized and cleared by the 
body.  However, in AD, Aß peptides are not properly cleared and can form aggregates.  This 
increase in local Aß concentration is known as amyloidosis.
16
  Aggregation of Aß follows a 
defined structural hierarchy.  Monomers can readily oligomerize to form amyloid-ß oligomers 
(AßO) of varying molecular weights from low-weight soluble dimers and trimers to high-weight 
insoluble octamers and larger species.
17
  These oligomers can then stack on each other to form 
long „strings‟ of protofibrils.  Once these protofibrils are formed, they will then twist around 
each other generating fully formed fibrils.  Lastly, these insoluble fibrils will then self-associate 
and condense, leading to the creation of the fully matured plaques.  The high degree of plaque 
formation found in AD brains compared to normal brains gave rise to the “amyloid hypothesis,” 
which states that Aß is the primary causal protein related to AD pathology.
18, 19
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Despite the prevalence of large Aß plaques in AD brains, there is increasing evidence 
suggesting that it is in fact not the plaques that are responsible for the neurotoxic effects seen in 
AD, but rather the low-weight soluble oligomers that are causing disruption of synaptic plasticity 
and cognitive impairment.
17
  Studies from brain samples of patients with AD show a correlation 
between the amount AßOs and the severity of dementia.
20, 21
  Although varying sizes and 
assemblies of oligomers, along with their respective mechanisms, have been suggested in the 
literature, there is no clear consensus that represents the exact or major mechanism of toxicity in 
vivo.    Only the requirement of AßOs is consistent.
 
 Aß-derived diffusible ligands (ADDLs) are 
globular structures of synthetic Aß42 that represent the smallest pieces of protofibrils.  Deshpande 
et al. examined the effects of high-weight oligomers, ADDLs, and fibrillar Aß added to primary 
human cortical neurons.  While all three species exhibited toxicity, the oligomers caused 
extensive cell death within 24 hr, compared to 5 days for ADDLs and 10 days at four-fold higher 
concentrations for Aß fibrils.
22
  In agreement, Hoshi et al. demonstrated low-weight spherical 
oligomeric Aß structures were significantly more toxic in cultured neurons by MTT assay, in 
comparison to Aß fibrils.
23
  Several other studies have also indicated that non-fibrillar, 
oligomeric forms of Aß are quite possibly the primary toxic species.
24-30   
 
1.1.2.1.1 Lipid Rafts and Amyloid-ß Oligomers 
 Lipid rafts (LR) are densely packed microdomains of cellular membranes consisting of 
various types of sphingolipids, glycolipids, lipoproteins, and cholesterol.
31, 32
  They serve as 
specific sites for the association of certain proteins and carbohydrates with the cell membrane, 
and influence membrane fluidity and membrane protein trafficking and regulation.
31, 33
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Recently, significant evidence has implicated LRs as a key cellular site in the formation of AßOs 
and the production of reactive oxygen species (ROS).
31, 32, 34
  Cells enriched in LR domains 
exhibit an accelerated rate of oligomerization, and disruption of these domains affects Aß 
membrane binding and protects cells from Aß-mediated toxicity.
32, 35
  Additionally, APP 
processing enzymes, ß- and γ-secretase, have been identified within the LR, suggesting these 
domains act as critical platforms for the production and oligomerization of Aß.
36-38
  While a 
single component of the LR has not yet been recognized to be the sole mediator of the 
oligomerization process, formation of AßOs has been shown to be dependent on metal ions, pH, 
and ganglioside interactions.
35, 39-42
  Due to the importance of AßOs in the development and 
progression of AD, LRs represent an attractive target for therapeutic intervention.   
 
1.1.2.2 Tau proteins 
 Tau, also known as microtubule-associated protein tau (MAPT), is the major protein 
associated with microtubules.  Functionally, tau‟s chief role is the stabilization of microtubule 
assemblies, which serve as cellular „roads‟ in the trafficking of proteins to and from the nucleus 
and dendrites or axons.
43, 44
  Under normal physiological conditions, tau proteins are 
dephosphorylated and bind tightly to microtubules.  Once the tubule has served its purpose, it is 
disassembled, and the individual tubulin proteins will be available to form new tubules, as 
needed.  In order to disassociate tau, the protein is phosphorylated, which decreases its binding 
affinity.  Under pathological conditions, however, tau proteins may become 
hyperphosphorylated, preventing their association with microtubules, and actually promoting 
their self-assembly into paired helical filaments that form the base structures of NFTs.
44-46
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Several kinases have been implicated in this increase in phosphorylation, including glycogen 
synthase kinase 3ß (GSK-3ß), cyclin-dependent kinase-5 (cdk5), and Ca
2+
/calmodulin-dependent 
protein kinase II (CaMKII).  Additionally, protein phosphatase 2A (PP2A) has been shown to be 
the major phosphatase responsible for removal of tau phosphate groups.
7, 47, 48
  Because of the 
strong correlation between the amount of NFTs present and the degree of cognitive decline, these 
enzymes have been explored as potential targets for AD-modifying therapeutics.  However, there 
is strong evidence proposing that increases in Aß preclude the formation of NFTs in disease 
progression.
49-51
  Additionally, the presence of NFTs has been seen in other neurodegenerative 
disorders, as well, collectively known as tauopathies and including frontotemporal dementia with 
Parkinsonism linked to chromosome 17 tau (FTDP-17 tau), Pick‟s disease, supranuclear palsy, 
chronic traumatic encephalopathy, among others.
52-55
  Together, these suggest Aß 
oligomerization and fibrillization occur upstream from NFT formation, and are also the main 
toxic species responsible for AD development. 
 
1.1.3 Oxidative Stress in AD 
 Oxidative imbalance occurs when the ability of endogenous antioxidants fails to 
adequately quench the production of oxidant species or ROS.  Consequently, this leads to 
cellular oxidative stress, which can go on to cause molecular oxidative damage, altered cellular 
function, and even cell death.
56, 57
  Cellular metabolic dysfunction is one contributor to oxidative 
stress and has been well documented in AD.  For example, there is an increase in oxidative 
utilization for energy in comparison to glucose utilization in AD patients.
58
  Furthermore, 
reduced metabolic function in the brain has been shown to precede any brain atrophy or 
  
8 
 
cognitive impairments.
59
  One critical organelle responsible for the metabolism and ROS 
production is mitochondria.  Improper functioning of mitochondria can lead to reduced energy 
production and increased oxidative stress, which are also characteristic in AD.
60, 61
  Indeed, the 
most consistent defects in AD mitochondria are deficiencies with pyruvate dehydrogenase 
complex, α-keto-glutarate dehydrogenase complex, and cytochrome oxidase (COX), all of which 
are heavily involved in the metabolic reduction of oxygenated species.
62-64
  Superoxide 
dismutase (SOD), an enzyme responsible for the conversion of the oxidative superoxide ion into 
molecular oxygen or hydrogen peroxide, also displays elevated expression levels compared to 
controls in AD brains and red blood cells, suggesting an innate compensatory mechanism against 
the rise of free radical damage from the disease pathology.
65-67
  Furthermore, Aß and APP have 
also been shown to directly interact with mitochondria, potentially causing increases in ROS 
associated with AD.
68-70
  Cytotoxic studies involving the addition of Aß to neuronal cell cultures 
demonstrated a protective effect when H2O2-degrading enzyme catalase was added to the media, 
illustrating a strong connection between Aß, ROS, and cell death.
71
    
 
 Additionally, redox-active metals have also been implicated in AD.  Biometals, in 
particular Cu
2+
, Fe
3+
, and Zn
2+
, are all capable of catalyzing the formation of the hydroxyl 
radical, and therefore, dyshomeostasis of these metals can lead to neuronal damage characterized 
by oxidative stress.
72, 73
  Moreover, the concentrations of these metals have been shown to be 
increased in Aß senile plaques in comparison to surrounding neuropils.
74
  In fact, there is 
evidence demonstrating the ability of Aß to bind these biometals, and in the case of Fe and Cu, 
convert them to their more reactive reduced states (Fe
2+
 and Cu
+
).  These reduced forms can then 
readily trap molecular oxygen and generate hydroxyl and peroxide free radicals via Fenton-like 
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redox chemistry.
75-77
  These findings implicate a strong role for metal ion dyshomeostasis in 
oxidative stress that contributes to AD pathology.
 
 
1.1.4 Neuroinflammation in AD 
In addition to oxidative stress, neuroinflammation has been shown to play an important 
role in the pathology of AD.  Under physiological conditions, neuroinflammation is a normal 
part of the innate immune system, protecting the CNS from invading organisms or harmful 
proteins released from necrotic or apoptotic cells.
78, 79
  Because of their „defensive‟ nature, these 
types of localized, acute inflammations are generally beneficial and are quickly shut down once 
the stimuli have been removed.  Any unintended damage is often limited and reversible.
78, 80
  
Under pathological conditions, however, these inflammatory reactions are not properly 
regulated, and excessive activation of microglia and release of pro-inflammatory signaling 
molecules can lead to permanent neuronal damage.  This kind of pathological inflammation is 
typically considered a low-grade chronic inflammation, leading to a slow, progressive increase in 
cytokine and chemokine concentration, and consequently cellular dysfunction.  Increased levels 
of inflammatory markers have been observed in AD brain tissue, including high levels of 
cytokines and chemokines, and evidence of increased microglial activation and astrocyte 
reactivity, both of which can also contribute to oxidative stress.
81, 82
  Interestingly, 
epidemiological studies have shown a decreased risk of developing AD concomitant with 
NSAID consumption.
83-85
  The exact etiology of the chronic inflammation observed in AD has 
not yet been fully elucidated.  Significant evidence, however, has demonstrated the inflammation 
triggering ability of the Aß peptide, either by direct activation of microglia and astrocytes 
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(mentioned in a later section) or by indirectly inducing neurodegeneration, which then signals the 
start of an inflammatory cascade.
9, 86
   
 
1.1.5 AD Treatments 
 Despite our ever-increasing understanding, there is as of yet no „cure‟ for AD.  Currently, 
the only FDA approved treatments for AD fall into two categories: acetylcholinesterase 
inhibitors and N-methyl D-asparate receptor antagonists.   
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Figure 4. Current FDA approved treatments for Alzheimer‟s disease. 
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1.1.5.1 Acetylcholinesterase inhibitors 
Analysis of neurotransmitters in the cerebral cortex shows a sharp reduction in a vast 
majority of species that correlates with neuronal loss.  One of the most consistent findings in AD 
brain samples was a decline in cholinergic transmission that was highly correlated to the degree 
of severity of AD.
87
  Therefore, it was hypothesized that a lack of acetylcholine was responsible 
for the manifested dementia seen in AD.  This gave rise to the “cholinergic hypothesis,” which 
suggests that AD dementia is caused by degeneration of cholinergic neurons, and consequently 
counteracting this deficiency by increasing concentrations of acetylcholine (ACh) would be 
beneficial in disease treatment.
88
  Indeed, CNS cholinergic antagonists, such as scopolamine, can 
induce a befuddled state that closely resembles AD dementia.
89
  Furthermore, it was proposed 
that the reduction of ACh may be related in part to degeneration of cholinergic neurons in the 
hippocampus and cerebral cortex, areas where a high degree neuronal loss is found, and the 
nucleus basalis of Meynert, which projects into several areas of the cortex.
90, 91
  According to the 
“amyloid hypothesis,” neurodegeneration leading to this cholinergic deficiency is caused by Aß. 
By logical extension, a viable approach to treating AD by increasing levels of ACh in the 
synapse would be to inhibit the enzyme responsible for the breakdown and metabolism of ACh, 
namely acetycholinesterase (AChE).  This is the primary reason why the only drugs available on 
the market for the treatment of mild to moderate AD are AChE inhibitors (AChEI).  Presently, 
there are four inhibitors approved by the FDA for the treatment of AD:  tacrine, donepezil, 
rivastigmine, and galantamine (Figure 4).  Tacrine represents the first FDA approved AChEI and 
is a potent centrally acting inhibitor.
92
  However, due to the severe side effects of use, including 
cramping, anorexia, nausea, vomiting, diarrhea, and liver toxicity, and the availability of later 
generation inhibitors, tacrine has been discontinued in the US.
93
  Donepezil is a selective, long-
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acting AChEI with little effect in peripheral tissues and produces modest improvements in 
cognitive scores in AD patients.  Rivastigmine and galantamine, also second generation AChEIs, 
yield a similar degree of enhancement as compared with donepezil.
93-95
  Adverse effects 
associated with donepezil, rivastigmine, and galantamine administration are comparable to those 
seen with tacrine, but are generally less frequent and severe.  Furthermore, use of these 
compounds is not limited by hepatotoxicity.  Due to the longer half-life of donepezil (once-daily 
dosing), it is generally more preferred over rivastigmine or galantamine (twice-daily dosing) and 
is also the only AChEI approved for moderate AD.
94, 95 
 
1.1.5.2 N-methyl D-aspartate receptor antagonists 
Glutamate is the most prevalent neurotransmitter found in the body and the primary 
activator of N-methyl-D-aspartate (NMDA) receptors.
96-98
  NMDA receptors (NMDAR) are 
ionotropic receptors, allowing the flow of Na
+
, Ca
2+
, and K
+
 into and out of the cell. While 
moderate activation of NMDARs is critical for synaptic plasticity, learning, and memory 
function, excessive activation sharply increases intracellular Ca
2+
 concentrations, leading to 
excitotoxicity.
97, 99, 100
  Dysfunction of glutaminergic neurotransmission has been associated with 
AD etiology, and therefore, targeting this system offers an alternative method to treatment, other 
than AChEIs.
100, 101
  Memantine (Figure 4) is the first and only FDA approved NMDAR 
antagonist at present, and is also the only approved treatment for late-stage, severe AD.
102, 103
  It 
functions by blocking NMDA channels in an activation-dependent manner, thereby limiting 
excessive, pathological activation without affecting normal physiological activation.
103, 104
  
Statistics regarding the efficacy of mematine treatment, however, are somewhat controversial.  
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One randomized clinical trial including 252 patients found that memantine significantly reduced 
mental deterioration.
104
  However, another double blind, placebo-controlled trial involving 350 
patients did not confirm this result.  No statistically significant benefit was found after 24 weeks, 
the study end point, on any primary or secondary outcomes measured.
105
  There is evidence 
although to suggest that a combination therapy with donepezil may provide greater benefits on 
cognition and behavior, as demonstrated in a recent 24 week trial including 322 patients.
106 
The main problem with both these classes of drugs is that they only offer symptomatic 
relief and are not treating the underlying pathology.  Supporting synaptic transmission in a 
steadily degenerating neuronal network may provide temporary reprieve, but does nothing to 
prevent the progressive deterioration.  Eventually, patients will fail to respond to these drug 
families as the disease advances.
93, 107
  Therefore, there is a strong impetus to find novel, 
effective therapies that target the cause of AD. 
 
1.1.5.3 Aß reduction approaches 
One other strategy for the treatment of AD has been to find drugs that would lower levels 
of Aβ in the brain.  To this end, ß-secretase inhibition, γ-secretase modulation, and Aß-
immunization approaches have been researched.
100
   Active immunization was initially explored 
against Aß, but has suffered significant setbacks.  One of the first clinical trials for an Aß-
antibody (AN1792) was conducted by Elan Pharmaceuticals, later Wyeth.  Initial studies showed 
success in reduction of Aß plaques in animal models.
108
  Phase II trials, however, were 
suspended due to reports of meningoencephalitis, an inflammatory reaction in the brain, from 
which 5 patients receiving the drug died.
109
  Following these results, passive immunization using 
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monoclonal antibodies was attempted.  So far, two monoclonal antibodies, Bapineuzumab 
(Pfizer and Johnson & Johnson) and Solanezumab (Eli Lilly), recently failed Phase III trials due 
to lack of improvement over placebo.
110, 111
  Despite these negative results, there are still several 
monoclonal antibodies undergoing clinical trials, notably Gantenerumab (Roche, Phase III), 
Aducanumab (Biogen Idec, Phase Ib), and BAN2401 (Eisai and Biogen Idec, Phase II).
112-115
 
Inhibition of beta secretase, also referred to as BACE, is a major therapeutic strategy, 
garnering a significant amount of attention and money.  One reason for this intense interest is 
that BACE knockout mice are healthy with no detectable pathological consequences.
116
  The 
major challenges facing BACE inhibitors are their molecular weight, which greatly affects their 
ability to cross the blood brain barrier.
117
  Even with this hurdle, several BACE inhibitors have 
made it to clinical trials.  Unfortunately, two of the first inhibitors to reach trials have failed.  
LY2811376 (Eli Lilly) was halted after Phase I trials due to high-dose toxicity.
118
  LY2886721 
(Eli Lilly) was stopped during Phase II trials over potential hepatotoxicity from abnormal liver 
tests.
119
  Recently, another inhibitor from Roche (RG7129) was terminated after Phase I trials.  
Notably, Merck has developed an inhibitor that has reached Phase III trials (MK-8931) and is 
still ongoing, set to end in 2018.
120
  Despite these setbacks, BACE still represents a highly 
pursued target by pharmaceutical companies.  Inhibition of gamma secretase,
121
 on the other 
hand, has lost a large degree support as viable strategy in Aß reduction.  Notch is a 
transmembrane protein essential for cell differentiation, specifically in the intestine and immune 
system, and like Aß, is cleaved by γ-secretase.122-126  Administration of γ-secretase inhibitors 
elicited severe side effects in clinical trials, including gastrointestinal toxicity and eosinophilia, 
presumably due to blockage on Notch processing.
123-126
  Both Semagacestat (Eli Lilly) and 
Avagacestat (BMS) failed clinical trials, Phase III and II, respectively, after performing worse 
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than placebo.
127, 128
  It has been suggested that γ-secretase modulators, preventing Aß cleavage 
with no effects on Notch, may still be a feasible strategy,
121
 but focus has mostly δed to ß-
secretase inhibitors. 
 
1.2 NLRP3 Inflammasome 
 As previously mentioned, neuroinflammation plays a significant impact in AD pathology. 
Interestingly, clinical trials of NSAIDs alone as a treatment for AD have so far been largely 
unsuccessful.
129-132
  This suggests that perhaps inflammation is primarily mediated via different 
pathways than those that NSAID act upon and that therapeutics targeting novel inflammatory 
proteins may be needed.  One inflammatory complex recently linked to AD pathology is the 
NLRP3 (NALP3/Cyropyrin) inflammasome (NLRP3I).  
 
 
1.2.1 Molecular Biology 
The inflammasome, so named as a combination between “inflammation” and the Greek 
suffix “soma”, meaning body, is a multimeric protein complex that facilitates the production of 
pro-inflammatory signaling factors.
133
  Under normal conditions, it is an essential part of the 
immune response, responsible for protecting tissue from cellular damage, metabolic stress, and 
infection.  However, excessive activation of the inflammasome can lead to acute or chronic 
inflammation, resulting in prolonged release of cytokines and chemokines.  Formation is 
triggered by danger-associated molecular patterns (DAMPs), typically cellular debris, or 
pathogen-associated molecular patterns (PAMPs), usually from invading organisms.
134, 135
  After 
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the complex is formed, it activates caspase-1, which rapidly produces interleukin-1ß (IL-1ß), a 
cytokine inducing the activation of several inflammatory cascades, from the inactive pro-form.  
This, in turn, leads to a form of cell death known as pyroptosis.
136 
 
1.2.1.1 The inflammasome complex 
 The inflammasome consists of three individual proteins: the sensing protein, the 
scaffolding protein, and caspase-1.  Pattern recognition receptors (PRR) are proteins or parts of 
proteins that recognize DAMPs and PAMPs.  In the humans, there are four families of PRRs: 
toll-like receptors (TLR), C-type lectin receptors (CLR), RIG-I-like receptors (RLR), and 
nucleotide-binding domain leucine-rich repeats (NLR).  Of these, TLRs and CLRs are cell-
membrane associated and respond to a variety of DAMPs and PAMPs, including peptides, 
glycopeptides, lipopeptides, and nucleic acids.  RLRs and NLRs are cytosolic sensors.  RLRs 
primarily respond to viral RNA and elicit an anti-viral response.  NLRs, on the other hand, 
respond to a multitude of stimuli, including pathogens and intracellular debris.
137, 138
  Notably, 
TLRs and NLRs can cooperate with each other to produce IL-1ß, facilitating generalized or 
specialized immune responses to various factors.
137
  In the human genome, 22 NLR genes have 
been identified, although not all have been verified to form an inflammasome.  Of all observed 
inflammasomes, three include sensing proteins from the NLR family: NLRP1, NLRP3, and 
NLRC4.  The AIM2 (absent in melanoma 2) inflammasome is the only non-NLR complex 
known thus far.
139
  Each sensor recognizes different stimuli.  The NLRP1 protein has been 
shown to be active in response to anthrax lethal toxin,
140
 whereas NLRC4 is specific for Gram-
negative bacteria with a type III or IV secretion system and flagellin.
141, 142
  It is proposed that 
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the AIM2 inflammasome is critical for host defense against bacterial and viral pathogens, as 
AIM2 recognizes dsDNA released in the cytosol.
143, 144
  As for the NLRP3 protein, it is the most 
studied of all inflammasomes and has been associated with a numerous range of diseases and 
pathogens, including crystalline material, pore-forming toxins, bacteria, viruses, and localized 
ROS.
145, 146
    
 Structurally, the NLRP3 protein contains three distinct regions.  The leucine rich-repeat 
domain (LRR) is responsible for the actual sensing of DAMPs and PAMPs.  In the inactive state, 
the LRR region self-associates with the nucleotide binding and oligomerization domain (NOD), 
the second region of the protein, and locks the molecule into a „closed‟ formation, preventing 
complex formation.  Once the LRR region recognizes its partnering molecular patterns, however, 
it induces a conformational change in the NOD that consequently opens up the pyrin domain 
(PYD).  Once the PYD is open, it is free to associate with its partner protein, apoptosis-
associated speck-like protein containing a caspase-recruitment domain (CARD) (ASC).
147
  The 
ASC protein primarily serves as an adapter protein, linking the NLR protein to pro-caspase-1.  It 
consists of two domains, the PYD, which interacts and binds with the PYD of NLRP3, and a 
CARD, that will bind to caspase-1.  Activation of ASC is characterized by aggregation of ASC 
to itself or NLRs upon their activation, forming the characteristic „specks‟ seen in 
immunohistological stains.
148, 149
  Some evidence has suggested that overactive ASC 
oligomerization can occur independently of NLR initiation in some instances, and still lead to 
caspase-1 binding and activation.
150
  Caspase-1 is the third component of the inflammasome.  
Once ASC binds to NLR, its CARD can now partner to pro-caspase-1‟s CARD, initiating the 
conversion of caspase from its pro form into the fully matured form.
151, 152
  Activated caspase-1 
proteolytically cleaves pro-IL-1ß and pro-IL-18 into their respective mature forms.  Of these, IL-
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1ß is a major initiator of downstream pro-inflammatory cascades.  Together, this complex 
represents the complete inflammasome (Figure 5). 
 
1.2.1.2 NLRP3 inflammasome activation pathway 
 Activation of the NLRP3 inflammasome requires two steps.  As previously mentioned, 
NLR proteins work in tandem with TLR proteins to tailor the inflammatory response based on 
the stimulus.
137
  The first step is the priming step, and typically involves activation of TLR 
receptors.  This will generate an increase in the transcription of pro-IL-1ß and NLRP3 via NF-κB 
stimulation, increasing their availability in the cytosol.  The second step is the triggering step.  
Here, a specific DAMP or PAMP will interact with the NLRP3, initiating the inflammasome 
formation pathway and ultimately, the cleavage of pro-IL-1ß (Figure 5).
138
  Notably, TLR 
activation alone has been known to lead to the expression of IL-1ß.  However, there is also an 
increase in local ATP concentrations, which can activate NLRP3.  Excessive ATP interacts with 
P2X7 receptors causing a dramatic increase in K
+
 efflux, which is analogous to the action of 
pore-forming toxins.  Recent evidence suggests that this may be acting as a previously unknown 
secondary potentiator in the inflammatory process, leading to NLRP3 complex formation.
153, 154
  
For these reasons, lipopolysaccharide (LPS) and ATP are typically used to prime and trigger 
NLRP3 inflammasome formation for in vitro analysis.
155-157 
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Figure 5. Activation of the NLRP3 inflammasome.  A. Cartoon representing the NLRP3 
inflammasome and the respective domains for each protein.  B. Depiction of the NLRP3 
activation pathway.  Activation of TLRs induces transcription of pro-IL-1ß and NLRP3.  
DAMPs and PAMPs then trigger the formation of the NLRP3 inflammasome, leading to 
processing of IL-1ß, which potentiates the inflammatory response.  Adapted from Bauernfeind et 
al.
138
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1.2.2 Applications 
 The NLRP3I specifically has been linked to the development and persistence of a number 
of pathologies, including AD, ischemia-reperfusion injury, obesity, and type II diabetes.
139, 158-161
  
There is strong evidence suggesting that activation of the NLRP3I in microglia is due to the 
excitatory interaction between Aß and NLRP3.  Akama and Van Eldik have shown that inducible 
nitric-oxide synthase (iNOS) expression, a pro-inflammatory marker, is highly upregulated upon 
stimulation of Aß in astrocytic cells.  This increase was determined to be preceded by and 
dependent on IL-1ß and TNF-α induction, suggesting a potential role for inflammasome 
formation.
162
  In a related study, Halle et al. revealed that IL-1ß release and caspase-1 activity 
are greatly increased in primary microglial cells upon addition of Aß in a dose-dependent 
fashion.  Furthermore, knock-out of ASC or NLRP3 both completely abolished this IL-1ß 
release, indicating that the NLRP3I is a major contributing factor to Aß-induced 
neuroinflammation in vitro.
163
  This was confirmed by follow-up investigations by Heneka et al. 
in AD mouse models.  NLRP3 or caspase-1 knock-outs in APP/PS1 transgenic mice resulted in 
significant improvements in cognitive function and reductions in IL-1ß and caspase-1 
concentrations.  Decreased deposition of Aß was also observed.  This clearly demonstrates a 
correlation between NLRP3I activation and AD pathology in vivo.
164 
 Ischemia and reperfusion injuries (IRI) occur when tissue or an organ goes through a 
period of ischemia, causing local deleterious effects due to hypoxia and hypoglycemia, and is 
then reperfused with blood flow, leading to more damage to the ischemic tissue, as well as 
surrounding systems, by introduction of neutrophils and the related inflammatory response to the 
necrotic tissue.
139
  Myocardial IRI due to myocardial infarction induces profound inflammation 
in cardiomyocytes that has been associated with high mortality rates.
165, 166
  This response has 
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been linked to the NLRP3 inflammasome.  Kawaguchi et al. has demonstrated increased levels 
of IL-1ß in heart tissue after IRI, leading to a rise in inflammatory cell infiltration and cytokine 
expression.  Moreover, in ASC or caspase-1 deficient mice, IL-1ß concentration, infarct size, and 
myocardial fibrotic tissue were all reduced following IRI.
167
  Other studies have shown caspase-1 
inhibition and IL-1 receptor antagonism to be protective against IRI induced apoptosis and 
adverse cardiac remodeling, as well.
168-171
   
 
1.3 Hypotheses and Aims 
 In order to address the various effects stemming from AD and treat the underlying causes 
of the disease, compounds exhibiting multifunctionality may yield more promising results than 
current treatment strategies.  To this end, two series of novel compounds were designed as 
multifunctional ligands, possessing anti-oxidative, anti-Aß oligomerization, and neuroprotective 
properties.  In chapter 2, the feasibility of using a bivalent design strategy will be explored, 
following positive results from previous reports.
172-174
  The hypothesis is that the use of 
compounds with a connection of a steroid analog to a multifunctional compound via a flexible 
linker will act as multifunctional, potent neuroprotectants.  In chapter 3, a second series 
employing the “hybrid molecule” approach will be examined, given its success in other areas.175  
The hypothesis here is that the blending of two compounds with known protective functions into 
a single novel entity will confer enhanced protective abilities.  Natural products curcumin 1, 
melatonin 2, and caprospinol 5, a cholesterol 3 analog and diosgenin 4 derivative, were all 
incorporated in these design approaches of chapters 2 and 3 (Figure 6).  The aim for these 
compounds was to find leads that impart significant protection in neuronal cells and to examine 
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their respective mechanisms of action.  This will also lend credence to the application of 
multifunctional compounds and help guide future synthetic designs.  In chapter 4, the hypothesis 
is that the inhibition of the NLRP3 inflammasome will provide beneficial anti-inflammatory 
effects that will lead to amelioration of pathological conditions.  To ascertain these goals, a third 
series of molecules were designed and synthesized as NLRP3 inhibitors, based on the structure 
of glyburide, a common anti-diabetic medication.  The aim for these analogs was to explore the 
feasibility of using this scaffold as an NLRP3 inhibitor and to discover any potential leads for 
further development in treating AD.  Furthermore, any positive effects found would bolster the 
inhibition of the NLRP3 inflammasome as a potential target for therapeutic intervention.  
Altogether, these compounds will further validate their respective design strategies and aid in the 
discovery of novel, drug therapys. 
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Figure 6. Natural products from which bivalent and hybrid compounds were designed. 
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2 Multifunctional Bivalent Compounds against Alzheimer’s Disease 
2.1 Project Design 
 Curcumin 1, a yellow spice and pigment isolated from the rhizome of Curcuma longa, 
has been traditionally and widely used as a food coloring.
176
  Recently, 1 has attracted extensive 
attention in biomedical research as multiple benefits of 1 have been discovered, including 
antioxidative, anti-inflammatory, biometal chelating, anti-proliferative, and anti-Aß activities, 
among others.
177, 178
  Because neuroinflammation, oxidative stress, dyshomeostasis of biometals, 
and amyloidosis have all been implicated in the pathology of AD, 1 has been tested in various 
AD models.  Both in vitro and in vivo studies have demonstrated the ability of 1 to prevent Aß-
induced toxicity and reduce levels of Aß in the brain, as well as levels of inflammatory cytokines 
and reactive oxygen species, demonstrating the potential of 1 as a candidate for treatment of AD 
in humans.
177
  However, due to its poor solubility, bioavailability, and gastrointestinal side 
effects, further development of 1 as an effective agent for AD has been somewhat limited.   
 Caprospinol 5, a derivative based on the diosgenin 4 steroidal structure, is a natural 
product found in the gynura japonica plant.
179
  It was discovered to have beneficial effects in AD 
models, when computational screening of potential 22R-hydroxycholesterol analogs found it had 
a closely related structure.
180
  Biological assays have revealed 22R-hydroxycholesterol, an 
intermediate in the formation of pregnolone from cholesterol, was present at lower levels in AD 
brains than age matched controls.
181
  Furthermore, once isolated, 22R-hydroxycholesterol was 
shown to be protective in Aß-induced toxicity of rat pheochromacytoma cells (PC12) and 
differentiated human NT2N neuron cells.
182
  Once identified, caprospinol was shown to retain 
these protective functions and, in contrast to 22R-hydroxycholesterol, was devoid of any 
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steroidogenic activity.
180
  The proposed mechanism for these effects is Aß monomer scavenging, 
reduction in plaque formations, and preserving proper respiratory chain function in 
mitochondria.
179
  Together, caprospinol represents an intriguing steroidal compound against AD 
pathology. 
The bivalent strategy approach is defined by its use of two distinct, active molecular 
species linked together via a spacer in order to hit dual molecular targets within close proximity 
with each other.  The use of bivalent strategies in exploration of protein-protein interactions has 
been particularly successful in opioid research.
183-185
  Moreover, this approach has been utilized 
in neurodegenerative research by development of novel acetylcholinesterase.
186  
Furthermore, 
this concept has been successfully exploited in the creation of two previous series of bivalent, 
multifunctional oligomerization inhibitors for potential use in AD.
172-174
  In following with these 
previous studies, bivalent ligands were designed utilizing curcumin as a multifunctional, 
oligomerization inhibitor connected to a steroid, acting as a lipid raft (LR) anchor.  The idea is to 
localize the beneficial effects of the multifunctional inhibitor to the lipid raft area, where Aß 
oligomerization and production of ROS is known to occur, illustrated in Figure 7.  Previous 
studies incorporated cholesterol and cholesterylamine as more traditional LR anchors, and 
polyamide linking structures.  In this series, the diosgenin 4 was chosen as a new anchor due to 
the positive effects seen in caprospinol, a derivative of diosgenin.  Additionally, the spacer was 
changed to a triethylene glycol structure to impart more flexibility in the linker.  The length of 
spacer was also increased up to 28 atoms to examine any trends in increasing length.  Curcumin 
was retained as the multifunctional inhibitor.   
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Figure 7. Cartoon representation of the proposed bivalent ligand strategy. 
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Figure 8. Designed bivalent multifunctional ligands. 
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2.2 Chemical Design and Syntheses 
 As mentioned, one of the primary goals with this series of molecules was to determine 
the possible effects of changing linker composition, linker length, and steroid anchor.  As 
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mentioned previously, diosgenin 4 was selected as the steroid portion of the ligand, hopefully 
engendering some of the positive characteristics seen in the ester derivative caprospinol 5 into 
the full bivalent structure.  For the linker, a triethylene glycol-based linker 25 with extension by 
an amide-connected alkyl chain (26-30) was chosen.  The ethylene subunit would be much more 
flexible than previously synthesized linkers, and the inclusion of multiple ether-connected H-
bond heteroatoms could potentially influence H2O solubility.
 
 Furthermore, linker lengths only 
up to 23 atoms long were explored earlier.  In this series, linkers from 22 atoms up to 28 atoms 
(37-40), adding 2 atoms each time, were designed.  Additionally, 17 and 21 atom spans (50 and 
36, respectively) were also synthesized, as these represent the optimal lengths previously 
reported.
172, 174
  Synthesis was achieved by first constructing the linker portion of the ligand, 
followed by coupling of the diosgenin structure 4, and lastly, clicking on the alkyne-curcumin 
analogs 46 and 47.  Previous reports revealed connection of the linker to the middle position, 
deemed the „M‟ position, of the alkyne on curcumin exhibited superior protection compared to 
the similar linkers connected to the phenolic oxygen position, or „P‟ position.172, 174  Attachment 
at both of these positions was also explored with this series.  After preliminary assays were 
conducted, control ligands were then made incorporating the most potent linker composition 
connected only to diosgenin or curcumin (20 and 21, respectively), to insure activity was 
dependent on the fully formed ligand structure and not a potential substructure or metabolite.   
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Scheme 1. Synthetic route for bivalent multifunctional ligands, part 1. 
 
2.2.1 Azide substitution onto triethylene glycol  
 Linkers were synthesized through a multistep process outlined in Scheme 1.  Triethylene 
glycol 22 was functionalized by substituting one of the hydroxyl groups for an azido group.  This 
was accomplished by first reacting 22 with mesyl chloride to form the methanesulfonate 
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intermediate at one end of the glycol chain.  In order to insure only one hydroxyl group was 
substituted, this step was conducted at low temperatures (0 °C) and in a very dilute solution.  The 
mesyl chloride was also diluted prior to addition and was very slowly dropped into the reaction 
mixture, over 2 to 4 h.  The methanesulfonate formed acts as a good leaving group and leaves the 
adjacent carbon susceptible to nucleophilic substitution, in this case by NaN3, yielding 
compound 23.  Despite directing the reaction toward single substitution, inevitably some starting 
material will be doubly substituted, forming the double azido side product 48.  Luckily, this side 
product was actually later utilized in the synthesis of the 17 atom spacers.   
 
2.2.2 Addition of the protected acetate group 
 Now that the azide moiety was successfully installed, the other end of the ethylene chain 
needed to be functionalized.  Ultimately, a carboxylic acid is necessary to form an ester coupling 
with the diosgenin steroid 4, but must remain protected while elongating the azido side of the 
linker.  To accomplish this, tert-butyl bromoacetate was selected.  NaH was added to 23 to 
remove the hydroxyl hydrogen (Scheme 1), forming a negatively-charged oxide ion.  Next, tert-
butyl bromoacetate was added in one portion.  The bromo substituted α-carbon undergoes 
nucleophilic attack by the preformed oxide ion, resulting in substitution with the oxygen atom, 
creating the carbon-oxygen bond seen in compound 24.   
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2.2.3 Staudinger reaction 
 First reported in 1919 by Hermann Staudinger, the Staudinger reaction involves the 
reaction of azides with triphenylphosphine to form phosphazides and release N2 gas.
187
  These 
can then be hydrolyzed with H2O giving the related amine and triphenylphosphine oxide.  Here, 
this reaction is utilized to reduce the relatively inert azide group to a reactive amine group.  
Although now typically associated with click reactions, it is interesting to note that in this case, 
the azide group is actually functioning as a precursor for a primary amine.  To achieve this, 
compound 24 was reacted with triphenylphosphine (TPP) in THF, to form the phosphazide.  
After 4 h, H2O was added to quench the reaction and release the primary amine 25 in good yield.  
Compound 25 represents half of the full linker and can now be coupled to azido-substituted fatty 
acids of varying lengths (26-30), described below. 
 
2.2.4 Azide substitution onto long chain carboxylic acids 
 Naturally, different spans of atoms must be incorporated into the linker composition to 
obtain spacers of varying size.  In order to attain the desired lengths, terminally substituted long 
chain carboxylic acids, more commonly known as fatty acids, were synthesized and combined 
with the previously created triethylene structure 25.  Because this end of the linker will be 
“clicking” with the alkyne-curcumin analogs 46 and 47, an azide group needed to be installed.  
To accomplish this, various bromo-fatty acids were reacted with NaN3 in DMF and H2O.  The 
resulting nucleophilic substitution afforded the newly substituted azido-fatty acids (26-30) in 
good yield.  It is important to note that the Rf values for these compounds on TLC are near 
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identical, but the successful addition of the azide can be easily confirmed by IR, specifically by a 
characteristic absorbance band at 2100 cm
-1
. 
 
2.2.5 Amide coupling and deprotection  
Azido-fatty acids 26-30 and compound 25 were coupled via an amide bond using the 
commonly employed EDC and HOBt coupling mechanism in DCM.  EDC is first reacted with 
the carboxylic acid to give the active O-acylisourea intermediate that is subsequently displaced 
by HOBt to form the activated ester.  Upon addition of the amine species 25, HOBt is removed 
by nucleophilic attack, resulting in products 31-35.  Now that the linker is completely formed, 
the tert-butyl protected ester group can be unmasked in preparation for coupling with diosgenin 
4.  Trifluoroacetic acid (TFA) was used to hydrolyze the tert-butyl group yielding the fully 
prepared linkers 36-40.  
 
2.2.6 Esterification with diosgenin 
 Linkers 36-40 were coupled with the diosgenin steroid 4 via ester-bond formation.  
Similar to the amide coupling, Steglich esterification was employed.
188
  DCC, another 
carbodiimide species, was first reacted with the acid to form the active O-acyliosurea 
intermediate, as before.  In this reaction, however, DMAP is used as a catalyst.  Because alcohols 
are much less nucleophilic than amines, DMAP will prevent any potential intramolecular 
rearrangements, specifically formation of the unwanted N-acylisourea species that might occur 
due to the slower addition of an alcohol.  Furthermore, the DMAP-linked intermediate can also 
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readily react with alcohols, efficiently transferring the acyl group forming the ester.  Once 
esterification is complete, the DMAP is regenerated and ready to react again.  The DCC derived 
urea side product is often difficult to remove during purificiation; however, it was easily filtered 
off after addition of cold EtOAc, in which compounds 41-45 were completely soluble. 
 
2.2.7 Azide-Alkyne ‘click’ reaction 
 The last part of the ligand to be connected was the multifunctional curcumin analog.  As 
noted, attachment at both the „M‟ and „P‟ positions, represented by alkyne-curcumin analogs 46 
and 47, respectively, was explored.  Significant quantities of compounds 46 and 47 had been 
synthesized as previously described
174
 and were still available for use.  As such, their 
construction was not repeated.  The classic copper-catalyzed „click‟ reaction, also known as the 
azide-alkyne Huisgen cycloaddition, was utilized for the last step in ligand assembly.  Due to the 
relatively inert azide and alkyne groups, „click‟ reactions are so named for their high degree of 
specificity, lack of side products, and robust nature.  Additionally, if other multifunctional 
effectors wished to be investigated, they need only be clicked to the alkyne, providing a high 
degree of interchangeability, and by extension, potential synthetic libraries.  As such, compounds 
41-45 were added to a THF/H2O solution along with 46 or 47 and stirred.  CuSO4 and sodium 
ascorbate were then added to catalyze the formation of the 1,2,3-triazole ring.  Ascorbate 
functions as a reducing agent converting Cu
2+ 
into the active Cu
+
 form, necessary for catalysis.  
Final products 8-17 were all isolated and collected in high yield.  Of particular note, after 
optimization of this protocol, it was found that a higher concentration of CuSO4 and ascorbate 
were required for efficient conversion than is typically described in the literature.  This could be 
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due to the amount and positioning of ether and carbonyl oxygen atoms in the linker that may be 
capable of chelating the copper, thus inhibiting its use in catalysis. 
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Scheme 2. Synthetic route for bivalent multifunctional ligands, part 2. 
2.2.8 Synthesis of 17-atom spacer analogs 18 and 19 
 Compounds 8-17 correspond to linker lengths of 21 to 28.  Unfortunately, reducing the 
alkyl portion of the linker to one atom would result in a total length of 18, one atom longer than 
is required.  Because of this, a truncated linker composed of the same chemical structures was 
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necessary.  To achieve this, compound 48, a side product in the creation of 23, was first 
functionalized by converting an azide to the primary amine.  This reaction was run using 
triphenylphosphine as described before; however, in this instance, a two phase solvent system 
(organic EtOAc and Et2O, and acidic water) was employed to insure only one azide would be 
reduced.  Once the phosphazide intermediate is formed in the organic phase, it is immediately 
cleaved by the H2O present in the solvent system, affording the primary amine.  Due to the 
hydrophilic nature of the amine group, the compound now prefers to exist in the water phase, 
preventing a secondary interaction with triphenylphosphine in the organic phase.  The newly 
synthesized compound 49 was then reacted with succinic anhydride.  Nucleophilic ring opening 
created a newly formed amide bond and carboxylic acid.  The resulting molecule 50 constitutes 
the full linker structure.  From here, 50 was reacted with diosgenin 4, and curcumin analogs 46 
and 47, as previously outlined, yielding final products 18 and 19.  
 
2.2.9 Synthesis of control compounds 20 and 21 
 After preliminary activities were assessed, control ligands were made incorporating the 
most potent linker composition connected only to diosgenin or curcumin.  To acquire these, 
compound 51 was clicked to 4-methyl-1-pentyne as previously described.  The product 20 
includes the triazole ring, seen in all ligands, and the middle carbons of the curcumin structure.  
Compound 21 was obtain by coupling 49 with 3-(methoxycarbonyl)propanoic acid 53, a methyl 
ester capped form of succinic acid, with EDC/HOBt, again, as previously described.  The 
resulting product 54 was clicked together with 46 giving final product 21 in good yield. 
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Scheme 3. Synthetic route for bivalent multifunctional ligands, part 3. 
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Scheme 4. Synthetic route for control compounds for bivalent series. 
 
2.3 Biological Studies 
 For simplicity, compounds may be abbreviated below by their linker length, attachment 
site, and use of diosgenin as a steroid; for example, compound 8 may be referred to as 21-MD, 
denoting a 21 atom spacer, connection at the „M‟ position, and „D‟ for diosgenin. 
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2.3.1 The MC65 neuroblastoma cell model 
 In order to characterize the biological activities of these compounds as potential AD-
modifying agents, an appropriate cell model for AD is necessary.  Therefore, the MC65 cell 
model was selected.  MC65 cells are SK-N-MC neuroblastoma cells that have been stably 
transfected to express the human APP-C99 fragment.  Under AD pathological conditions, this 
fragment arises after the cleavage of APP by ß-secretase.  It is then subsequently processed by γ-
secretase to produce Aß.  Indeed, MC65 cells have been shown to produce both the C99 protein 
and Aß.
189
  The transfected gene in the MC65 cell line is conditionally expressed using the 
tetracycline (TC) responsive promoter system.  Growth medium is supplemented with TC to 
insure the gene promoter region is blocked and cells grow normally.  Upon TC removal (-TC), 
RNA polymerase can now freely transcribed the specified gene, leading to production of the C99 
fragment and consequently, Aß.  This overexpression of Aß in MC65 cells leads to aberrant 
cellular function, increase in oxidative stress, and ultimately, cell death, which has been well 
characterized.
189-191
  Moreover, in this model, Aß is produced intracellularly, which better 
mimics AD in vivo, unlike other models, i.e. SH-SY5Y or PC-12, where exogenous Aß is added 
to the cell medium.  Therefore, MC65 cells serve as a suitable model for AD in vitro.  
 
2.3.2 Neuroprotective ability of bivalent ligands in MC65 cells 
The full series of designed and successfully synthesized bivalent compounds were first 
screened for their neuroprotective ability in MC65 cells.  MC65 cells were incubated with 
indicated compounds for 72 h in the absence of TC.  Viability was then assessed by MTT assay.  
Briefly, cells are incubated with MTT for 4 h, after which the medium is removed and the 
  
39 
 
remaining formazan crystals produced by viable cells are dissolved in DMSO.  Absorbance is 
then measured at 570 nm.  All compounds were assayed at a concentration of 3 µM to identify 
active structures with reasonable potency.  Ligands were plotted as pairs in ascending linker 
length, with the „M‟ position on the left and the „P‟ position on the right.  As seen in Figure 10, 
curcumin 1 and diosgenin 2 exhibited only weak protective abilities at this concentration, and 
interestingly, caprospinol 5 actually showed no protection at all.  Caprospinol, though protective 
in some cell models of AD, has not been previously characterized in MC65 cells, and may not 
exhibit activity at these concentrations or in this model.  For all ligands, attachment at the „M‟ 
position was significantly more protective than the „P‟ position, excluding 26-PD, which was 
similar to the 26-MD analog.  In fact, only compounds 21-MD and 26-MD imparted any 
significant protection compared to the -TC control, and even then, it was slight (~20% increase 
from -TC).  This preference for the „M‟ position is in agreement with the reported cholesterol 
and cholesterylamine series, highlighting the importance of the connection site.
172, 174
  
Compounds 18, 8, 9, and 10 all exhibited strong neuroprotective activity, increasing viability to 
80% or greater, demonstrating that these ligands can effectively rescue MC65 cell death.  After 
24 atoms of spacer, however, protective function dropped significantly (~25% reduction), 
suggesting that too long of an extension may not be positioning the curcumin and steroid 
structures in a proper fashion.  Moreover, no protection was observed for control compounds 20 
and 21, containing just the spacer connected to only diosgenin or curcumin, respectively.  This 
confirms that the presence of all three pieces of the ligand is required for activity and validates 
the bivalent design strategy.  From here, dose-response studies of the „M‟-attached ligands were 
carried out to determine EC50s.  As shown in Figure 10, all ligands again showed significant 
protection at 3 µM that ultimately decreased to negligible values as concentration was reduced to 
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0.01 µM.  Notably, compounds 18 and 8 (17-MD and 21-MD) were the only ligands able to raise 
viability to 90% or more.  They exhibited the best potencies, as well, with EC50s of 111.7 ± 9.0 
nM and 231.7 ± 15.1 nM, respectively.  Not surprisingly, these spacers were also the optimal 
lengths revealed from the previous series.
 
 As the linker length is increased, the general trend is a 
reduction in potency and efficacy, although again, 26-MD was the exception that proves the rule, 
with an EC50 of 309.0 ± 1.5 nM.  Altogether, these results further substantiate the preference of 
the „M‟ position and support the notion that optimal spacers are shorter than 22 atoms.  Based on 
these results, compounds 18 and 8 (17-MD and 21-MD, respectively) were selected for follow-
up studies of biological characterization.   
 
2.3.3 Antioxidative properties of 18 and 8 in MC65 cells 
 One goal of the desired combination of 1 and 4 was to retain the antioxidative properties 
of the curcumin moiety and consequently reduce oxidative stress that contributes to AD 
pathology.  Oxidative stress has also been indicated as one potential effector in imparting 
neurotoxicity upon the accumulation of intracellular Aß in MC65 cells.
189
  Therefore, 
compounds 18 and 8 were evaluated for their antioxidative ability in MC65 cells.  To accomplish 
this, a DCFH-DA (2,7-dichlorodihydrofluorescein diacetate) dye was used.  In vitro, DCFH-DA 
will be de-esterified to DCFH, and then upon interaction with ROS, this will become oxidized to 
produce 2,7-dichlorofluorescein, which is highly fluorescent and can be measured, in this case, 
by flow cytometry.
192
  As shown in Figure 10, removal of TC led to a significant increase in 
intracellular oxidative stress compared to the +TC control (108% increase), as measured by 
fluorescence intensity.  This rise in ROS is completely prevented by addition of 18 at a 
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concentration as low as 0.1 µM, consistent with its EC50 from the MTT assay.  Similarly, ligand 
8 was able to significantly reduce ROS production as well, with concentrations down to 0.3 µM, 
also matching its EC50 from the MTT assay.  Because the potencies for 18 and 8 in rescuing cell 
viability correspond closely with ROS reduction, this suggests that antioxidative ability may be 
the major mechanism of neuroprotection for these multifunctional compounds.  Furthermore, 
these results also strongly correlate oxidative stress with viability for MC65 cells under -TC 
conditions, linking Aß production to increased ROS concentrations. 
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Figure 10. Screening of bivalent series in MC65 cells, MTT assay and ROS reduction. A. 
Neuroprotective effects of full series of bivalent ligands.  MC65 cells were treated with indicated 
compounds at 3 µM for 72 h.  Cell viability was measured by MTT assay.  Data were expressed 
as mean percentage viability (n=3) with parallel +TC cultures set at 100% viability.  Error bars 
represent SEM. B. Dose response of „M‟ position ligands. MC65 cells were treated with 
indicated compounds at indicated concentrations for 72 h.  Cell viability was measured by MTT 
assay.  Data were expressed as mean percentage viability (n=3) with parallel +TC cultures set at 
100% viability.  Error bars represent SEM. C. Antioxidative properties of 18 and 8.  MC65 cells 
treated with 18 or 8 for 48 hr.  ROS production was measured by DCFH-DA assay.  Data were 
expressed as mean percentage viability (n=3) with parallel +TC cultures set at 100% viability.  
Error bars represent SEM.  * p < 0.05 
(1µM) 
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2.3.4 Effects of 18 and 8 on Aß oligomerization 
 In order to test whether these ligands are indeed having an effect on AßO formation as 
hypothesized, Aß oligomerization in MC65 cells was analyzed by western blot.  Cells were 
treated with 18 and 8 for 48 h.  Samples were then collected, separated by SDS-PAGE, and 
probed with 6E10 antibody to bind Aß oligomers.  As expected, inclusion of TC in the cell 
medium completely blocked Aß expression, and removal of TC led to a vast increase in Aß 
oligomers (Figure 11).  This increase was significantly suppressed by both 18 and 8 in a dose-
dependent manner, confirming the anti-oligomerization properties of these ligands.  In 
conjunction with the reduction of ROS production, this result provides additional evidence 
showing the close relation of oxidative stress and AßO formation.  Moreover, it suggests that 
inhibition of Aß oligomerization is also an important mechanism of action for these ligands, and 
demonstrates their multifunctional nature, further supporting the bivalent design strategy. 
 
2.3.5 Effects of 18 and 8 on overall Aß production 
 To provide more evidence that 18 and 8 are actually preventing oligomerization and not 
simply inhibiting Aß production, total Aß concentrations were calculated by ELISA.  MC65 cell 
samples were treated with 18 or 8 for 48 h.  Conditioned medium was collected and added to 
plates precoated with BNT77 antibody.  Concentrations of both Aß40 and Aß42 were measured by 
using BA27 and BC05 antibodies, respectively.  Consistent with the western blot, addition of TC 
to the cell medium completely blocked Aß production, and naturally, removal led to a sharp 
increase (Figure 11).  Treatment with 18 or 8 had no significant impact on Aß40 or Aß42 
concentrations, except 18 at 0.1 µM, which while significant, was practically negligible (< 10% 
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increase).  These results indicate that both ligands are in fact having no effect on Aß production, 
and their influence on AßO formation is truly due to their anti-oligomerization properties. 
A
ß
4
0
 C
o
n
c
e
n
tr
a
ti
o
n
 (
p
M
)
-T
C
+
T
C
8
 -
 1
µ
M
8
 -
 0
.3
µ
M
8
 -
 0
.1
µ
M
1
8
 -
 1
µ
M
1
8
 -
 0
.3
µ
M
1
8
 -
 0
.1
µ
M
0
2 0 0
4 0 0
6 0 0
8 0 0
1 0 0 0
*
A
ß
4
2
 C
o
n
c
e
n
tr
a
ti
o
n
 (
p
M
)
-T
C
+
T
C
8
 -
 1
µ
M
8
 -
 0
.3
µ
M
8
 -
 0
.1
µ
M
1
8
 -
 1
µ
M
1
8
 -
 0
.3
µ
M
1
8
 -
 0
.1
µ
M
0
2 0
4 0
6 0
8 0
*
*
T
o
ta
l 
A
ß
 o
li
g
o
m
e
r
 a
m
o
u
n
t
r
e
la
ti
v
e
 t
o
 -
T
C
 c
o
n
tr
o
l
-T
C
+
T
C
1
8
 -
 1
u
M
1
8
 -
 0
.3
u
M
1
8
 -
 0
.1
u
M
8
 -
 1
u
M
8
 -
 0
.3
u
M
8
 -
 0
.1
u
M
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
1 .2
A B
C
D
 
Figure 11. Effects of 18 and 8 on Aß oligomerization and production in MC65 cells. A and B. 
Effects of 18 and 8 on AßO formation.  MC65 cells were treated 18 or 8 at indicated 
concentrations for 48 h.  Western blot analysis (A) shows amounts of AßO for each testing 
condition.  Total amount of AßOs as measured by total band intensity was expressed relative to 
the -TC control (B).  Data represent a single representative assay.  C and D. Total Aß 
concentration in MC65 cells.  MC65 cells were treated with 18 or 8 at indicated concentrations 
for 48 h.  Total Aß40 (C) and Aß42 (D) concentrations were calculated by ELISA.  Data are 
expressed as mean concentration (n=3).  Error bars represent SEM.  * p< 0.05 
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2.4 Conclusion 
A series of bivalent compounds containing curcumin 1 and diosgenin 4, both natural 
products shown to have favorable properties against AD pathology, were designed and 
successfully synthesized.  Biological screening in MC65 neuroblastoma cells revealed 
compounds 18 and 8 as lead compounds with strong neuroprotective activity.  It was also found 
that the „M‟ position was greatly prefered to the „P‟ position, and that protection was diminished 
as linker length was increased past 24 atoms.  Moreover, control compounds lacking either the 
steroid or curcumin moiety exhibited no protection, validating the bivalent design strategy.  
Preliminary mechanistic investigations of compounds 18 and 8 established their anti-oxidative 
abilities in MC65 cells, and also demonstrated their anti-Aß oligomerization properties by 
western blotting.  This was reinforced by Aß ELISA, which confirmed that 18 and 8 have no 
effect on Aß production.   
These results encourage further investigation and mechanistic characterization of these 
ligands.  Evidence that these compounds are associating with lipid rafts can be addressed by 
fluoresence microscopy studies, due to the inherent fluorescent properties of the curcumin 
structure.  Additionally, studies with artifical liposomes containing various LR components, 
namely cholesterol, sphingolipids, and gangliosides, could also be conducted to characterize LR 
interactions.  Direct protein interactions between ligands and Aß are typically characterized by 
Thioflavin T binding and may offer insight into the Aß binding ability.  Biometal binding should 
also be investigated to confirm if these ligands retain these properties from the parent compound, 
curcumin.  Before any in vivo studies could be attempted, BBB penetration ability would 
certainly need to be assessed.  Altogether, these findings support the bivalent design approach as 
a viable strategy in providing new chemical diagnostic tools or therapeutics.  
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3 Multifunctional Hybrid Compounds against Alzheimer’s Disease 
3.1 Project Design 
 Natural products have proven to be reliable resources in providing effective therapeutics 
for a variety of diseases.  Recently, several small natural compounds with polypharmacological 
profiles have been shown to be of potential use in neurodegenerative disorders, among which 
curcumin 1 and melatonin 2 have been implicated by extensive studies as potential AD treatment 
agents.  As described in chapter 2, curcumin exhibits a wide range of neuroprotective features in 
models of AD, including Aß-oligomerization, anti-oxidation, and biometal binding.
193-195
  
Melatonin, the major secretory product of the pineal gland, plays an essential role in the 
regulation of the circadian rhythm.
196
  In addition, 2 can be produced in various tissues and 
organs, and participates in diverse functions through both receptor-dependent and independent 
ways, including free radical scavenging, immune response, and mood monitoring, among 
others.
197, 198  
Notably, circadian dysfunction and the reduction of 2 have both been observed in 
AD, suggesting the potential of 2 in AD treatment.
199, 200
  Indeed, 2 has been tested both in vitro 
and in vivo as a potential treatment for AD.
201
  It has been demonstrated that 2 can rescue cell 
toxicity and death induced by Aβ via multiple mechanisms.202  In transgenic AD mouse models, 
2 has also been shown to improve cognition, reduce Aβ deposition and neuroinflammation.201, 203 
Clinical studies in AD patients with 2 also suggested beneficial effects, especially in sleep 
quality and reduced sundowning.
204
  But more studies are needed to explore and investigate the 
usefulness of 2 as a treatment for AD.  Furthermore, 2 has a relatively short half-life (< 30 
min).
205
  Therefore, novel analogs of 2 are needed for further investigation and development. 
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Recently, the “hybrid molecule” strategy has seen increased attention in drug design and 
development as previously reviewed.
175
  The core idea of this strategy is the design of novel 
ligands by combining the known „pharmacophoric sub-unities‟ of two or more bioactive 
compounds to achieve a new architecture with pre-selected characteristics.  It has been used 
successfully to optimize pharmacokinetic properties, to potentially reduce undesired off-target 
effects, and modify drug selectivity and mode of action.
175
  Given the demonstrated 
neuroprotective effects of 1 and 2 in various AD models and patients, the hybrid strategy should 
provide novel chemical scaffolds that retain the functional natures of 1 and 2, and also provide 
certain advantages, such as 1) enhanced potency by self-synergy within one molecule that may 
not be achievable by a traditional combination of separately dosed agents; and 2) improved 
pharmacokinetic properties and reduced toxic side effects compared to the administration of 
multiple agents. Furthermore, this hybrid strategy may provide new compounds with novel 
mechanisms of action, thus representing an attract strategy to identify promising leads for further 
development.    
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Figure 12. Designed curcumin and melatonin hybrid, and related analogs. 
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3.2 Chemical Design and Syntheses 
 This series of compounds were designed to explore the substituents of the phenyl ring in 
the curcumin portion of the hybrid structure.  Initially, compound 54 was synthesized as the 
representative hybrid between curcumin and melatonin, and assayed for any in vitro activity.  
After 54 was proven to be active, its lead structure was used as the basis for the remaining series.  
Analogs 55-57 were used to deconstruct the ring and determine the contribution of the methoxy 
and hydroxyl groups individually.  Compounds 58-63 contain different alkyl additions and 
removals to the methoxy and hydroxyl groups, as well as the phenyl ring, to examine the 
positional preference of these analogs and the nature of their electron-donating effects.  
Compounds 64-67 were used to investigate the feasibility of replacing the phenyl ring with 
different isoteres and to assess the preference of the heteroatoms on these rings.  Finally, 
compound 68 was designed to determine whether the conjugation of the ketone into the ring via 
the alkene and its associated electronic and structural properties were integral, after initial assays 
revealed 56 to be fairly active. 
  
50 
 
O
O
O O
O
O
(Ph)3P H2N
NH
OCH3
70
(Ph)3P
O
N
H
O NH
OCH3
72
H3CO
HO
H
O
(Ph)3P
O
N
H
O NH
OCH3
72
H
O
R
O
N
H
O
68
NH
OCH3
HO
Cl
69
PPh3
NaH, DMPU, THF
71
Xylene 
140°C
73
Benzene
55°C
O
N
H
O
H3CO
HO
NH
OCH3
54
NaH, DMPU, THF
DMSO, H2O
100°C
O
N
H
O
56
NH
OCH3
HO
H2, Pd/C
MeOH
56, 61, 62
55, 57-60, 63-67
71% 57%
31%
29%
31%
72%
 
Scheme 5. Synthetic route of curcumin and melatonin hybrid compounds. 
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3.2.1 Phosphine addition and amide formation 
 Ethyl 4-chloroacetoacetate 69 was added to a solution of triphenylphosphine in benzene 
to create the phosphonium Wittig reagent 70.  The triphenylphosphine substituent was chosen 
because it would effectively „protect‟ and prepare the γ-carbon for alkene formation at a later 
step.  Next, an amine exchange reaction was performed in xylenes at high temperatures.  Here, 
the nucleophilic primary amine of 5-methoxytryptamine 71 attacks the carbonyl carbon of 70 to 
form the quaternary intermediate.  The ethoxy substituent becomes subsequently protonated and 
eliminated, forming the amide linked product 72 and ethanol.  Originally, toluene was used as 
the solvent, but this resulted in very low yields.  Use of xylenes, however, lead to the typically 
higher yields expected from this reaction.  The more common EDC/HOBt coupling route was 
not chosen.  Not only would this procedure introduce an extra step into the synthetic route, 
leading to potential losses in starting material and reduction in overall yields associated with 
longer synthetic schemes, but also hydrolysis of the ethyl ester to form the ß-ketocarboxylic acid 
could result decarboxylation, leading to formation of the methyl ketone.  This is a commonly 
used mechanism in ketone installation, but would lead to unwanted products in this situation.  
Moreover, due to the nucleophilic nature of the γ-carbon in the phosphorane group, activation of 
the α-carbon by EDC/HOBt, following deprotection of the ethyl ester, could potentially lead to a 
self-reaction, forming an unwanted conjugated polymer.   
 
3.2.2 Wittig reaction   
 The Wittig reaction, also known as Wittig olefination, was originally described by Georg 
Wittig in 1954 for whom the reaction is named.
206
  It is characterized by its use of a triphenyl 
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phosphonium ylide, often and appropriately called a Wittig reagent, reacted with a ketone or 
aldehyde to give an alkene and the oxidized triphenylphosphine oxide.  The negatively charged 
carbanion of the ylide acts a nucleophile and attacks the carbonyl carbon of the aldehyde to form 
a carbon-carbon bond.  In this case, the NaH base aids in the formation of the carbanion, which 
is also stabilized by the adjacent ketone group.  The steric bulk of the aldehyde and the stability 
of the carbanion make the carbon-carbon bond formation the rate-limiting step, which leads to 
preference of the E-isomer.  As expected, virtually no Z-isomer is formed, as observed in the 
NMR of compound 54 (Figure 13).  After this new bond is formed, carbon-carbon rotation gives 
a betaine type structure, which then leads to the oxaphosphetane intermediate.  Elimination of 
triphenylphosphine oxide results in the fully formed alkene product.  Of all compounds 55-67, 
only 56, 61, and 62 failed to react properly under the given conditions, and interestingly, all of 
these analogs contain a phenyl hydroxyl group.  The NaH base used to form the ylide is 
deprotonating the phenolic oxygen, giving rise to a phenoxide anion, which consequently 
interferes in the reaction and prevents the Wittig reaction from occurring.  For these compounds, 
removal of the base and changing to a DMSO/H2O system under high heat afforded the desired 
products.  Notably, compound 54 also contains a phenolic group and repeat reactions using 
DMSO/H2O led to significantly higher yields.  The newly formed alkene can be easily reduced 
using H2 gas and a Pd/C catalyst in methanol to form a saturated alkane.  Compound 68 was 
synthesized in this fashion. 
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Figure 13. NMR spectrum of compound 54.  The coupling constant (J) between the two vicinal 
protons of the alkene formed in the Wittig reaction is 16 Hz, indicating a trans-conformation.  
Adapted from Chojnacki et al.
207
 
 
 
3.3 Biological Studies 
3.3.1 Neuroprotective ability of 54 in MC65 cells  
Compound 54, the representative hybrid between curcumin and melatonin, was first 
synthesized and evaluated for its neuroprotective activity.  For this, an MTT viability assay was 
used in MC65 cells as previously described under TC removal conditions.  Initially, we tested 54 
at a concentration of 0.3 µM in order to develop active lead structures with a reasonable potency.  
Curcumin 1 and melatonin 2 alone, and the combination of 1 and 2 were compared as controls.  
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As shown in Figure 14, no neuroprotection was observed at this concentration in MC65 cells for 
any of the controls.  These results are consistent with previously reported results of 1 in MC65 
cells.
172, 174
  This also indicates that although 2 has been reported to have activity in other cellular 
models of neurodegenerative disorders, it might not be sufficient to protect MC65 cells under 
these testing conditions.  Notably, hybrid 54 significantly protected MC65 cells from -TC 
induced cell death (~61% increase in cell viability), which suggests that the combination of the 
essential features of 1 and 2 can provide new chemical scaffolds with novel pharmacology, and 
54 could serve as a lead structure for further molecular development.  Further dose-response 
studies of 54 established an EC50 of 134.2 ± 4.5 nM for its neuroprotection of MC65 cells 
(Figure 14). 
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Figure 14. Biological characterization of representative hybrid compound 54. A. Effects of 1, 2, 
and 54 in MC65 cells.  Cells were treated with indicated compounds at 0.3 µM under +TC or -
TC conditions for 72 h.  Cell viability was assessed by MTT assay.  Data were expressed as 
mean percentage viability (n=3) with parallel +TC cultures set at 100% viability.  Error bars 
represent SEM.  B. Dose response of 54 in MC65 cells.  Viability was assessed by MTT assay.  
Data were expressed as mean percentage viability (n=3) with parallel +TC cultures set at 100% 
viability.  Error bars represent SEM.  C. ROS inhibition of 54 in MC65 cells.  Cells were treated 
with 54 for 48 h, then DCFH-DA (25 μM) was loaded and fluorescence intensity was analyzed at 
485 nm (excitation) and 530 nm (emission). Data were presented as a mean percentage of 
fluorescence intensity (n=3).  Error bars represent SEM. D. Metal chelating ability of 54.  
Curcumin 1 and 54 were incubated with CuSO4, FeCl2, or ZnCl2 at room temperature for 10 min. 
UV-vis spectrum was recorded from 250 nm to 600 nm.  Adapted from Chojnacki et al.207 
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3.3.2 Antioxidative ability of 54 in MC65 cells 
 One goal of the desired hybridization of 1 and 2 was to reduce oxidative stress that 
contributes to AD pathology.  Therefore, compound 54 was evaluated for its antioxidative 
activity in MC65 cells using a DCFH-DA dye and flow cytometry, as previously outlined.  As 
shown in Figure 14, upon removal of TC, intracellular oxidative stress, as measured by 
fluorescence intensity, is significantly increased compared to normal growing MC65 cells in the 
presence of TC (52% increase).  Notably, 54 suppressed intracellular oxidative stress in a dose-
dependent manner with an IC50 of ~134 nM.  Although the antioxidative activity of 54 is 
comparable to the previously reported antioxidative activity of 1,
172, 174
 it also significantly 
protected MC65 cells from cell death while 1 did not under the same experimental conditions 
(Figure 14).  These results may suggest that the antioxidative effects of 1 and 54 are perhaps 
through different mechanisms, thus further supporting the hypothesis that the rational design of 1 
and 2 hybrids can provide novel compounds that can both retain the activities of the parent 
compounds and provide superior potency and protection.  
 
3.3.3 Metal ion chelating ability of 54 
The ability of 54 to chelate biometals was also assessed, to ascertain whether changing 
the ß-diketone structure of 1 to a ß-ketone amide structure would affect biometal binding 
potential.  Furthermore, dyshomeostasis of metal ions has been indicated as one of the 
pathologies of AD,
 
and it has been suggested that metal ions are involved in the assembly and 
neurotoxicity of Aß, and may contribute to oxidative stress.
72, 73, 208
  Therefore, compounds with 
biometal chelating properties may provide an additional layer of beneficial activity in developing 
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multifunctional compounds as AD-modifying agents.  As shown in Figure 14, 54 did not 
complex with any of the tested metals (Cu
2+
, Fe
2+
, and Zn
2+
), while 1 did bind to Cu
2+
 and Fe
2+
, 
but not Zn
2+
 under the same conditions, consistent with the reported results from the literature.
172, 
209
  This suggests that the amide moiety of 54 eliminates the formation of the enol form of the ß-
diketone, and consequently reduces its metal binding capacity.  This also further supports the 
integral role of the ß-diketone structure in biometal binding ability, as demonstrated in the 
literature.
209
  Additionally, because biometals may be playing a significant role in the production 
of ROS, this could account for the similarities in ROS reduction, yet differences in 
neuroprotection, as previously noted.  Again, this suggests that the hybrid strategy not only 
provides novel scaffolds that retain certain properties analogous to the parent molecules, but can 
also produce compounds with different mechanisms of action.  
 
3.3.4 Neuroprotective abilities of the designed analogs in MC65 cells 
 After confirming the neuroprotective abilities and anti-oxidative characteristics of 54, the 
full series of analogs were designed and successfully synthesized, as noted before.  All 
compounds were then screened for their protective activity in MC65 cells under -TC conditions 
at 0.3 µM (Figure 15) by MTT assay.  Removal of the 4-OH group from 54, as demonstrated by 
compound 55, led to a complete loss of neuroprotection in MC65 cells.  However, removal of 3-
OCH3 did not affect biological activity, as compound 56 exhibited significant protection at the 
tested concentration.  Remarkably, 56 can be recognized as the hybrid of melatonin and 
raspberry ketone, another natural product, thus further supporting the use of the hybrid strategy.  
These results clearly indicate that the 4-OH is indispensable for the neuroprotective activity of 
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54.  This notion is further demonstrated by the results of the unsubstituted analog 57, the 4-OCH3 
analog 58, the 3,4-methylenedioxy analog 59, and the 3,4-dimethoxy analog 60, all of which 
exhibited significantly diminished protective ability (<30% viability for all).  These results could 
also indicate that H-bond interactions with the 4-OH group may be playing an important role in 
the biological activity of 54.  Interestingly, replacement of the 3-OCH3 group of 54 with an -OH 
group, as demonstrated by 61, led to a significant loss of neuroprotection (~60% loss) in 
comparison to 56.  Similarly, adding a -OCH3 group to the 5-position of 54 (62) also reduced the 
protective abilities by about 30% compared to 54.  This may suggest that there are unfavorable 
H-bond or electronic interactions when an -OH group is at the 3-position.  Additionally, the 
specific interaction site with the 4-OH moiety may not be able to tolerate steric hindrance at the 
5-position, a notion further reflected by compound 63.  Compound 63 contains a -N(CH3)2 
substitution at the para-position of the phenyl ring and showed weak neuroprotection (~20% 
protection compared to the -TC control).  Replacement of the 4-OH-phenyl ring of 54 with a 
pyridine ring resulted in two compounds, with the 3-substituted pyridine analog 64 being 
completely inactive, while the 4-substituted pyridine analog 65 was moderately active in 
protecting MC65 cells (~33% increase in protection compared to the -TC control).  The activity 
of 65 might compare somewhat to the protective activity of 56 since the nitrogen of the pyridine 
ring is in the same position as the 4-OH group in compound 56 and can also potentially 
participate in H-bond interactions.  Moreover, for the furan substituted analogs 66 and 67, no 
neuroprotection was observed for the 2-furan substituted analog 66, while the 3-furan substituted 
analog 67 exhibited moderate protection (~48% increase in protection compared to the -TC 
control), which is consistent with the results of 64 and 65 considering the positions of the oxygen 
in the furan ring.   
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To investigate the contribution of the conjugated double bond between the phenyl ring 
and the ß-ketone, compound 68 was synthesized and assayed at a concentration of 0.3 µM.  
Notably, 68 also exhibited significant and comparable protection of MC65 cells with that of 56, 
suggesting that the conformationally rigid double bond and the conjugation system with the 
phenyl ring is not necessary to produce the neuroprotection observed for these analogs.  
Furthermore, the electronic effects of the substitutions on the phenyl ring may not play an 
essential role in the biological activity of this chemotype, which is consistent with the results of 
55-63.  Since compounds 56 and 68 exhibited near-full protection of MC65 cells, the dose-
response of these compounds was obtained to assess their neuroprotective potency.  As shown in 
Figure 15, the EC50s for 56 and 68 to protect MC65 cells were 23.05 ± 5.23 and 27.60 ± 9.40 
nM, respectively, which is about 5-fold more potent than 54.  Because 56 and 68 showed similar 
neuroprotective potencies in MC65 cells, either both 56 and 68, or 68 alone, were tested in 
subsequent mechanistic investigations.  
 
Figure 15. Full series screening of hybrid compounds and dose response of 56 and 68. A. 
Neuroprotective effects of full series of hybrid compounds.  MC65 cells were treated with 
indicated compounds at 0.3 µM under +TC or -TC conditions for 72 h.  Cell viability was 
assessed by MTT assay.  Data were expressed as mean percentage viability (n=4) with parallel 
+TC cultures set at 100% viability.  Error bars represent SEM.  B. Dose response of 56 and 68.  
MC65 cells were treated with 56 or 68 at indicated concentrations under -TC conditions for 72 h.  
Cell viability was assessed by MTT assay.  Data were expressed as mean percentage viability 
(n=3) with parallel +TC cultures set at 100% viability. Adapted from Chojnacki et al.
207
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3.3.5 Antioxidative ability of 56 and 68 in MC65 cells 
 Following the same line of reasoning with compound 54, the anti-oxidative activity of 56 
and 68 were measured using the DCFH-DA assay.  As shown in Figure 16, both 56 and 68 dose-
dependently suppressed ROS production with IC50s of ~63 nM and ~68 nM, respectively, both of 
which are slightly less potent than their EC50s from the MTT assay.  This supports the hypothesis 
that these hybrids are acting in a multifunctional fashion, and that their other protective abilities 
may be upstream from ROS production.  Furthermore, because MC65 cells express large 
quantities of AßOs and oxidative stress has been implicated in the death of MC65 cells, this 
suggests that the production of AßOs eventually funnels into ROS production, leading to 
cytotoxicity.  In order to confirm this idea, N-acetylcysteine (NAC) and Trolox (6-hydroxy-
2,5,7,8-tetramethyl chroman-2-carboxylic acid) were tested for their protection in MC65 cells 
under the same assay conditions as 68.  Trolox functions as a chain-breaking antioxidant and is 
particularly effective against lipid peroxidation.
210-212
  Notably, like 68, Trolox significantly 
protected MC65 cells from -TC-induced cytotoxicity at concentrations as low as 10 µM.  NAC, 
on the other hand, acts primarily as a hydrogen peroxide scavenger, and only partially rescued 
viability at 8 and 16 mM concentrations (Figure 16), which is consistent with previously reported 
results.
172
  Given the fact that Trolox and NAC have different mechanisms of antioxidation, this 
may suggest that ROS-induced lipid peroxidation is the major pathway involved in the death of 
MC65 cells.  Taken together, these results strongly support the idea that oxidative stress is the 
convergent event after the production of AßOs in MC65 cells that ultimately leads to cell death.  
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Figure 16. Antioxidative properties of Trolox, NAC, 56, and 68 in MC65 cells. A. Antioxidative 
ability of 56 and 68.  MC65 cells were treated with 56 or 68 at indicated concentrations under -
TC conditions for 48 h, then DCFH-DA (25 μM) was loaded and fluorescence intensity was 
analyzed at 485 nm (excitation) and 530 nm (emission).  Data were presented as a mean 
percentage of fluorescence intensity (n=3).  Error bars represent SEM.  B. Neuroprotective 
ability of known antioxidants.  MC65 cells were treated with Trolox or NAC at indicated 
concentrations under -TC conditions for 72 h. Cell viability was assessed by MTT assay. Data 
were expressed as mean percentage viability (n=3) with parallel +TC cultures set at 100% 
viability. Error bars represent SEM.  C. Neuroprotective ability of Trolox and 68 in an oxidative 
stress model.  HT22 cells were treated with Trolox or 68 at indicated concentrations before 
addition of H2O2 (500 µM) and incubated for 24 h.  Cell viability was assessed by MTT assay.  
Data were expressed as mean percentage viability (n=3) with parallel H2O2-free cultures set at 
100% viability.  Error bars represent SEM. Adapted from Chojnacki et al.
207
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3.3.6 Effects of 56 and 68 on AßO production 
 As previously mentioned, under -TC conditions, MC65 cells can produce intracellular 
AßOs that eventually lead to cell death.  Therefore, the inhibitory effects of 56 and 68 on the 
production of AβOs were investigated.  As shown in Figure 17, both 56 and 68 dose-dependently 
suppressed the production of higher weight AßOs, including tetramers, pentamers, and 
heptamers.  However, the potencies in suppressing AßOs were significantly lower than the 
potencies for protecting MC65 cells from -TC induced cytotoxicity (Figure 15).  Much like the 
anti-oxidative ability of 56 and 68, this may suggest that the suppression of AßOs contributes 
only partially to their multifunctional, neuroprotective function, and moreover, may not 
constitute the major mechanism of action.  To further explore the effects on Aß aggregation, 68 
was tested for its ability to inhibit Aß42 fibril formation using the thioflavin T (ThT) assay.  
Compound 1, known to inhibit Aß fibrillization, was tested as a positive control.  As shown in 
Figure 17, 1 inhibited the formation of Aß42 fibrils (25 µm or longer) by ~27% at 10 µM, 
consistent with reported results.
194
  However, no significant inhibition was observed for 68 even 
at concentrations as high as 100 µM, strongly signifying that 68 cannot bind to Aß42 directly and 
inhibit its fibrillization.  Atomic force microscopy (AFM) studies of Aß42 aggregation also 
confirmed that 68 showed no inhibition on both fibrillization and oligomerization of Aß42 under 
the same assay conditions (Figure 17). 
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Figure 17. Effects of 54 and 68 on Aß oligomerization. A. MC65 cells were treated with 
indicated compounds at indicated concentrations for 24 h immediately after the removal of TC.  
Lysates from cultures were analyzed by Western blotting using 6E10 antibody.  The image 
represents the results from one of three independent experiments. B. Aß42 was added to solutions 
of 1 and 68 at indicated concentrations for 48 h. Thioflavin T (ThT) was then added, and 
fluorescence intensity was analyzed at 446 nm (excitation) and 490 nm (emission). Data were 
presented as a mean percentage of fluorescence intensity (n = 3). Error bars represent SEM. C. 
Aß42 fibrils and oligomers were incubated with a solution of 68 in a 1:1 ratio for 24 h.  Aggregate 
morphology was visualized by AFM.  Adapted from Chojnacki et al.
207
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Figure 18. Effects of Mito-TEMPO, TRO19622, and 68 on ROS formation in MC65 cells. A. 
Effects on viability of TRO19622 and Mito-TEMPO in MC65 cells.  Cells were treated with 
Mito-TEMPO or TRO-19622 at indicated concentrations under normal growth conditions (+TC) 
for 72 h.  Cell viability was assessed by MTT assay.  Data were expressed as mean percentage 
viability (n=3) with parallel +TC cultures set at 100% viability.  Error bars represent SEM.  B. 
Neuroprotective ability of Mito-TEMPO. MC65 cells were treated with Mito-TEMPO at 
indicated concentrations under -TC conditions for 72 h. Cell viability was assessed by MTT 
assay.  Data were expressed as mean percentage viability (n=3) with parallel +TC cultures set at 
100% viability.  C. Neuroprotective ability of TRO-19622.  MC65 cells were treated with TRO-
19622 as described above.  Data were expressed as mean percentage viability (n=3) with parallel 
+TC cultures set at 100% viability.  D. Neuroprotective ability of Mito-TEMPO and 68 against 
rotenone-induced toxicity.  MC65 cells were treated with indicated compounds at indicated 
concentrations for 2 h before addition of rotenone for 48 h.  Cell viability was assessed by MTT 
assay.  Data were expressed as mean percentage viability (n=3) with parallel +TC cultures set at 
100% viability. Error bars represent SEM. Adapted from Chojnacki et al.
207
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3.3.7 Effects on H2O2-induced cytotoxicity in HT22 cells 
 As touched upon previously, the demonstrated antioxidative ability of 56 and 68 in MC65 
cells could be produced through different mechanisms.  Although these compounds do not 
directly bind Aß, as evidenced above, interference with the production of AßOs, disruption of 
interactions between AßOs and various partner proteins, or direct antioxidant effects could all be 
potential mechanisms of action.  Therefore, possible mechanisms of 68‟s antioxidative properties 
were investigated.  Since we have demonstrated that 68 does not inhibit the aggregation of Aß 
and inhibits the production of AßOs with a significantly lower potency compared to its 
neuroprotection potency, analog 68‟s ability to protect HT22 cells from H2O2-induced 
cytotoxicity was used.  HT22 cells, an immortalized murine hippocampal line, are another 
widely used neuronal cell model, particularly for cellular oxidative stress.
213, 214
  The results from 
this assay would help rule out the possibility of 68 acting directly as an antioxidant.  As shown in 
Figure 18, H2O2 (500 µM) led to significant HT22 cell death (~58%).  As expected, the known 
antioxidant Trolox dose-dependently protected HT22 cells from H2O2-induced cytotoxicity with 
full rescue at 300 µM.  However, no protection was observed for 68 up to 0.3 µM.  Altogether, 
these results indicate that the effects of 68 observed in MC65 cells are not through direct 
antioxidative ability, signifying that 68 may be functioning somewhere between the production 
of AßOs and the accumulation of ROS, for example, at interactions between AßO and partner 
proteins. 
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3.3.8 Effects of 68 on rotenone-induced toxicity in MC65 cells 
Since mitochondria are the main sites of intracellular ROS generation,
215, 216
 68 was 
assayed for its ability to act inside mitochondria to exhibit its antioxidative and neuroprotective 
activities.  Taking this into consideration, two control were first tested for their neuroprotective 
properties in MC65 cells under TC removal conditions: TRO-19622, a mitochondrial 
permeability transition pore (mPTP) inhibitor,
217
 and Mito-TEMPO, a known mitochondrial 
ROS (mitoROS) specific scavenger.
218
  Both compounds were intially tested under normal 
growth conditions (+TC) in MC65 cells to identify concentrations with no cytotoxic effects, 
ruling out any potential biased interpretation of the following assays.  As shown in Figure 18, 
Mito-TEMPO did not show toxic effects up to 10 µM and TRO-19622 did not show cytotoxicity 
up to 25 µM.  Therefore, these two concentrations were chosen as maximums for their respective 
compounds in subsequent assays.  Notably, shown in Figure 18, Mito-TEMPO dose-dependently 
protected MC65 cells from -TC-induced cytotoxicity, while TRO-19622 did not show any 
protection up to 25 µM (Figure 18).  Combined with the results of 68‟s antioxidative and 
neuroprotective effects, this may indicate that AßOs, produced upon TC removal, interact with 
certain mitochondrial membrane proteins to generate mitochondrial specific ROS in a mPTP-
independent manner.  To advance this idea further, protection of rotenone-induced cytotoxicty in 
MC65 cells was also explored.  Rotenone is a potent neurotoxin that has been demonstrated to 
inhibit mitochondrial complex I and is linked to mitoROS production.  As shown in Figure 18 
rotenone greatly promoted death of MC65 cells (76%) at 10 µM.  Mito-TEMPO significantly 
protected MC65 cells from cell death at 3 and 10 µM in a dose-dependent manner, while 68 did 
not impart any protection up to 1 µM, concentrations known to rescue MC65 cells from -TC-
induced cytotoxicity.  Collectively, these results propose that upon production, AßOs enter or 
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interact with the mitochondrial membrane to produce mitoROS that ultimately lead to the death 
of MC65 cells, and 68 blocks this interaction, which accounts for its antioxidative and 
neuprotective activities as demonstrated by the aforementioned assays.  Because AßOs have 
been shown to promote tau hyperphosphorylation, neurofibrillary tangle formation, synaptic 
alteration, and neurodegeneration,
30, 219, 220
 the ability of 68 to block protein-protein interactions 
between AßOs with its various partners implies a potential of this chemotype as a new template 
to develop novel, effective AD-modifying agents.  Further studies are warranted to elucidate 
more detailed mechanisms of this compound.  
 
3.3.9 Metal ion chelating ability of 56 and 68   
Compound 54 was previously shown not to chelate biometals, including Cu
2+
, Fe
2+
, and 
Zn
2+
, and this was ascribed to the structural change of the ß-diketone into a ß-ketone amide.  To 
confirm this assertion and also to rule out the possible involvement of other structural moieties in 
biometal chelation, 56 and 68 were tested for their ability to chelate biometal ions.  Consistent 
with 54, both compounds failed to form complexes with any of the three biometals (Figure 19). 
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Figure 19. Metal chelating ability of 56 and 68. Compounds 56 (A) and 68 (B) were incubated 
with CuSO4, FeCl2, or ZnCl2 at room temperature for 10 min.  UV-vis spectrum was recorded 
from 250 nm to 600 nm.  Adapted from Chojnacki et al.
207 
 
3.3.10 BBB penetration assay 
 Considering AD management would be a long term care process for patients, oral 
administration would significantly improve patient compliance, which is sometimes just as 
important as drug toxicity and resistance.  Based on this, compound 68 was assayed for its blood-
brain barrier (BBB) permeability in male CD1 mice (n=6) by oral administration at a dose of 50 
mg/kg.  To quantify accurately the amount of 68 delivered into brain tissue and prevent the 
possibility of biased interpretation from vascular trapping, mice were perfused prior to tissue 
collection in order to wash out completely the vascular blood.  After oral administration, plasma 
samples were collected at 0.25, 0.5, 1, and 24 h, and brain samples were collected at 1 and 24 h.  
Collected samples were analyzed by LC-MS/MS and the results are shown in Table 1.  
Compound 68 exhibited a quick absorption profile with plasma concentrations reaching 773 ± 
309.86 nM (n=6) 15 min after oral administration and only slightly above this after 1 h.  
Concentrations of 68 in the plasma and brain after 1 h were 883 ± 350 nM and 555 ± 188 nM, 
respectively.  This clearly demonstrates that 68 can quickly and efficiently reach brain tissue 
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after oral ingestion, confirming its BBB permeability.  After 24 h, the plasma and brain 
concentrations dropped to 31 ± 12 nM and 47 ± 11 nM, respectively.  It is important to note that 
the brain concentration of 68 at this time point still remains above the neuroprotective EC50 of 68 
in MC65 cells (28 ± 10 nM), suggesting that a once daily regimen should supply a sufficient 
amount of compound 68 for the brain tissue to be therapeutically effective. 
 
Table 1. Plasma and brain concentrations of 68 after oral administration in CD1 mice.  
 15 min 30 min 1 h 24 h 
Plasma 774 ± 310 795 ± 301 883 ± 350 31 ± 12 
Brain   555 ± 188 47 ± 11 
 
 
3.4 Conclusion 
      A series of hybrids of curcumin 1 and melatonin 2 were designed as potential 
multifunctional neuroprotectants for AD and successfully synthesized.  Preliminary biological 
characterization of 54 established the feasibility of utilizing a hybrid compound strategy in 
providing novel chemotypes with novel pharmacology.  Further SAR studies of analog 54 
revealed 56 and 68 as lead compounds with potent neuroprotective properties in MC65 
neuroblastoma cells.  Initial mechanistic studies suggested that antioxidative effects might be a 
major neuroprotective mechanism, and it is likely that the observed antoxidative effects of 56 
and 68 are through interference of interactions of AßOs with mitochondria in MC65 cells.  
Furthermore, 68 has been shown to penetrate the BBB efficiently after oral adminsitration in 
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intact mice, confirming that it is orally bioavailable and therapeutically relevant concentrations 
are attainable in the CNS.   
These results strongly encourage further optimization of 68 as a new lead in the 
development of more potent analogs.  Compounds exploring structural modification of the indole 
ring and ß-ketone amide are certainly warranted and would provide more comprehensive SAR 
data for better rational design.  Due to the anti-oxidative properties of these ligands, assays 
examining their effects in other neurodegenerative disorders, for example Parkinson‟s or 
Huntington‟s diseases, could potentially be conducted.  This would have the effect of either 
exhibiting the broader therapeutic implications of these ligands or demonstrating the specificity 
these ligands have toward Aß-related toxicity, providing more mechanistic insight.  Naturally, in 
vivo studies must be performed to ascertain if and how these compounds affect AD pathology.  
AßO concentration and deposition in the brain would need to be examined, in addition to 
mitochondrial function and overall tissue viability.  Altogether, these findings support the 
hybridization strategy as a novel design approach to provide effective disease-modifying agents 
for AD. 
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4 NLRP3 Inhibitors 
4.1 Project Design 
 Glyburide (70) also known as Glibenclamide, was first developed in 1966 as a 
hypoglycemic agent, and is now the mostly used drug for the treatment of type 2 diabetes 
mellitus (T2DM).
221
  It is of the sulfonylurea class of anti-diabetics and works by inhibiting 
ATP-sensitive K
+
 (KATP) channels in pancreatic ß cells causing membrane depolarization that 
opens voltage-gated Ca
2+
 channels.  This calcium influx leads to the secretion of insulin, which 
ultimately reduces blood glucose.
222
  Mechanistically, glyburide binds the ATP-binding cassette 
(ABC) transporter domain of the K
+
 channel, which is sensitive to sulfonylurea moieties.  In 
addition to KATP channels, ABC transporter ABCA1
 
has also been suggested to be a potential 
target for glyburide.
223, 224
  Notably, glyburide has also been known to exhibit anti-inflammatory 
activity.  Recent epidemiological studies have revealed that T2DM patients were protected from 
death associated with pulmonary bacterial-associated sepsis, and this increase in survival was 
correlated to a rise in anti-inflammatory gene expression profiles in blood leukoctyes.
225
  In fact, 
glyburide was first shown to decrease IL-1ß production and release in 1997.
226
  Follow up 
studies have determined that this effect is specific to the NLRP3 inflammasome.  Unfortunately, 
the use of glyburide as a NLRP3 inhibitor in vivo would require several hundred-fold higher 
doses than those used in diabetes to achieve significant anti-inflammatory activity, which would 
inevitably lead to lethal hypoglycemia.
227
 
Because the sulfonylurea moiety in the glyburide molecule is chiefly involved in the 
binding of KATP channels, one study by Lamkanfi et al. explored the effects of removing this 
group.  Interestingly, it was shown that removal of the cyclohexylurea moiety abolishes 
  
72 
 
glyburide‟s insulin secretion ability, yet retains some activity on NLRP3 inhibition.227  The 
analog described in the report, 74, contains a sulfonyl chloride group, which is highly susceptible 
to nucleophilic attack.  Therefore, this compound would likely be unstable in a physiological 
environment.  Notably, no further studies were pursued.  Based on these findings, however, we 
hypothesize that glyburide analogs free of the cyclohexylurea group containing stable sulfonyl 
moieties could exhibit NLRP3 inhibition without affecting blood glucose levels. 
To this end, a series of novel compounds based on analog 74‟s scaffold were designed 
and synthesized (Figure 20).  Inhibition of IL-1ß, the major cytokine produced from NLRP3 
inflammasome activation, was used as the primary metric of activity and for elucidation of any 
structure-activity relationships (SAR).  Additionally, various aspects of NLRP3 formation and 
function, including ASC aggregation, caspase-1 activity, and cellular viability, were also 
investigated, both in vitro and in vivo.    
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4.2 Chemical Design and Syntheses 
 Compounds 71, 72, 73, and 87 were initially designed to examine the necessity of the 
sulfonyl group and the effectiveness of stabilizing the sulfonyl chloride, reported by Lamkanfi et 
al.
227
  After preliminary biological characterization, compound 72 was found to be highly active.  
From here, the remaining analogs were based on 72’s structure.  Compounds 74-80 were 
designed to explore the space around the sulfonamide and determine the effects of various 
substitutions of the nitrogen atom.  Compounds 81-86 were synthesized to deconstruct the 
benzamide ring and investigate the effects of altering substituents to the ring.  Lastly, compounds 
88 and 89 contain changes in the alkyl chain linking the two rings: 88 with a reduced carbonyl 
carbon to examine the necessity of the amide group and 89 with the addition an extra amine to 
explore its hydrogen bonding capabilities and to increase potentially water solubility. 
 
4.2.1 Amide coupling 
 The synthetic route for this series of glyburide analogs is outlined in Scheme 6.  Initially, 
compounds 87, 71, 72, and 73 were synthesized.  The remaining analogs were synthesized after 
preliminary assays for the first compounds were conducted.  5-chloro-2-methoxybenzoic acid 90 
and phenethylamine 91 were coupled via an amide bond using EDC and HOBt as carboxyl 
activating agents, and Et3N as an acid trap.  The resulting product 87 contains the general 
scaffold of glyburide lacking the sulfonyl substituent, and later was actually used as a negative 
control in some assays.  A reaction utilizing thionyl chloride to create an acid chloride 
intermediate was also used to create the amide bond seen in a majority of the designed analogs.  
Here, thionyl chloride was added to different benzoic acids and refluxed to form the acid 
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chloride intermediate.  Because this substituent is highly susceptible to nucleophilic attack, even 
from weak nucleophiles, it was not isolated.  Removal of thionyl chloride via rotary evaporation 
followed by addition of the amine species yielded the amide species in good yield.  Typically, 4-
(2-aminoethyl)benzenesulfonamide 92, with the sulfonamide group already installed, was used 
as the starting material, affording analogs 81, 82, 83, and 85 in one step.  For analogs 84 and 86, 
this protocol was not used, as the unprotected hydroxyl group leads to unwanted intramolecular 
reactions.  Instead the EDC/HOBt protocol was used.   
 
4.2.2 Aromatic sulfonation 
 Addition of the sulfonyl chloride group to the unsubstituted phenyl ring was 
accomplished by aromatic sulfonation.  Compound 87 was dissolved in concentrated 
chlorosulfonic acid and heated to 75 °C for 1~2 h.  After cooling back to room temperature, the 
reaction was slowly poured onto a crushed ice and water solution, due to the strong reactivity of 
the excess acid.  The sulfonyl chloride product 71 was then extracted into DCM for purification.  
Substitution at the para position is greatly preferred over the ortho position due to steric 
hindrance, giving isomeric ratios of 95:5 or more.  Initial reactions were heated to 100 °C, as 
originally reported, but this actually leads to increased formation of the unwanted ortho product.  
Purification of the para-substituted product was performed by column chromatography.  Despite 
some of the instabilities of the sulfonyl chloride group and the high ratio of para product, it is 
preferable to isolate the desired isomer at this step and not continue directly to subsequent steps.  
This is because it was later discovered that separation of isomers of the various sulfonamides 
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final products was more difficult to achieve, often accomplished by recrystallization, which can 
significantly reduce product yield. 
 
4.2.3 Sulfonamide formation 
 Adding various amines to 71, often at room temperature, readily converts the sulfonyl 
chloride group into a sulfonamide moiety, through nucleophilic substitution.  Reactions 
containing amines in hydrochloride salt form were premixed with an acid trap base, typically 
triethlyamine or N-methylmorpholine, to give the free base form of the amine.  Compound 73 
was accomplished through a similar mechanism to form the sulfonic acid derivative.  However, 
because the oxygen in water is a significantly weaker nucleophile than the other amines used, the 
reaction needed to be heated (~100 °C) to provide enough energy for substitution. 
 
4.2.4 Reductive amination 
 Compounds 88 and 89 were designed to explore the amide and alkyl chains linking the 
two phenyl rings of compound 72.  Compound 88 lacks the carbonyl oxygen, effectively 
changing the amide to an amine.  Compound 89 has an added secondary amine linked to the 
amide in order to potentially increase water solubility.  Both analogs were successfully 
synthesized by reductive amination.  Here, the individual aldehyde and amine starting materials 
were added together in the presence of acetic acid to form the respective imine in situ.  
NaCNBH3 in MeOH was then added as a reducing agent, directly reducing the imine to the 
desired amine in good yield.   
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4.3 Biological Studies 
 As mentioned previously, the NLRP3 inflammasome has been implicated in a variety of 
diseases and disorders.  In particular, it plays a major role in AD, but also cardiac related 
inflammation, namely myocardial infarction, ischemia-reperfusion injury, and peritonitis.  Due to 
the availability of animal resources, murine models of amyloid myocardial infarction (AMI) and 
peritonitis were chosen for biological screening in vivo.  Additionally, two cell lines, both 
expressing the NLRP3 inflammasome, were chosen for in vitro studies: J774.A1 murine 
macrophages and HL-1 cardiomyocytes.  As previously mentioned, compounds 71, 72, 73, and 
87 were initially synthesized and biologically characterized for their effects on cell viability in 
HL-1 cardiomyocytes.  From here, lead compound 72 was assayed extensively for its anti-
inflammatory properties.  The remaining series were then synthesized and screened for IL-1ß 
reduction in J774.A1 macrophages. 
 
4.3.1 Effects on HL-1 cell viability 
To examine compounds 71, 72, 73, and 87 for their effects on NLRP3 inflammasome-
induced cell death, HL-1 cardiomyocytes were used.  HL-1 cells were treated with LPS and ATP 
to induce inflammasome formation, which subsequently leads to a decrease in cell viability.  The 
amount of cell death was measured by the Trypan Blue exclusion method (Figure 21).  
Compounds were dosed before administration of ATP at 400 µM, in accordance with 
Lamkanfi‟s report. Compound 71 showed some protection from LPS/ATP induced cell death, 
consistent with its reported effects on NLRP3 inhibition.
227
  Notably, compound 72 exhibited the 
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strongest protection.  Due to this and the inherent instabilities of the sulfonyl chloride group 
previously mentioned, compound 72 was chosen for further testing. 
 
4.3.2 NLRP3 inflammasome formation prevention in vitro 
Cultured J774.A1 mouse macrophages were treated with LPS followed by ATP to induce 
the formation of the NLRP3 inflammasome, and the release of mature IL-1ß in the supernatant 
was measured (Figure 21).  Treatment with compound 72 significantly limited IL-1ß release after 
LPS and ATP challenge (Figure 21).  To determine whether 72 also inhibited the formation of 
the inflammasome in cardiomyocytes, cultured adult HL-1 cardiomyocytes were treated with 
LPS and ATP, which induces the formation of the NLRP3 inflammasome.  Inflammasome 
activation was measured by immunocytochemistry for ASC aggregates, caspase-1 activity, and 
inflammatory cell death.  All of these effects were prevented or significantly reduced by 
treatment with 72 (Figure 21).  ATP binding to P2X7 receptors leads to K
+
 efflux from the cell 
and subsequent activation of the NLRP3 inflammasome.  Accordingly, addition of nigericin, a 
pore forming toxin allowing for K
+
 efflux, along with LPS also leads to NLRP3 activation, 
independent of the P2X7 receptor.  This pathway of activation was prevented by compound 72, 
as well (Figure 21).  The activation of inflammasomes that use sensors other than NLRP3, but 
are still complexed with caspase-1 (AIM2, triggered by exogenous dual strand DNA; NLRC4, 
triggered by flagellin), were not inhibited by compound 72 (Figure 22).  Together, this 
demonstrates 72s specificity for the NLRP3 inflammasome and shows that its effects are neither 
due to P2X7 interaction nor caspase-1 inhibition. 
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Figure 21. Various effects of glyburide and 72 on markers of inflammasome activation. A. 
Compounds 71 and 72 show better protection of cell death in HL-1 cardiomyocytes compared to 
glyburide 70.  B. LPS/ATP stimulates IL-1ß release in J774.A1 macrophages that is inhibited by 
70 and 72.  C. Comparative ratio of protection of 70 and 72 in HL-1 cells.  D. Caspase-1 activity 
is increased in response to LPS/ATP, which is prevented by 70 and 72.  E. Compounds 70 and 
72 prevent ASC aggregation upon LPS/ATP stimulation.  F and G. Example stains of ASC 
aggregates without LPS/ATP (F) and with LPS/ATP (G). *p<0.05  Adapted from Marchetti et 
al.
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4.3.3 Effects on blood glucose in vivo 
Compared to the glyburide structure, 72 lacks the cyclohexylurea moiety involved in the 
activation of the release of insulin.  As such compound 72 was well tolerated when given at 
doses as high as 500 mg/kg for 7 days, showing no significant effects on survival, body weight, 
appetite, or behavior.  Compound 72 also exhibited no effects on plasma glucose levels, whereas 
glyburide led to a significant reduction in glucose levels as early as 2 h.  Additionally, glyburide 
was lethal within 3 days in 50% of mice treated with 100 mg/kg every 6 h for 3 doses, and in 
100% of mice after daily doses of 500 mg/kg, due to severe hypoglycemia in all cases (Figure 
22).  This further confirms the importance of the cyclohexylurea group for KATP binding and the 
insulin secreting effects of glyburide, which are not seen for 72. 
 
4.3.4 Inhibition of the NLRP3 inflammasome in acute myocardial infarction in mouse 
To determine whether compound 72 inhibited the NLRP3 inflammasome in vivo, a model 
of severe regional myocardial ischemia due to surgical coronary ligation (30 min) followed by 
reperfusion (24 h) was used.  Treatment with 72 led to a significant (>90%) reduction in caspase-
1 activity in heart tissue measured 24 h after ischemia (Figure 24).  A significant reduction in the 
infarct size, measured with TTC (>40% reduction) or troponin I levels (>70% reduction), was 
also observed when compared with vehicle alone (Figure 24).  This demonstrates compound 72‟s 
effectiveness in vivo. 
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Figure 22. Effects of 72 on NLRC4 and AIM2 inflammasome stimulation and blood glucose. A 
and B. Compound 72 prevents cell death and reduces caspase-1 activity in HL-1 cardiomyocytes 
stimulated with LPS/Nigericin, which activates the NLRP3 inflammasome. C and D. Flagellin 
and Poly:dAdT induce cell death and caspase-1 activation in HL-1 through the NLRC4 and 
AIM2 inflammasomes, respectively, both of which are unaffected by addition of 72.  E. 
Compound 72 does not significantly change glucose levels after 2 h after a single dose (100 
mg/kg), compared to glyburide (132.5 mg/kg equimolar to 72).  F. Glyburide shows 50% 
mortality in healthy CD1 mice after 48 h.  Compound 72 exhibited no effects mortality.  Both 
were dosed every 6 h for 24 h total. *p<0.05  Adapted from Marchetti et al.
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4.3.5 Inhibition of the NLRP3 inflammasome in a model of acute peritonitis in mouse 
Inflammation of the peritoneum, known as peritonitis, is known to be dependent on 
NLRP3 activation.  In order to determine if compound 72 can inhibit the NLRP3 inflammasome 
in vivo independent of the effects of myocardial ischemia/infarction, zymosan A was used to 
induce peritonitis in the mouse.  Pre-treatment with 72 (5, 20, and 100 mg/kg) limited the 
severity of the peritonitis in a dose-dependent manner, as measured by the intensity of leukocyte 
infiltration in the peritoneal cavity (Figure 23).  Together with the AMI results, these further 
exhibit compound 72‟s activity on the NLRP3 inflammasome in vivo, independent of the 
inflammatory stimulus. 
 
Figure 23. Effects of 72 in a model of acute peritonitis in the mouse. A schematic of the study 
design is provided.  A significant increase in the number of cells recovered from the peritoneal 
cavity was examined 6 h after treatment with zymosan, which was significantly reduced by 
treatment with 72 or glyburide. Adapted from Marchetti et al.
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Figure 24. Effects of 72 in a model of acute myocardial infarction in the mouse. A and B. 
Representative images of the TTC staining for infarct size, and a representative scheme of the 
AMI assay.  C and D. Compound 72 shows significant reduction in infarct size without 
difference in area-at-risk.  E. Compound 72 reduces caspase-1 activity in the heart 24 h after 
ischemia-reperfusion.  F. Serum cardiac troponin I levels are greatly increased after ischemia-
reperfusion, which is significantly prevented by 72.  * p < 0.05  Adapted from Marchetti et al.
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4.3.6 Inhibition of IL-1ß production in J774.A1 murine macrophages 
 Compounds 71-89 were assayed for their ability to reduce IL-1ß release in J774.A1 cells 
upon stimulation with LPS and ATP (Figure 25 and Table 2).  Cells were treated with LPS and 
ATP as previously described, and all compounds were dosed at 50 µM.  The relative ability of 
compounds to reduce IL-1ß release compared to the LPS/ATP control is given in Table 2.  
Notably, all compounds exhibit some activity in decreasing of IL-1ß concentration, the worst 
being compound 84 reducing to only 66%.  The top compounds, 76, 87, and 80, showed slightly 
higher inhibitory ability compared to 72.  Structurally, these compounds are very similar to 72.  
Addition of methyl groups to the sulfonamide, compounds 76 and 77, both exhibited protection 
greater than 70% and seem to be well tolerated.  Larger substituents, 74 and 75, significantly 
decreased activity, indicating too much bulk cannot be added to the sulfonamide portion of the 
compound.  Interestingly, the hydrazine analog 79 was less effective than 72, whereas the 
hydroxamate analog 80 displayed stronger activity than 72.  This may suggest that 80 is acting as 
a pro-drug, masking compound 72, or that the electronic properties of the oxygen atom is 
preferable to the nitrogen.  The sulfonic acid 73 also decreased IL-1ß, although it was not 
effective in rescuing cell death in HL-1 cells, shown in Figure 21.  Compounds 81 and 83, both 
lacking the methoxy group, were much less active than 72.  Compound 82, without the chloro 
group, while not as active as 72, was still more effective than 81 and 83.  The hydroxy analog 84 
exhibited the lowest degree of activity, and the methylamine analog 86 showed moderate 
activity.  Together, these indicate the importance of the methoxy group to activity.  Incorporation 
of a nitrogen atom into the ring 85 also led to a loss of inhibition.  Addition of an amine group 
into the chain linking the two rings 89 had no effect on function, while reduction of the amide to 
an amine 88 significantly reduced activity.  Despite 87‟s apparent effectiveness, it was 
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previously shown to have no effect in prior assays (Figure 21), highlighting the importance of the 
sulfonamide moiety.  
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Figure 25. Screening of full series of glyburide analogs against IL-1ß release. The full series of 
glyburide analogs assayed for their prevention of IL-1ß release in J774.A1 cells stimulated with 
LPS and ATP.  Compounds were dosed at 50 µM. 
 
Table 2. Inhibition of IL-1ß release expressed as % inhibition compared to control. Data as seen 
in Figure 25 are expressed as percent inhibition compared to the LPS/ATP control with SEM. 
 
Compound % Inhibition SEM
Ctrl 0.59% 0.03%
LPS+ATP 100.00% 6.35%
71 44.29% 17.69%
72 17.56% 7.23%
73 30.85% 6.12%
74 61.68% 23.94%
75 55.54% 4.07%
76 6.44% 1.75%
77 27.11% 6.50%
79 43.95% 14.19%
80 9.91% 3.99%
81 47.46% 3.25%
82 21.81% 7.68%
83 48.13% 0.07%
84 65.70% 20.97%
85 24.91% 6.69%
86 31.88% 1.65%
87 8.92% 2.55%
88 47.58% 3.77%
89 17.63% 6.17%  
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4.4 Conclusion 
 The NLRP3 inflammasome is a central mediator in inflammatory response in a variety of 
diseases and pathologies, including myocardial infarction and AD.
229
  Glyburide, a common anti-
diabetic medication, has been known to have anti-inflammatory properties, specifically reducing 
the production IL-1ß.
227
  Here, a series of glyburide analogs were synthesized and screened for 
their NLRP3 inhibiting effects.  Compound 72 was shown to inhibit production of IL-1ß, prevent 
ASC aggregation, and reduce caspase-1 activity, all of which are related to formation of the 
NLRP3 inflammasome.  Furthermore, compound 72 reduced infarct size and prevented 
leukocyte migration in the peritoneum in vivo.  In addition to compound 72, compounds 76, 80, 
and 89 all showed a similar, if not stronger, efficacy in reducing IL-1ß production in J774.A1 
macrophages.   
Further exploration into optimization for more potent analogs is certainly warranted.  
Compounds incorporating groups with the potential to form covalent bonds could aid in 
structural biology assays investigating the exact binding mode and position of these analogs.  
This would provide value information aiding in the rational optimization of this scaffold.  
Additionally, assays looking at microglial inflammasome activation would confirm the potential 
of these compounds for use in neuroinflammatory models.  BBB penetration would also need to 
be addressed.  Based on the positive in vivo results seen here, formal toxicology studies are 
necessary, as well, if further preclinical studies are to be conducted.  Altogether, these analogs 
represent the first class of NLRP3 inhibitors reported to have activity both in vitro and in vivo.    
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5 Experimental Methods 
5.1 Chemical Syntheses 
Reagents and solvents were obtained from commercial suppliers and used as received 
unless otherwise indicated. Reactions were monitored by thin-layer chromatography (TLC) 
(precoated silica gel 60F254 plates, EMD Chemicals) and visualized with UV light or by 
treatment with phosphomolybdic acid (PMA), ninhydrin, or iodine. Column chromatography 
was performed on silica gel (200-300 mesh, Fisher Scientific) using solvents as indicated. 
1
H 
NMR and 
13
C NMR spectra were routinely recorded on a Bruker ARX 400 spectrometer. The 
NMR solvent used was CDCl3 or d6-DMSO as indicated. Tetramethylsilane (TMS) was used as 
the internal standard. Infrared spectra were obtained on a Thermo Nicolet FT-IR with a Smart 
iTR attachment.  Exact masses were identified using a PerkinElmer AxION 2 TOF mass 
spectrometer.  The purity of target compounds was determined by HPLC using a Varian 100-5 
C18 250×4.6 mm column with UV detection (280 nm and 360 nm for hybrid compounds, and 
350nm and 440nm for bivalent compounds and NLRP3 inhibitors) (50% H2O in acetonitrile and 
0.1% TFA, and 30-50% H2O in methanol and 0.1% TFA, for hybrid compounds; 30% 
acetonitrile in methanol, for bivalent compounds; 50% acetonitrile in H2O, for NLRP3 
inhibitors) to be ≥ 95%.  
5.1.1 Bivalent Compounds 
 2-(2-(2-azidoethoxy)ethoxy)ethanol (23). Triethylene glycol 22 (50 g, 333 mmol) was 
added to THF (450 mL) and Et3N (69.6 mL, 499 mmol), and cooled to 0 °C for 30 min. To this, 
mesyl chloride (12.8 mL, 166 mmol) diluted in THF (50 mL) was added slowly, dropwise, over 
3 h.  The solution was then allowed to warm to room temperature and stirred for another 3 h.  
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The solution was then concentrated under reduced pressure.  The resulting concentrate was then 
dissolved in a 95% EtOH/5% H2O solution (200 mL).  To this solution, NaN3 (16.2 g, 249 
mmol) was added, and the solution was refluxed overnight.  The solution was then concentrated 
again under reduced pressure, and then dissolved in Et2O and washed thrice with H2O.  The ether 
layer was then dried and concentrated.  The crude residue was purified by column 
chromatography (EtOAc/Hexanes: 10/90 to 60/40) to give 23 (21.5 g, 37%) as a yellow oil.  The 
double substituted side product 1,2-bis(2-azidoethoxy)ethane 48 (4.1 g, 5%) was also collected 
as a yellow oil. 
1
H NMR (400 MHz, CDCl3) δ 3.74 (t, J = 5.30 Hz, 2H), 3.67 - 3.71 (m, 6H), 
3.61 (t, J = 4.50 Hz, 2H), 3.41 (t, J = 5.20 Hz, 2H). 
 tert-butyl 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy) acetate (24). Compound 23 (10 g, 57 
mmol) was dissolved in THF and cooled to 0 °C.  To this, NaH (1.5 g, 63 mmol) was added and 
the reaction was stirred for 30 min, and then allowed to warm to room temperature.  Then tert-
butyl bromoacetate (10.52 mL, 71.25 mmol) was added, and the reaction was heated to reflux for 
4 h.  The reaction was then cooled to room temperature and quenched with H2O.  The solution 
was then concentrated, and more H2O was added.  The product was then extracted into EtOAc, 
and the organic layer was concentrated under reduced pressure. The crude residue was purified 
by column chromatography (EtOAc/Hexanes: 20/80 to 60/40) to give 24 (1.51 g, 30%) as a 
yellow oil.  
1
H NMR (400 MHz, CDCl3) δ 4.03 (s, 2H), 3.65 - 3.74 (m, 10H), 3.39 (t, J = 5.02 
Hz, 2H), 1.48 (s, 9H). 
 tert-butyl 2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy) acetate (25). Compound 24 (1.5 g, 5.2 
mmol) was dissolved in THF (10 mL) and then triphenylphosphine (2.72 g, 10.4 mmol) was 
added, and the reaction was stirred for 4 h at room temperature.  H2O was then added to quench 
the reaction.  THF was removed under reduced pressure, and the remaining water layer was 
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basified to pH 10.  The product was then extracted into DCM.  The organic layer then 
concentrated, and the resulting residue was purified by column chromatography 
(EtOAc/Hexanes: 50/50 to 95/5) to afford 25 (1.1 g, 78%) as a viscous oil.  
1
H NMR (400 MHz, 
CDCl3) δ 4.02 (s, 2H), 3.68 - 3.73 (m, 4H), 3.62 - 3.68 (m, 4H), 3.51 (t, J = 5.20 Hz, 2H), 2.86 (t, 
J = 5.20 Hz, 2H). 
 Procedure A. 5-azidopentanoic acid (26).  5-bromovaleric acid (2 g, 11.0 mmol) was 
dissolved in DMF (40 mL) and H2O (10 mL), and cooled to 0 °C.  NaN3 (1.79 g, 27.5 mmol) 
was then added, and the reaction was stirred for 30 min.  The reaction was then allowed to warm 
to room temperature and stirred overnight.  The reaction was then acidified to pH 3, and the 
product was extracted into Et2O.  The organic layer was then washed extensively with acidified 
H2O, and concentrated to give 26 (740 mg, 47%) as a clear oil.  Azide was confirmed by IR 
absorbance band at 2100 cm
-1
.  
1
H NMR (400 MHz, CDCl3) δ 10.27 (br. s, 1H), 3.31 (t, J = 6.53 
Hz, 2H), 2.40 (t, J = 7.00 Hz, 2H), 1.63 - 1.76 (m, 4H). 
 6-azidohexanoic acid (27). 6-bromohexanoic acid (4 g, 20.5 mmol) was reacted with 
NaN3 (2.67 g, 41.0 mmol) following Procedure A to give 27 (3.2 g, 90%). 
1
H NMR (400 MHz, 
CDCl3) δ 6.72 (br. s, 1H), 3.28 (t, J = 6.90 Hz, 2H), 2.33 (t, J = 7.40 Hz, 2H), 1.59 - 1.70 (m, 
4H), 1.38 - 1.50 (m, 2H). 
 8-azidooctanoic acid (28). 8-bromooctanoic acid (2 g, 8.96 mmol) was reacted with NaN3 
(1.17 g, 17.9 mmol) following Procedure A to give 28 (1.49 g, 89%). 
1
H NMR (400 MHz, 
CDCl3) δ 10.44 (br. s, 1H), 3.26 (t, J = 6.90 Hz, 2H), 2.34 (t, J = 7.53 Hz, 2H), 1.54 - 1.69 (m, 
4H), 1.30 - 1.43 (m, 6H). 
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 10-azidodecanoic acid (29). 10-bromodecanoic acid (1 g, 4.00 mmol) was reacted with 
NaN3 (648 mg, 10.0 mmol) following Procedure A to give 29 (760 mg, 90%). 
1
H NMR (400 
MHz, CDCl3) δ 10.89 (br. s, 1H), 3.26 (t, J = 7.03 Hz, 2H), 2.35 (t, J = 7.53 Hz, 2H), 1.54 - 1.69 
(m, 4H), 1.28 - 1.37 (m, 10H). 
 12-azidododecanoic acid (30). 12-bromododecanoic acid (1 g, 3.59 mmol) was reacted 
with NaN3 (583 mg, 8.97 mmol) following Procedure A to give 30 (590 mg, 68%). 
1
H NMR 
(400 MHz, CDCl3) δ 10.92 (br. s, 1H), 3.26 (t, J = 7.03 Hz, 2H), 2.35 (t, J = 7.53 Hz, 2H), 1.55 - 
1.68 (m, 4H), 1.27 - 1.38 (m, 14H). 
 Procedure B. tert-butyl 2-(2-(2-(2-(5-azidopentanamido)ethoxy)ethoxy)ethoxy) acetate 
(31). Compound 26 (300 mg, 1.14 mmol) and Et3N (318 µL, 2.28 mmol) were dissolved in DMF 
(25 mL), and cooled to 0 °C.  EDC (328 mg, 1.71 mmol) was then added.  After 30 min, HOBt 
(231 mg, 1.71 mmol) was then added.  After another 30 min, compound 25 was then added.  The 
reaction was then allowed to warm to room temperature and stirred overnight.  The solution was 
then concentrated under reduced pressure.  H2O was then added and the product was extracted 
into EtOAc.  The organic layer was then concentrated, and the crude residue was purified by 
column chromatography (DCM/MeOH: 100/0 to 95/5) to afford 31 (330 mg, 75%) as a viscous 
oil. 
1
H NMR (400 MHz, CDCl3) δ 6.30 (br. s, 1H), 4.02 (s, 2H), 3.68 - 3.74 (m, 4H), 3.61 - 3.68 
(m, 4H), 3.56 (t, J = 5.00 Hz, 2H), 3.45 (q, J = 5.20 Hz, 2H), 3.29 (t, J = 6.80 Hz, 2H), 2.23 (t, J 
= 7.20 Hz, 2H), 1.69 - 1.75 (m, 2H), 1.61 - 1.67 (m, 2H), 1.48 (s, 9H). 
 tert-butyl 2-(2-(2-(2-(6-azidohexanamido)ethoxy)ethoxy)ethoxy) acetate (32). Compound 
27 (239 mg, 1.52 mmol) was reacted with compound 25 (400 mg, 1.52 mmol) following 
Procedure B to give 32 (376 mg, 62%). 
1
H NMR (400 MHz, CDCl3) δ 6.21 (br. s, 1H), 4.02 (s, 
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2H), 3.68 - 3.74 (m, 4H), 3.61 - 3.68 (m, 4H), 3.56 (t, J = 5.14 Hz, 2H), 3.45 (q, J = 5.19 Hz, 
2H), 3.27 (t, J = 6.90 Hz, 2H), 2.20 (t, J = 7.40 Hz, 2H), 1.57 - 1.72 (m, 4H), 1.48 (s, 9H), 1.38 - 
1.45 (m, 2H). 
 tert-butyl 2-(2-(2-(2-(8-azidooctanamido)ethoxy)ethoxy)ethoxy) acetate (33). Compound 
28 (282 mg, 1.52 mmol) was reacted with compound 25 (400 mg, 1.52 mmol) following 
Procedure B to give 33 (170 mg, 26%). 
1
H NMR (400 MHz, CDCl3) δ 6.19 (br. s, 1H), 4.04 (s, 
2H), 3.70 - 3.77 (m, 4H), 3.63 - 3.70 (m, 4H), 3.58 (t, J = 5.02 Hz, 2H), 3.47 (q, J = 5.35 Hz, 
2H), 3.27 (t, J = 6.90 Hz, 2H), 2.20 (t, J = 7.53 Hz, 2H), 1.57 - 1.70 (m, 4H), 1.50 (s, 9H), 1.32 - 
1.43 (m, 6H). 
 tert-butyl 2-(2-(2-(2-(10-azidodecanamido)ethoxy)ethoxy)ethoxy) acetate (34). 
Compound 29 (325 mg, 1.52 mmol) was reacted with compound 25 (400 mg, 1.52 mmol) 
following Procedure B to give 34 (490 mg, 70%). 
1
H NMR (400 MHz, CDCl3) δ 6.27 (br. s, 1H), 
4.02 (s, 2H), 3.68 - 3.75 (m, 4H), 3.61 - 3.68 (m, 4H), 3.56 (t, J = 5.00 Hz, 2H), 3.45 (q, J = 5.27 
Hz, 2H), 3.25 (t, J = 6.90 Hz, 2H), 2.18 (t, J = 7.65 Hz, 2H), 1.52 - 1.66 (m, 4H), 1.48 (s, 9H), 
1.27 - 1.37 (m, 10H). 
 tert-butyl 2-(2-(2-(2-(12-azidododecanamido)ethoxy)ethoxy)ethoxy) acetate (35). 
Compound 30 (366 mg, 1.52 mmol) was reacted with compound 25 (400 mg, 1.52 mmol) 
following Procedure B to give 35 (400 mg, 54%). 
1
H NMR (400 MHz, CDCl3) δ 6.14 (br. s, 1H), 
4.02 (s, 2H), 3.68 - 3.75 (m, 4H), 3.61 - 3.68 (m, 4H), 3.56 (t, J = 5.00 Hz, 2H), 3.45 (q, J = 5.02 
Hz, 2H), 3.25 (t, J = 7.03 Hz, 2H), 2.17 (t, J = 7.50 Hz, 2H), 1.56 - 1.67 (m, 4H), 1.48 (s, 9H), 
1.25 - 1.35 (m, 14H). 
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Procedure C. 2-(2-(2-(2-(5-azidopentanamido)ethoxy)ethoxy)ethoxy) acetic acid (36). 
Compound 31 (330 mg, 0.85 mmol) was dissolved in a 10% TFA in DCM solution (5 mL) and 
stirred overnight at room temperature.  The solution was concentrated under reduced pressure, 
and then washed extensively with Heptane to remove any residual TFA. After the final 
concentration, compound 36 was left as a viscous oil in quantitative yield. 
1
H NMR (400 MHz, 
CDCl3) δ 6.99 (br. s., 1H), 6.30 (br. s., 1H), 4.19 (s, 2H), 3.78 - 3.82 (m, 2H), 3.68 - 3.75 (m, 
4H), 3.63 - 3.66 (m, 2H), 3.57 (t, J = 4.70 Hz, 2H), 3.50 (q, J = 4.85 Hz, 2H), 3.29 (t, J = 6.65 
Hz, 2H), 2.39 (t, J = 7.40 Hz, 2H), 1.68 - 1.77 (m, 2H), 1.59 - 1.68 (m, 2H). 
2-(2-(2-(2-(6-azidohexanamido)ethoxy)ethoxy)ethoxy) acetic acid (37). Compound 32 
(367 mg, 0.91 mmol) was deprotected following Procedure C giving compound 37 as a viscous 
oil in quantitative yield. 
1
H NMR (400 MHz, CDCl3) δ 7.93 (br. s., 1H), 7.11 (br. s., 1H), 4.20 (s, 
2H), 3.78 - 3.83 (m, 2H), 3.69 - 3.75 (m, 4H), 3.64 - 3.68 (m, 2H), 3.59 (t, J = 4.70 Hz, 2H), 3.48 
- 3.54 (m, 2H), 3.27 (t, J = 6.78 Hz, 2H), 2.39 (t, J = 7.50 Hz, 2H), 1.55 - 1.72 (m, 4H), 1.35 - 
1.47 (m, 2H). 
2-(2-(2-(2-(8-azidooctanamido)ethoxy)ethoxy)ethoxy) acetic acid (38). Compound 33 
(170 mg, 0.45 mmol) was deprotected following Procedure C giving compound 38 as a viscous 
oil in quantitative yield. 
1
H NMR (400 MHz, CDCl3) δ 6.77 (br. s., 2H), 4.18 (s, 2H), 3.77 - 3.81 
(m, 2H), 3.68 - 3.73 (m, 4H), 3.62 - 3.66 (m, 2H), 3.57 (t, J = 4.70 Hz, 2H), 3.48 (q, J = 4.68 Hz, 
2H), 3.25 (t, J = 6.90 Hz, 2H), 2.30 (t, J = 7.40 Hz, 2H), 1.54 - 1.68 (m, 4H), 1.31 - 1.38 (m, 6H).  
2-(2-(2-(2-(10-azidodecanamido)ethoxy)ethoxy)ethoxy) acetic acid (39). Compound 34 
(490 mg, 1.22 mmol) was deprotected following Procedure C giving compound 39 as a viscous 
oil in quantitative yield. 
1
H NMR (400 MHz, CDCl3) δ 6.97 (br. s., 2H), 4.19 (s, 2H), 3.78 - 3.82 
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(m, 2H), 3.68 - 3.74 (m, 4H), 3.63 - 3.66 (m, 2H), 3.58 (t, J = 4.80 Hz, 2H), 3.50 (q, J = 4.80 Hz, 
2H), 3.25 (t, J = 7.03 Hz, 2H), 2.35 (t, J = 7.78 Hz, 2H), 1.48 - 1.67 (m, 4H), 1.25 - 1.35 (m, 
10H). 
2-(2-(2-(2-(12-azidododecanamido)ethoxy)ethoxy)ethoxy) acetic acid (40). Compound 
35 (400 mg, 0.82 mmol) was deprotected following Procedure C giving compound 40 as a 
viscous oil in quantitative yield. 
1
H NMR (400 MHz, CDCl3) δ 7.00 (br. s., 1H), 6.80 (br. s., 1H), 
4.18 (s, 2H), 3.78 - 3.81 (m, 2H), 3.68 - 3.74 (m, 4H), 3.62 - 3.66 (m, 2H), 3.57 (t, J = 4.80 Hz, 
2H), 3.49 (q, J = 4.77 Hz, 2H), 3.25 (t, J = 7.03 Hz, 2H), 2.32 (t, J = 7.60 Hz, 2H), 1.54 - 1.67 
(m, 4H), 1.25 - 1.36 (m, 14H). 
Procedure D. (1'S,2R,2'S,4'S,5R,7'S,8'R,9'S,12'S,13'R,16'S)-5,7',9',13'-tetramethyl-5'-
oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0
2
,
9
.0
4
,
8
.0
13
,
18
]icosan]-18'-en-16'-yl 2-(2-(2-(2-(5-
azidopentanamido)ethoxy)ethoxy)ethoxy)acetate (41). Compound 36 (250 mg, 0.75 mmol) and 
DCC (171 mg, 0.83 mmol) were dissolved in DCM (10 mL) and cooled to 0 °C.  To this 
solution, diosgenin 4 (344 mg, 0.83 mmol) was added.  DMAP (46 mg, 0.38 mmol) was then 
added, and the reaction was allowed to warm to room temperature and stirred overnight.  The 
organic layer was concentrated under reduced pressure.  The remaining solid was dissolved in 
EtOAc and cooled to 4 °C for 2 h.  Then solution was then filtered again to remove residual 
DCC.  The remaining solution was purified by column chromatography (1. EtOAc/Hexanes: 
50/50; 2. DCM/MeOH: 100/0 to 97/3) giving compound 41 (140 mg, 25%) as a white solid. 
1
H 
NMR (400 MHz, CDCl3) δ 6.25 (br. s., 1H), 5.38 (d, J = 4.52 Hz, 1H), 4.64 - 4.75 (m, 1H), 4.41 
(q, J = 7.50 Hz, 1H), 4.12 (s, 2H), 3.68 - 3.76 (m, 4H), 3.61 - 3.67 (m, 4H), 3.56 (t, J = 5.00 Hz, 
2H), 3.45 (q, J = 5.20 Hz, 2H), 3.37 (t, J = 11.00 Hz, 1H), 3.29 (t, J = 6.78 Hz, 2H), 2.34 (d, J = 
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7.78 Hz, 2H), 2.22 (t, J = 7.28 Hz, 2H), 1.94 - 2.05 (m, 2H), 1.82 - 1.92 (m, 3H), 1.41 - 1.81 (m, 
19H), 1.24 - 1.28 (m, 2H), 1.04 (s, 3H), 0.97 (d, J = 7.03 Hz, 4H), 0.79 (t, J = 3.14 Hz, 6H). 
(1'S,2R,2'S,4'S,5R,7'S,8'R,9'S,12'S,13'R,16'S)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-
2,6'-pentacyclo[10.8.0.0
2
,
9
.0
4
,
8
.0
13
,
18
]icosan]-18'-en-16'-yl 2-(2-(2-(2-(6-
azidohexanamido)ethoxy)ethoxy)ethoxy)acetate (42). Compound 37 (423 mg, 1.22 mmol) was 
reacted with diosgenin 4 (556 mg, 1.34 mmol) following Procedure D yielding compound 42 
(276 mg, 30%) as a white solid. 
1
H NMR (400 MHz, CDCl3) δ 6.14 (br. s., 1H), 5.38 (d, J = 4.52 
Hz, 1H), 4.63 - 4.74 (m, 1H), 4.41 (q, J = 7.40 Hz, 1H), 4.11 (s, 2H), 3.68 - 3.75 (m, 4H), 3.61 - 
3.67 (m, 4H), 3.56 (t, J = 5.02 Hz, 2H), 3.45 (q, J = 5.02 Hz, 2H), 3.37 (t, J = 11.00 Hz, 1H), 3.27 
(t, J = 6.90 Hz, 2H), 2.34 (d, J = 8.03 Hz, 2H), 2.19 (t, J = 7.53 Hz, 2H), 1.95 - 2.05 (m, 2H), 
1.83 - 1.92 (m, 3H), 1.62 - 1.80 (m, 9H), 1.36 - 1.55 (m, 7H), 1.07 - 1.34 (m, 7H), 1.04 (s, 3H), 
0.97 (d, J = 6.78 Hz, 4H), 0.79 (t, J = 3.14 Hz, 6H). 
(1'S,2R,2'S,4'S,5R,7'S,8'R,9'S,12'S,13'R,16'S)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-
2,6'-pentacyclo[10.8.0.0
2
,
9
.0
4
,
8
.0
13
,
18
]icosan]-18'-en-16'-yl 2-(2-(2-(2-(8-
azidooctanamido)ethoxy)ethoxy)ethoxy)acetate (43). Compound 38 (151 mg, 0.40 mmol) was 
reacted with diosgenin 4 (182 mg, 0.44 mmol) following Procedure D yielding compound 43 
(213 mg, 68%) as a white solid. 
1
H NMR (400 MHz, CDCl3) δ 6.12 (br. s., 1H), 5.38 (d, J = 5.02 
Hz, 1H), 4.64 - 4.74 (m, 1H), 4.41 (q, J = 7.50 Hz, 1H), 4.11 (s, 2H), 3.68 - 3.75 (m, 4H), 3.61 - 
3.68 (m, 4H), 3.56 (t, J = 5.00 Hz, 2H), 3.45 (q, J = 4.50 Hz, 2H), 3.37 (t, J = 11.00 Hz, 1H), 3.25 
(t, J = 6.90 Hz, 2H), 2.34 (d, J = 7.53 Hz, 2H), 2.18 (t, J = 7.40 Hz, 2H), 1.94 - 2.03 (m, 2H), 
1.82 - 1.92 (m, 3H), 1.61 - 1.81 (m, 11H), 1.07 - 1.53 (m, 16H), 1.04 (s, 3H), 0.97 (d, J = 7.03 
Hz, 4H), 0.79 (t, J = 3.14 Hz, 6H). 
  
96 
 
(1'S,2R,2'S,4'S,5R,7'S,8'R,9'S,12'S,13'R,16'S)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-
2,6'-pentacyclo[10.8.0.0
2
,
9
.0
4
,
8
.0
13
,
18
]icosan]-18'-en-16'-yl 2-(2-(2-(2-(10-
azidodecanamido)ethoxy)ethoxy)ethoxy)acetate (44). Compound 39 (545 mg, 1.35 mmol) was 
reacted with diosgenin 4 (618 mg, 1.49 mmol) following Procedure D yielding compound 44 
(405 mg, 37%) as a white solid. 
1
H NMR (400 MHz, CDCl3) δ 6.09 (br. s., 1H), 5.38 (d, J = 4.02 
Hz, 1H), 4.64 - 4.74 (m, 1H), 4.41 (q, J = 6.53 Hz, 1H), 4.11 (s, 2H), 3.68 - 3.76 (m, 4H), 3.60 - 
3.68 (m, 4H), 3.56 (t, J = 5.02 Hz, 2H), 3.45 (q, J = 5.27 Hz, 2H), 3.34 - 3.41 (m, 1H), 3.25 (t, J 
= 6.90 Hz, 2H), 2.34 (d, J = 7.28 Hz, 2H), 2.14 - 2.21 (m, J = 7.40, 7.40 Hz, 2H), 1.93 - 2.06 (m, 
2H), 1.83 - 1.89 (m, 3H), 1.50 - 1.80 (m, 17H), 1.08 - 1.38 (m, 14H), 1.04 (s, 3H), 0.97 (d, J = 
7.03 Hz, 4H), 0.79 (t, J = 2.80 Hz, 6H). 
(1'S,2R,2'S,4'S,5R,7'S,8'R,9'S,12'S,13'R,16'S)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-
2,6'-pentacyclo[10.8.0.0
2
,
9
.0
4
,
8
.0
13
,
18
]icosan]-18'-en-16'-yl 2-(2-(2-(2-(12-
azidododecanamido)ethoxy)ethoxy)ethoxy)acetate (45). Compound 40 (381 mg, 0.89 mmol) was 
reacted with diosgenin 4 (402 mg, 0.97 mmol) following Procedure D yielding compound 45 
(391 mg, 53%) as a white solid. 
1
H NMR (400 MHz, CDCl3) δ 6.09 (br. s., 1H), 5.38 (d, J = 5.02 
Hz, 1H), 4.64 - 4.74 (m, 1H), 4.41 (q, J = 7.50 Hz, 1H), 4.11 (s, 2H), 3.68 - 3.75 (m, 4H), 3.61 - 
3.68 (m, 4H), 3.56 (t, J = 5.00 Hz, 2H), 3.45 (q, J = 5.20 Hz, 2H), 3.37 (t, J = 11.00 Hz, 1H), 3.25 
(t, J = 7.03 Hz, 2H), 2.34 (d, J = 7.53 Hz, 2H), 2.17 (t, J = 7.50 Hz, 2H), 1.94 - 2.03 (m, 2H), 
1.83 - 1.92 (m, 3H), 1.53 - 1.81 (m, 16H), 1.12 - 1.36 (m, 19H), 1.04 (s, 3H), 0.97 (d, J = 6.78 
Hz, 4H), 0.79 (t, J = 3.14 Hz, 6H). 
Procedure E. (1'S,2R,2'S,4'S,5R,7'S,8'R,9'S,12'S,13'R,16'S)-5,7',9',13'-tetramethyl-5'-
oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0
2
,
9
.0
4
,
8
.0
13
,
18
]icosan]-18'-en-16'-yl 2-(2-(2-[2-(5-(4-
[(2Z,4E)-2-[(2E)-1-hydroxy-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-ylidene]-5-(4-
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hydroxy-3-methoxyphenyl)-3-oxopent-4-en-1-yl]-1H-1,2,3-triazol-1-
yl)pentanamido)ethoxy]ethoxy)ethoxy)acetate (8). Compound 41 (30 mg, 0.041 mmol) and 
compound 46 (18 mg, 0.045 mmol) were added together in a 50/50 THF/H2O solution (2 mL).  
CuSO4 (6.5 mg, 0.041 mmol) and sodium ascorbate (8.1 mg, 0.041 mmol) were then added, and 
the reaction was stirred at 35 °C for 24 h.  More H2O was added, and the product was extracted 
into EtOAc.  The organic layer was then concentrated under reduced pressure.  The remaining 
solid was purified by column chromatography (DCM/MeOH: 100/0 to 95/5) to afford compound 
8 (45 mg, 96%) as a dark orange solid. 
1
H NMR (400 MHz, CDCl3) δ 7.69 (d, J = 15.31 Hz, 1H), 
7.59 (d, J = 15.81 Hz, 1H), 7.35 (s, 1H), 7.09 (dd, J = 1.76, 8.28 Hz, 2H), 7.02 (dd, J = 1.76, 7.03 
Hz, 2H), 6.93 (s, 1H), 6.90 (dd, J = 0.75, 8.28 Hz, 2H), 6.69 (d, J = 16.06 Hz, 1H), 6.31 (br. s., 
1H), 5.36 (br. s., 1H), 4.67 (s, 1H), 4.41 (q, J = 7.53 Hz, 1H), 4.27 (t, J = 7.15 Hz, 2H), 4.06 (s, 
1H), 4.08 (d, J = 9.29 Hz, 2H), 3.93 (s, 3H), 3.91 (s, 3H), 3.60 - 3.73 (m, 8H), 3.54 (t, J = 4.89 
Hz, 2H), 3.34 - 3.50 (m, 6H), 2.33 (d, J = 7.03 Hz, 2H), 2.09 (s, 2H), 1.95 - 2.01 (m, 2H), 1.83 - 
1.89 (m, 4H), 1.47 - 1.75 (m, 18H), 1.19 - 1.28 (m, 3H), 1.02 (d, J = 2.26 Hz, 3H), 0.97 (d, J = 
6.78 Hz, 4H), 0.76 - 0.81 (m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 194.5, 183.2, 169.9, 148.8, 
148.2, 147.0, 147.0, 145.1, 142.4, 139.4, 127.9, 126.8, 124.2, 123.3, 122.7, 122.2, 118.0, 115.0, 
109.9, 109.3, 80.8, 70.9, 70.6, 70.2, 69.9, 66.9, 62.2, 56.5, 56.2, 56.1, 50.0, 41.7, 40.3, 39.8, 39.3, 
38.1, 36.9, 36.8, 35.3, 32.1, 31.9, 31.5, 30.3, 29.7, 28.9, 27.8, 24.8, 22.4, 20.9, 19.3, 17.1, 16.3, 
14.5. 
 (1'S,2R,2'S,4'S,5R,7'S,8'R,9'S,12'S,13'R,16'S)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-
2,6'-pentacyclo[10.8.0.0
2
,
9
.0
4
,
8
.0
13
,
18
]icosan]-18'-en-16'-yl 2-(2-(2-[2-(6-(4-[(2Z,4E)-2-[(2E)-1-
hydroxy-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-ylidene]-5-(4-hydroxy-3-methoxyphenyl)-
3-oxopent-4-en-1-yl]-1H-1,2,3-triazol-1-yl)hexanamido)ethoxy]ethoxy)ethoxy)acetate (9). 
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Compound 42 (35 mg, 0.047 mmol) was reacted with compound 46 (21 mg, 0.052 mmol) 
following Procedure D affording compound 9 (32 mg, 59%) as a dark orange solid. 
1
H NMR 
(400 MHz, CDCl3) δ 7.69 (d, J = 15.31 Hz, 1H), 7.58 (d, J = 15.81 Hz, 1H), 7.33 (s, 1H), 7.07 
(dd, J = 1.51, 8.28 Hz, 2H), 7.01 (dd, J = 1.63, 8.41 Hz, 2H), 6.90 (dd, J = 2.26, 8.28 Hz, 2H), 
6.88 (d, J = 15.06 Hz, 1H), 6.68 (d, J = 15.81 Hz, 1H), 6.01 - 6.24 (m, 1H), 5.36 (br. s., 1H), 4.66 
(t, J = 9.29 Hz, 1H), 4.41 (q, J = 6.90 Hz, 1H), 4.25 (q, J = 6.86 Hz, 2H), 4.04 - 4.12 (m, 3H), 
3.92 (s, 3H), 3.89 (s, 3H), 3.60 - 3.75 (m, 9H), 3.54 (q, J = 4.80 Hz, 2H), 3.36 - 3.46 (m, 4H), 
2.32 (t, J = 6.80 Hz, 2H), 2.06 (t, J = 7.53 Hz, 1H), 1.92 - 2.03 (m, 3H), 1.73 - 1.89 (m, 7H), 1.43 
- 1.64 (m, 12H), 1.05 - 1.33 (m, 8H), 1.02 (d, J = 2.26 Hz, 4H), 0.97 (dd, J = 1.40, 6.80 Hz, 3H), 
0.94 - 0.99 (m, 1H), 0.75 - 0.81 (m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 194.5, 183.1, 169.8, 
148.9, 148.3, 147.1, 147.1, 145.0, 142.3, 139.4, 127.8, 126.7, 124.1, 123.3, 122.7, 122.2, 117.9, 
115.1, 115.0, 110.0, 109.2, 80.8, 74.7, 70.8, 70.5, 70.2, 70.0, 69.9, 68.7, 66.8, 62.2, 56.4, 56.1, 
56.0, 50.1, 50.0, 41.6, 40.3, 39.7, 39.2, 38.1, 36.9, 36.7, 36.0, 35.7, 32.0, 31.8, 31.4, 30.3, 29.9, 
29.7, 28.8, 27.7, 26.0, 25.9, 24.8, 24.7, 20.8, 19.3, 17.1, 16.2, 14.5.  
 (1'S,2R,2'S,4'S,5R,7'S,8'R,9'S,12'S,13'R,16'S)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-
2,6'-pentacyclo[10.8.0.0
2
,
9
.0
4
,
8
.0
13
,
18
]icosan]-18'-en-16'-yl 2-(2-(2-[2-(8-(4-[(2Z,4E)-2-[(2E)-1-
hydroxy-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-ylidene]-5-(4-hydroxy-3-methoxyphenyl)-
3-oxopent-4-en-1-yl]-1H-1,2,3-triazol-1-yl)octanamido)ethoxy]ethoxy)ethoxy)acetate (10). 
Compound 43 (67.5 mg, 0.068 mmol) was reacted with compound 46 (30.4 mg, 0.075 mmol) 
following Procedure D affording compound 10 (67 mg, 84%) as a dark orange solid. 
1
H NMR 
(400 MHz, CDCl3) δ 7.69 (d, J = 15.31 Hz, 1H), 7.58 (d, J = 15.81 Hz, 1H), 7.31 (s, 1H), 7.06 (d, 
J = 8.28 Hz, 2H), 7.00 (dd, J = 1.76, 10.54 Hz, 2H), 6.90 (d, J = 8.03 Hz, 2H), 6.85 (s, 1H), 6.68 
(d, J = 15.81 Hz, 1H), 6.32 (t, J = 5.14 Hz, 1H), 5.36 (br. s., 1H), 4.62 - 4.72 (m, 1H), 4.34 - 4.44 
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(m, 1H), 4.19 - 4.28 (m, 2H), 4.10 (s, 1H), 4.06 (s, 2H), 3.89 (s, 3H), 3.91 (s, 3H), 3.60 - 3.75 (m, 
9H), 3.52 - 3.58 (m, 2H), 3.33 - 3.47 (m, 4H), 2.33 (t, J = 5.65 Hz, 2H), 2.10 (t, J = 7.53 Hz, 1H), 
1.93 - 2.04 (m, 3H), 1.42 - 1.89 (m, 21H), 1.06 - 1.23 (m, 10H), 1.02 (d, J = 2.01 Hz, 4H), 0.97 
(dd, J = 2.13, 6.90 Hz, 3H), 0.95 - 0.99 (m, 1H), 0.76 - 0.81 (m, 6H); 
13
C NMR (100 MHz, 
CDCl3) δ 194.6, 183.1, 169.8, 148.3, 147.2, 145.1, 142.4, 139.4, 127.7, 124.1, 123.1, 122.7, 
122.2, 117.7, 115.2, 110.1, 109.3, 107.7, 80.8, 74.6, 70.8, 70.8, 70.5, 70.2, 70.0, 68.8, 66.8, 62.1, 
56.4, 56.1, 56.0, 50.0, 41.6, 40.3, 39.7, 39.2, 38.1, 36.9, 36.7, 36.4, 32.0, 31.8, 31.4, 30.3, 30.1, 
29.7, 29.0, 28.8, 28.7, 27.7, 26.2, 25.6, 20.8, 19.3, 17.1, 16.2, 14.5. 
 (1'S,2R,2'S,4'S,5R,7'S,8'R,9'S,12'S,13'R,16'S)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-
2,6'-pentacyclo[10.8.0.0
2
,
9
.0
4
,
8
.0
13
,
18
]icosan]-18'-en-16'-yl 2-(2-(2-[2-(10-(4-[(2Z,4E)-2-[(2E)-1-
hydroxy-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-ylidene]-5-(4-hydroxy-3-methoxyphenyl)-
3-oxopent-4-en-1-yl]-1H-1,2,3-triazol-1-yl)decanamido)ethoxy]ethoxy)ethoxy)acetate (11). 
Compound 44 (11 mg, 0.014 mmol) was reacted with compound 46 (6.3 mg, 0.015 mmol) 
following Procedure D affording compound 11 (18 mg, 95%) as a dark orange solid. 
1
H NMR 
(400 MHz, CDCl3) δ 7.70 (d, J = 15.30 Hz, 1H), 7.58 (d, J = 16.06 Hz, 1H), 7.19 - 7.32 (m, 1H), 
7.05 - 7.09 (m, 2H), 7.00 (dd, J = 1.80, 12.60 Hz, 2H), 6.90 (d, J = 8.28 Hz, 2H), 6.85 (s, 1H), 
6.68 (d, J = 15.81 Hz, 1H), 6.30 (s, 1H), 5.37 (br. s., 1H), 4.69 (br. s., 1H), 4.39 - 4.45 (m, 1H), 
4.22 - 4.29 (m, 2H), 4.05 - 4.12 (m, 3H), 3.89 - 3.94 (m, 6H), 3.59 - 3.76 (m, 9H), 3.52 - 3.59 (m, 
2H), 3.34 - 3.48 (m, 4H), 2.33 (d, J = 8.03 Hz, 2H), 2.14 (t, J = 7.40 Hz, 1H), 2.00 (dd, J = 5.90, 
13.43 Hz, 3H), 1.81 (br. s., 21H), 1.10 - 1.18 (m, 14H), 1.02 - 1.04 (m, 4H), 0.97 (s, 4H), 0.77 - 
0.80 (m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 193.3, 181.4, 174.7, 147.6, 131.6, 130.9, 128.9, 
124.0, 122.7, 113.6, 110.8, 109.3, 93.1, 90.4, 87.0, 82.5, 81.8, 80.8, 70.5, 70.2, 66.9, 62.1, 61.6, 
56.4, 41.6, 40.3, 38.1, 36.9, 36.7, 31.9, 31.4, 30.3, 30.2, 29.4, 28.8, 22.7, 19.3, 17.1, 16.3, 14.1. 
  
100 
 
 (1'S,2R,2'S,4'S,5R,7'S,8'R,9'S,12'S,13'R,16'S)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-
2,6'-pentacyclo[10.8.0.0
2
,
9
.0
4
,
8
.0
13
,
18
]icosan]-18'-en-16'-yl 2-(2-(2-[2-(12-(4-[(2Z,4E)-2-[(2E)-1-
hydroxy-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-ylidene]-5-(4-hydroxy-3-methoxyphenyl)-
3-oxopent-4-en-1-yl]-1H-1,2,3-triazol-1-yl)dodecanamido)ethoxy]ethoxy)ethoxy)acetate (12). 
Compound 45 (30 mg, 0.036 mmol) was reacted with compound 46 (16.1 mg, 0.040 mmol) 
following Procedure D affording compound 12 (36.4 mg, 82%) as a dark orange solid. 
1
H NMR 
(400 MHz, CDCl3) δ 7.70 (d, J = 15.31 Hz, 1H), 7.59 (d, J = 15.81 Hz, 1H), 7.19 - 7.33 (m, 1H), 
7.07 (dd, J = 1.88, 8.16 Hz, 2H), 7.00 (dd, J = 1.63, 11.42 Hz, 2H), 6.90 (d, J = 8.03 Hz, 2H), 
6.86 (s, 1H), 6.69 (d, J = 15.81 Hz, 1H), 6.32 (br. s., 1H), 5.37 (br. s., 1H), 4.68 (d, J = 5.27 Hz, 
1H), 4.40 (td, J = 7.59, 14.93 Hz, 1H), 4.20 - 4.29 (m, 2H), 4.11 (d, J = 2.76 Hz, 2H), 4.06 (s, 
1H), 3.91 (d, J = 5.77 Hz, 6H), 3.60 - 3.76 (m, 8H), 3.56 (dd, J = 2.26, 5.02 Hz, 2H), 3.33 - 3.49 
(m, 5H), 2.33 (d, J = 7.28 Hz, 2H), 2.17 (t, J = 7.65 Hz, 2H), 1.93 - 2.04 (m, 3H), 1.40 - 1.91 (m, 
24H), 1.06 - 1.21 (m, 14H), 1.03 (s, 4H), 0.97 (d, J = 6.78 Hz, 4H), 0.78 (m, 6H); 
13
C NMR (100 
MHz, CDCl3) δ 183.1, 148.4, 147.1, 147.0, 126.6, 124.1, 123.3, 122.7, 115.0, 109.9, 109.3, 80.8, 
70.8, 70.5, 70.2, 68.8, 66.9, 62.1, 56.4, 56.0, 50.0, 41.6, 40.3, 39.7, 38.1, 36.9, 36.7, 32.0, 31.8, 
31.4, 30.3, 29.7, 29.3, 28.8, 27.7, 20.8, 19.3, 17.1, 16.3, 14.5. 
 (1'S,2R,2'S,4'S,5R,7'S,8'R,9'S,12'S,13'R,16'S)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-
2,6'-pentacyclo[10.8.0.0
2
,
9
.0
4
,
8
.0
13
,
18
]icosan]-18'-en-16'-yl 2-[2-(2-(2-[5-(4-(4-[(1E,3Z,6E)-3-
hydroxy-7-(4-hydroxy-3-methoxyphenyl)-5-oxohepta-1,3,6-trien-1-yl]-2-
methoxyphenoxymethyl)-1H-1,2,3-triazol-1-yl)pentanamido]ethoxy)ethoxy)ethoxy]acetate (13). 
Compound 41 (30 mg, 0.041 mmol) was reacted with compound 47 (18 mg, 0.045 mmol) 
following Procedure D affording compound 13 (41 mg, 89%) as a dark orange solid. 
1
H NMR 
(400 MHz, CDCl3) δ 7.69 (s, 1H), 7.59 (d, J = 15.06 Hz, 1H), 7.09 (dd, J = 6.70, 22.00 Hz, 2H), 
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7.03 - 7.16 (m, 1H), 6.94 (d, J = 7.28 Hz, 1H), 6.49 (d, J = 15.81 Hz, 1H), 6.39 (s, 1H), 5.36 (d, J 
= 3.00 Hz, 1H), 4.68 (d, J = 8.03 Hz, 1H), 4.32 - 4.45 (m, 3H), 4.11 (s, 2H), 3.95 (s, 2H), 3.88 - 
3.94 (m, 3H), 3.71 (d, J = 8.03 Hz, 4H), 3.61 - 3.66 (m, 4H), 3.55 (t, J = 4.70 Hz, 2H), 3.41 - 
3.51 (m, 4H), 3.37 (t, J = 11.00 Hz, 2H), 2.33 (d, J = 7.53 Hz, 2H), 2.19 - 2.26 (m, 2H), 1.94 - 
2.03 (m, 4H), 1.83 - 1.90 (m, 4H), 1.75 - 1.79 (m, 2H), 1.45 - 1.73 (m, 16H), 1.26 (d, J = 1.00 
Hz, 3H), 1.06 - 1.20 (m, 4H), 1.02 (s, 3H), 0.97 (d, J = 6.78 Hz, 4H), 0.77 - 0.82 (m, 6H); 
13
C 
NMR (100 MHz, CDCl3) δ 172.3, 169.9, 139.4, 122.7, 109.3, 80.8, 74.7, 70.8, 70.5, 70.5, 70.1, 
69.9, 68.7, 66.8, 62.1, 56.4, 55.9, 49.9, 41.6, 40.3, 39.7, 39.2, 38.0, 36.9, 36.7, 35.3, 32.0, 31.8, 
31.4, 30.3, 29.6, 28.8, 27.7, 22.4, 20.8, 19.3, 17.1, 16.3, 14.5. 
 (1'S,2R,2'S,4'S,5R,7'S,8'R,9'S,12'S,13'R,16'S)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-
2,6'-pentacyclo[10.8.0.0
2
,
9
.0
4
,
8
.0
13
,
18
]icosan]-18'-en-16'-yl 2-[2-(2-(2-[6-(4-(4-[(1E,3Z,6E)-3-
hydroxy-7-(4-hydroxy-3-methoxyphenyl)-5-oxohepta-1,3,6-trien-1-yl]-2-
methoxyphenoxymethyl)-1H-1,2,3-triazol-1-yl)hexanamido]ethoxy)ethoxy)ethoxy]acetate (14). 
Compound 42 (100 mg, 0.135 mmol) was reacted with compound 47 (60.2 mg, 0.148 mmol) 
following Procedure D affording compound 14 (101 mg, 65%) as a dark orange solid. 
1
H NMR 
(400 MHz, CDCl3) δ 7.64 (s, 1H), 7.59 (dd, J = 3.14, 15.69 Hz, 2H), 7.04 - 7.15 (m, 5H), 6.93 (d, 
J = 8.03 Hz, 1H), 6.49 (dd, J = 4.77, 15.81 Hz, 2H), 6.19 (br. s., 1H), 5.86 (s, 1H), 5.81 (s, 1H), 
5.36 (br. s., 1H), 4.67 (br. s., 1H), 4.38 - 4.46 (m, 1H), 4.34 (t, J = 7.03 Hz, 2H), 4.10 (s, 2H), 
3.95 (s, 3H), 3.92 (s, 3H), 3.60 - 3.75 (m, 10H), 3.52 - 3.56 (m, 2H), 3.33 - 3.47 (m, 5H), 2.33 (d, 
J = 6.78 Hz, 2H), 2.14 - 2.20 (m, 3H), 1.62 - 2.06 (m, 18H), 1.22 - 1.49 (m, 8H), 1.03 (s, 3H), 
0.97 (d, J = 6.78 Hz, 4H), 0.77 - 0.81 (m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 183.6, 182.9, 
169.8, 149.8, 149.6, 148.0, 146.9, 140.7, 140.1, 139.4, 128.9, 127.7, 122.9, 122.7, 122.5, 122.2, 
121.8, 114.9, 113.9, 110.6, 109.7, 109.3, 101.2, 80.8, 74.7, 70.8, 70.5, 70.5, 70.2, 69.9, 68.8, 
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66.9, 63.1, 62.1, 56.4, 56.0, 53.4, 50.2, 50.0, 41.6, 40.3, 39.7, 39.2, 38.1, 36.9, 36.7, 36.0, 35.9, 
32.0, 31.8, 31.4, 30.3, 30.0, 29.7, 28.8, 27.7, 26.1, 24.8, 20.8, 19.3, 17.1, 16.2, 14.5. 
 (1'S,2R,2'S,4'S,5R,7'S,8'R,9'S,12'S,13'R,16'S)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-
2,6'-pentacyclo[10.8.0.0
2
,
9
.0
4
,
8
.0
13
,
18
]icosan]-18'-en-16'-yl 2-[2-(2-(2-[8-(4-(4-[(1E,3Z,6E)-3-
hydroxy-7-(4-hydroxy-3-methoxyphenyl)-5-oxohepta-1,3,6-trien-1-yl]-2-
methoxyphenoxymethyl)-1H-1,2,3-triazol-1-yl)octanamido]ethoxy)ethoxy)ethoxy]acetate (15). 
Compound 43 (100 mg, 0.130 mmol) was reacted with compound 47 (58 mg, 0.143 mmol) 
following Procedure D affording compound 15 (109 mg, 71%) as a dark orange solid. 
1
H NMR 
(400 MHz, CDCl3) δ 7.55 - 7.64 (m, 1H), 7.59 (dd, J = 3.51, 16.06 Hz, 2H), 7.03 - 7.15 (m, 5H), 
6.93 (d, J = 8.53 Hz, 1H), 6.49 (dd, J = 4.52, 15.81 Hz, 2H), 6.14 (br. s., 1H), 5.86 (s, 1H), 5.81 
(s, 1H), 5.38 (br. s., 1H), 4.70 (br. s., 1H), 4.37 - 4.44 (m, 1H), 4.33 (t, J = 7.15 Hz, 2H), 4.11 (s, 
2H), 3.95 (s, 3H), 3.92 (s, 3H), 3.60 - 3.76 (m, 10H), 3.53 - 3.57 (m, 2H), 3.33 - 3.47 (m, 5H), 
2.34 (d, J = 7.53 Hz, 2H), 2.16 (t, J = 7.53 Hz, 3H), 1.61 - 2.02 (m, 18H), 1.12 - 1.38 (m, 12H), 
1.03 (s, 3H), 0.97 (d, J = 6.78 Hz, 4H), 0.76 - 0.81 (m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 
183.5, 182.9, 173.1, 169.8, 149.7, 149.6, 148.0, 146.9, 140.7, 140.1, 139.4, 128.9, 127.7, 122.9, 
122.8, 122.7, 122.4, 122.2, 121.8, 120.7, 114.9, 113.9, 110.6, 109.7, 109.3, 101.2, 80.8, 74.7, 
70.8, 70.5, 70.5, 70.2, 70.0, 68.8, 66.9, 63.1, 62.1, 56.4, 56.0, 56.0, 50.4, 50.0, 41.6, 40.3, 39.7, 
39.2, 38.1, 36.9, 36.7, 36.4, 32.0, 31.8, 31.4, 30.3, 30.1, 28.9, 28.8, 28.6, 27.7, 26.3, 25.4, 20.8, 
19.3, 17.1, 16.3, 14.5. 
 (1'S,2R,2'S,4'S,5R,7'S,8'R,9'S,12'S,13'R,16'S)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-
2,6'-pentacyclo[10.8.0.0
2
,
9
.0
4
,
8
.0
13
,
18
]icosan]-18'-en-16'-yl 2-[2-(2-(2-[10-(4-(4-[(1E,3Z,6E)-3-
hydroxy-7-(4-hydroxy-3-methoxyphenyl)-5-oxohepta-1,3,6-trien-1-yl]-2-
methoxyphenoxymethyl)-1H-1,2,3-triazol-1-yl)decanamido]ethoxy)ethoxy)ethoxy]acetate (16). 
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Compound 44 (100 mg, 0.125 mmol) was reacted with compound 47 (56 mg, 0.138 mmol) 
following Procedure D affording compound 16 (128 mg, 85%) as a dark orange solid. 
1
H NMR 
(400 MHz, CDCl3) δ 7.64 (br. s., 1H), 7.59 (dd, J = 3.89, 15.69 Hz, 2H), 7.05 - 7.14 (m, 5H), 
6.81 (d, J = 7.53 Hz, 1H), 6.49 (dd, J = 3.89, 15.69 Hz, 2H), 6.17 (br. s., 1H), 5.37 (d, J = 4.52 
Hz, 2H), 4.63 - 4.74 (m, 1H), 4.41 (q, J = 7.40 Hz, 1H), 4.33 (t, J = 7.28 Hz, 2H), 4.11 (s, 2H), 
3.95 (s, 3H), 3.92 (s, 3H), 3.60 - 3.76 (m, 10H), 3.52 - 3.58 (m, 2H), 3.33 - 3.50 (m, 5H), 2.34 (d, 
J = 7.78 Hz, 2H), 2.16 (t, J = 7.53 Hz, 2H), 1.67 - 2.05 (m, 20H), 1.33 - 1.56 (m, 9H), 1.06 - 1.23 
(m, 7H), 1.03 (s, 3H), 0.97 (d, J = 7.03 Hz, 4H), 0.79 (t, J = 3.01 Hz, 6H); 
13
C NMR (100 MHz, 
CDCl3) δ 154.8, 149.1, 122.7, 109.3, 95.8, 80.8, 77.2, 74.7, 70.8, 70.5, 70.2, 68.8, 66.9, 62.1, 
56.4, 49.9, 41.6, 40.3, 39.7, 39.2, 36.7, 32.0, 31.4, 30.3, 29.7, 29.2, 28.8, 20.8, 19.3, 17.1, 16.3, 
14.5. 
 (1'S,2R,2'S,4'S,5R,7'S,8'R,9'S,12'S,13'R,16'S)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-
2,6'-pentacyclo[10.8.0.0
2
,
9
.0
4
,
8
.0
13
,
18
]icosan]-18'-en-16'-yl 2-[2-(2-(2-[12-(4-(4-[(1E,3Z,6E)-3-
hydroxy-7-(4-hydroxy-3-methoxyphenyl)-5-oxohepta-1,3,6-trien-1-yl]-2-
methoxyphenoxymethyl)-1H-1,2,3-triazol-1-yl)dodecanamido]ethoxy)ethoxy)ethoxy]acetate 
(17). Compound 45 (100 mg, 0.121 mmol) was reacted with compound 47 (54 mg, 0.133 mmol) 
following Procedure D affording compound 17 (103 mg, 69%) as a dark orange solid. 
1
H NMR 
(400 MHz, CDCl3) δ 7.64 (s, 1H), 7.59 (dd, J = 3.89, 15.69 Hz, 2H), 7.03 - 7.15 (m, 5H), 6.93 (d, 
J = 8.28 Hz, 1H), 6.50 (d, J = 3.51 Hz, 2H), 6.12 (br. s., 1H), 5.86 (s, 1H), 5.81 (s, 1H), 5.38 (br. 
s., 1H), 4.70 (br. s., 1H), 4.38 - 4.44 (m, 1H), 4.33 (t, J = 7.40 Hz, 2H), 4.11 (s, 2H), 3.95 (s, 3H), 
3.92 (s, 3H), 3.59 - 3.76 (m, 10H), 3.53 - 3.57 (m, 2H), 3.34 - 3.47 (m, 5H), 2.34 (d, J = 8.28 Hz, 
2H), 2.16 (t, J = 7.53 Hz, 3H), 1.61 - 2.02 (m, 18H), 1.21 - 1.33 (m, 20H), 1.03 (s, 3H), 0.97 (d, J 
= 7.03 Hz, 4H), 0.79 (t, J = 3.14 Hz, 6H); 
13
C NMR (100 MHz, CDCl3) δ 183.6, 182.9, 173.3, 
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169.8, 149.8, 149.6, 148.0, 146.9, 140.7, 140.1, 139.4, 128.9, 127.7, 122.9, 122.7, 122.5, 122.2, 
121.8, 114.9, 114.0, 110.7, 109.8, 109.3, 101.2, 80.8, 74.7, 70.8, 70.5, 70.5, 70.2, 70.0, 68.8, 
66.9, 63.2, 62.2, 58.4, 56.4, 56.0, 56.0, 50.5, 50.0, 41.6, 40.3, 39.7, 39.2, 38.1, 36.9, 36.7, 36.7, 
32.0, 31.8, 31.4, 30.3, 30.2, 29.7, 29.4, 29.4, 29.3, 29.3, 28.9, 28.8, 27.7, 26.5, 25.7, 20.8, 19.3, 
18.4, 17.1, 16.2, 14.5. 
 2-(2-(2-azidoethoxy)ethoxy)ethanamine (49). 1,2-bis(2-azidoethoxy)ethane 48 (4.8 g, 
20.7 mmol), the side product from the synthesis of 2-(2-(2-azidoethoxy)ethoxy)ethanol 23, was 
dissolved in a solution of Et2O/EtOAc/5%HCl (30 mL/30 mL/30 mL) and cooled to 0 °C.  
Triphenylphosphine was added slowly, portion-wise to the solution over 1 h.  The reaction was 
stirred overnight.  The organic layer was discarded, and the water layered was basified to pH 
~12.  The product was extracted into DCM and then concentrated under reduced pressure 
yielding compound 49 (2.2 g, 64%) as a viscous oil. 
1
H NMR (400 MHz, CDCl3) δ 3.69 (t, J = 
5.00 Hz, 2H), 3.63 - 3.70 (m, 4H), 3.52 (t, J = 5.27 Hz, 2H), 3.40 (t, J = 5.02 Hz, 2H), 2.87 (t, J = 
5.14 Hz, 2H), 1.72 (br. s., 2H). 
 3-(2-(2-(2-azidoethoxy)ethoxy)ethylcarbamoyl)propanoic acid (50). Compound 49 (1.0 
g, 4.85 mmol), succinic anhydride (1.84 g, 19.40 mmol), and Et3N (0.5 mL) were dissolved in 
DCM (15 mL).  The solution was stirred at room temperature overnight.  The solution was 
washed with 1 N HCl, and then the organic layer was concentrated under reduced pressure.  The 
resulting residue was purified by column chromatography (DCM/MeOH/AcOH: 95/5/0 to 
92/7.9/0.1) giving compound 50 (400 mg, 30%) as a white solid. 
1
H NMR (400 MHz, CDCl3) δ 
6.39 (br. s., 1H), 3.71 (t, J = 4.80 Hz, 2H), 3.63 - 3.68 (m, 4H), 3.57 (t, J = 5.00 Hz, 2H), 3.48 (q, 
J = 5.10 Hz, 2H), 3.42 (t, J = 5.00 Hz, 2H), 2.69 (t, J = 6.40 Hz, 2H), 2.53 (t, J = 6.40 Hz, 2H). 
  
105 
 
 (1'S,2R,2'S,4'S,5R,7'S,8'R,9'S,12'S,13'R,16'S)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-
2,6'-pentacyclo[10.8.0.0
2
,
9
.0
4
,
8
.0
13
,
18
]icosan]-18'-en-16'-yl 3-(2-[2-(2-
azidoethoxy)ethoxy]ethylcarbamoyl)propanoate (51). Compound 50 (1.4 g, 4.89 mmol) was 
reacted with diosgenin 4 (2.23 g, 5.38 mmol) following Procedure D to give compound 51 (1.4 
g, 42%) as a white solid. 
1
H NMR (400 MHz, CDCl3) δ 6.08 (br. s., 1H), 5.36 (d, J = 5.52 Hz, 
1H), 4.54 - 4.67 (m, 1H), 4.41 (q, J = 7.50 Hz, 1H), 3.69 (t, J = 5.00 Hz, 2H), 3.62 - 3.66 (m, 
4H), 3.56 (t, J = 5.14 Hz, 2H), 3.46 (q, J = 5.19 Hz, 2H), 3.40 (t, J = 5.02 Hz, 2H), 2.71 (s, 1H), 
2.63 (t, J = 7.03 Hz, 2H), 2.47 (t, J = 7.03 Hz, 2H), 2.32 (d, J = 7.28 Hz, 2H), 1.94 - 2.05 (m, 
2H), 1.81 - 1.90 (m, 3H), 1.56 - 1.77 (m, 10H), 1.41 - 1.53 (m, 3H), 1.28 (dt, J = 6.40, 12.86 Hz, 
1H), 1.06 - 1.23 (m, 3H), 1.03 (s, 3H), 0.97 (d, J = 7.03 Hz, 4H), 0.79 (t, J = 3.14 Hz, 6H). 
 (1'S,2R,2'S,4'S,5R,7'S,8'R,9'S,12'S,13'R,16'S)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-
2,6'-pentacyclo[10.8.0.0
2
,
9
.0
4
,
8
.0
13
,
18
]icosan]-18'-en-16'-yl 3-(2-[2-(2-(4-[(2Z,4E)-2-[(2E)-1-
hydroxy-3-(4-hydroxy-3-methoxyphenyl)prop-2-en-1-ylidene]-5-(4-hydroxy-3-methoxyphenyl)-
3-oxopent-4-en-1-yl]-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy]ethylcarbamoyl)propanoate (18). 
Compound 51 (250 mg, 0.37 mmol) was reacted with compound 46 (167 mg, 0.41 mmol) 
following Procedure E to give compound 18 (158 mg, 40%) as a dark orange solid. 
1
H NMR 
(400 MHz, CDCl3) δ 7.70 (d, J = 15.06 Hz, 1H), 7.60 (d, J = 16.06 Hz, 1H), 7.09 (d, J = 8.28 Hz, 
2H), 7.01 - 7.05 (m, 2H), 6.94 (s, 1H), 6.90 (d, J = 8.28 Hz, 2H), 6.71 (d, J = 15.81 Hz, 1H), 6.36 
(br. s., 1H), 5.96 - 6.07 (m, 2H), 5.33 (br. s., 1H), 4.36 - 4.48 (m, 4H), 4.07 (s, 1H), 3.93 - 3.95 
(m, 3H), 3.92 (s, 3H), 3.77 - 3.83 (m, 2H), 3.36 - 3.53 (m, 10H), 3.27 - 3.35 (m, 3H), 2.63 (t, J = 
6.78 Hz, 2H), 2.44 - 2.53 (m, 2H), 2.29 (d, J = 8.53 Hz, 2H), 1.98 (dd, J = 6.02, 12.55 Hz, 2H), 
1.60 - 1.89 (m, 10H), 1.42 - 1.53 (m, 4H), 1.05 - 1.29 (m, 5H), 1.01 (d, J = 2.76 Hz, 3H), 0.97 (d, 
J = 7.03 Hz, 4H), 0.76 - 0.81 (m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 154.8, 149.1, 122.7, 109.3, 
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95.8, 80.8, 77.2, 74.7, 70.8, 70.5, 70.2, 68.8, 66.9, 62.1, 56.4, 49.9, 41.6, 40.3, 39.7, 39.2, 36.7, 
32.0, 31.4, 30.3, 29.7, 29.2, 28.8, 20.8, 19.3, 17.1, 16.3, 14.5. 
 (1'S,2R,2'S,4'S,5R,7'S,8'R,9'S,12'S,13'R,16'S)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-
2,6'-pentacyclo[10.8.0.0
2
,
9
.0
4
,
8
.0
13
,
18
]icosan]-18'-en-16'-yl 3-[2-(2-[2-(4-(4-[(1E,3Z,6E)-3-
hydroxy-7-(4-hydroxy-3-methoxyphenyl)-5-oxohepta-1,3,6-trien-1-yl]-2-
methoxyphenoxymethyl)-1H-1,2,3-triazol-1-yl)ethoxy]ethoxy)ethylcarbamoyl]propanoate (19). 
Compound 51 (250 mg, 0.37 mmol) was reacted with compound 47 (167 mg, 0.41 mmol) 
following Procedure E to give compound 19 (201 mg, 51%) as a dark orange solid. 
1
H NMR 
(400 MHz, CDCl3) δ 7.84 (s, 1H), 7.59 (dd, J = 5.40, 15.69 Hz, 2H), 7.11 (s, 2H), 7.12 (dd, J = 
1.80, 7.90 Hz, 1H), 7.06 (dd, J = 1.38, 7.91 Hz, 2H), 6.93 (d, J = 8.28 Hz, 1H), 6.48 (dd, J = 
4.27, 15.81 Hz, 2H), 6.11 (s, 1H), 5.79 - 5.87 (m, 2H), 5.33 (s, 2H), 4.55 (t, J = 5.02 Hz, 3H), 
4.35 - 4.44 (m, 1H), 3.95 (s, 3H), 3.91 (s, 3H), 3.89 (t, J = 5.00 Hz, 3H), 3.50 - 3.59 (m, 5H), 
3.44 - 3.50 (m, 4H), 3.33 - 3.44 (m, 4H), 2.68 (s, 1H), 2.61 (t, J = 6.78 Hz, 2H), 2.45 (t, J = 6.90 
Hz, 2H), 2.30 (d, J = 6.78 Hz, 2H), 1.98 (d, J = 13.05 Hz, 2H), 1.58 - 1.88 (m, 10H), 1.27 (d, J = 
5.02 Hz, 2H), 1.04 - 1.20 (m, 4H), 1.02 (s, 3H), 0.96 (d, J = 7.03 Hz, 4H), 0.76 - 0.80 (m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 182.6, 181.9, 171.4, 170.6, 148.6, 146.9, 145.8, 142.6, 139.7, 
139.1, 138.7, 126.7, 123.3, 121.9, 121.4, 121.3, 120.8, 113.9, 112.8, 109.5, 108.7, 108.3, 100.3, 
79.8, 73.2, 69.5, 69.2, 68.9, 68.3, 65.8, 62.0, 61.1, 55.4, 55.0, 49.4, 48.9, 40.6, 39.2, 38.7, 38.3, 
37.0, 35.9, 35.7, 31.0, 30.8, 30.4, 29.9, 29.3, 28.8, 27.8, 27.1, 26.7, 19.8, 18.3, 16.1, 15.2, 13.5. 
 (1'S,2R,2'S,4'S,5R,7'S,8'R,9'S,12'S,13'R,16'S)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxane-
2,6'-pentacyclo[10.8.0.0
2
,
9
.0
4
,
8
.0
13
,
18
]icosan]-18'-en-16'-yl 3-(2-(2-(2-[4-(2-methylpropyl)-1H-
1,2,3-triazol-1-yl]ethoxy)ethoxy)ethylcarbamoyl)propanoate (20). Compound 51 (110 mg, 0.16 
mmol) was reacted with 4-methyl-1-pentyne (15 mg, 0.18 mmol) following Procedure E to give 
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compound 20 (100 mg, 81%) as a white solid. 
1
H NMR (400 MHz, CDCl3) δ 7.41 (s, 1H), 6.16 
(br. s., 1H), 5.36 (d, J = 4.52 Hz, 1H), 4.54 - 4.66 (m, 1H), 4.52 (t, J = 5.27 Hz, 2H), 4.41 (q, J = 
7.50 Hz, 1H), 3.89 (t, J = 5.14 Hz, 2H), 3.54 - 3.60 (m, 4H), 3.50 (t, J = 5.00 Hz, 2H), 3.43 (q, J 
= 5.50 Hz, 2H), 3.37 (t, J = 11.00 Hz, 1H), 2.64 (t, J = 7.00 Hz, 2H), 2.59 (d, J = 7.03 Hz, 2H), 
2.48 (t, J = 7.00 Hz, 2H), 2.32 (d, J = 7.53 Hz, 2H), 1.91 - 2.02 (m, 3H), 1.81 - 1.89 (m, 3H), 
1.66 - 1.80 (m, 3H), 1.64 (s, 6H), 1.40 - 1.56 (m, 4H), 1.06 - 1.34 (m, 5H), 1.03 (s, 3H), 0.97 (d, 
J = 7.03 Hz, 3H), 0.95 (s, 3H), 0.93 (s, 3H), 0.76 - 0.82 (m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 
172.4, 171.5, 147.1, 139.7, 122.4, 122.3, 109.3, 80.8, 74.3, 70.5, 70.3, 69.9, 69.7, 66.9, 62.1, 
56.5, 50.1, 50.0, 41.6, 40.3, 39.8, 39.3, 38.1, 37.0, 36.8, 34.8, 32.1, 31.8, 31.4, 31.1, 30.3, 29.9, 
28.8, 28.7, 27.7, 22.3, 20.8, 19.3, 17.1, 16.3, 14.5. 
 Methyl 3-(2-(2-(2-azidoethoxy)ethoxy)ethylcarbamoyl)propanoate (54). Compound 49 
(1.0 g, 4.85 mmol) was reacted with 3-(methoxycarbonyl)propanoic acid 53 (700 mg, 5.33 
mmol) following Procedure B to give compound 54 (1.26 g, 81%) as a white solid. 
1
H NMR 
(400 MHz, CDCl3) δ 6.12 (br. s., 1H), 3.69 (s, 3H), 3.70 (t, J = 4.80 Hz, 2H), 3.62 - 3.68 (m, 
4H), 3.56 (t, J = 5.02 Hz, 2H), 3.46 (q, J = 5.20 Hz, 2H), 3.40 (t, J = 5.02 Hz, 2H), 2.67 (t, J = 
7.03 Hz, 2H), 2.49 (t, J = 6.90 Hz, 2H). 
 Methyl 3-(2-[2-(2-(4-[(2Z,4E)-2-[(2E)-1-hydroxy-3-(4-hydroxy-3-methoxyphenyl)prop-
2-en-1-ylidene]-5-(4-hydroxy-3-methoxyphenyl)-3-oxopent-4-en-1-yl]-1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy]ethylcarbamoyl)propanoate (21). Compound 54 (100 mg, 0.312 mmol) was 
reacted with compound 46 (127 mg, 0.312 mmol) following Procedure E to give compound 21 
(100 mg, 44%) as an orange solid. 
1
H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 15.31 Hz, 1H), 
7.61 (d, J = 15.81 Hz, 1H), 7.00 - 7.12 (m, 2H), 7.09 (d, J = 7.80 Hz, 2H), 6.93 - 6.99 (m, 1H), 
6.90 (d, J = 7.78 Hz, 2H), 6.71 (d, J = 15.81 Hz, 1H), 6.45 - 6.55 (m, 1H), 4.46 (q, J = 4.30 Hz, 
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2H), 4.07 (br. s., 1H), 3.91 (s, 3H), 3.88 (s, 3H), 3.80 (q, J = 5.27 Hz, 2H), 3.66 (s, 3H), 3.65 (s, 
3H), 3.52 (s, 3H), 3.48 - 3.51 (m, 2H), 3.37 - 3.48 (m, 4H), 3.28 - 3.34 (m, 2H), 2.66 (t, J = 6.40 
Hz, 2H), 2.50 (td, J = 6.93, 13.49 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 194.5, 183.2, 173.4, 
148.8, 148.2, 147.0, 146.9, 145.2, 142.4, 127.8, 126.7, 124.1, 123.1, 122.1, 117.9, 114.9, 114.9, 
110.1, 109.9, 70.5, 70.2, 70.0, 69.9, 69.7, 69.5, 56.1, 56.1, 51.7, 39.2, 30.9, 30.9, 29.3, 29.3. 
 
5.1.2 Hybrid Compounds 
Ethyl 4-(triphenylphosphoranylidene)acetoacetate (70). Triphenylphosphine (14.4 g, 55.3 
mmol) was added to a solution of ethyl 4-chloroacetoacetate 69 (8.4 g, 60.8 mmol) in benzene 
(35 mL) and stirred for 24 h at 55 °C. The solution was then cooled to room temperature, and the 
precipitate was collected by filtration and washed with benzene. The solid precipitate was then 
dissolved in H2O (10 mL). To this solution, a 1 N NaHCO3 solution (10 mL) was added, and the 
resulting precipitate was collected by filtration, washed with H2O, and then dried under reduced 
pressure to afford compound 70 (15.3 g, 71%) as a white solid. 
1
H NMR (400 MHz, CDCl3) δ 
7.72 - 7.60 (m, 6H), 7.60 - 7.50 (m, 3H), 7.45 (m, 6H), 4.19 (q, J = 7.13 Hz, 2H), 3.81 (m, 1H), 
3.35 (s, 2H), 1.28 (t, J = 7.13 Hz, 3H).  
N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-3-oxo-4-(triphenyl-λ5-phosphanylidene) 
butanamide (72). Compound 70 (5.0 g, 13.0 mmol) and 5-methoxytryptamine 71 (2.6 g, 13.7 
mmol) were added together in xylene (25 mL), and the solution was heated to reflux for 3 h. The 
solution was then cooled to room temperature and concentrated under reduced pressure. The 
crude residue was purified by column chromatography (MeOH/DCM: 2/98) to give compound 
72 (3.9 g, 57%) as an off-white solid. 
1
H NMR (400 MHz, CDCl3) δ 8.32 (br. s., 1H), 7.89 (br. 
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s., 1H), 7.70 - 7.51 (m, 9H), 7.50 - 7.39 (m, 6H), 7.19 (d, J = 8.76 Hz, 1H), 7.04 (d, J = 2.42 Hz, 
1H), 6.93 (d, J = 2.06 Hz, 1H), 6.82 (dd, J = 8.76, 2.42 Hz, 1H), 3.91 (m, 1H), 3.87 (s, 3H), 3.55 
(m, 2H), 3.31 (s, 2H), 2.89 (t, J = 7.46 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 186.87, 169.47, 
153.97, 133.07, 132.97, 132.37, 131.37, 129.06, 128.94, 127.89, 126.63, 125.73, 122.69, 113.28, 
112.30, 111.77, 100.46, 100.00, 55.95, 39.45, 25.66.  
Procedure F. 5-(4-hydroxy-3-methoxyphenyl)-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-3-
oxopent-4-enamide (54). Compound 72 (0.25 g, 0.47 mmol) was added to a solution of NaH 
(0.075 g, 1.87 mmol) in DMPU/THF (2 mL/2.2 mL) and cooled to 0 °C for 30 min.  To this, 
vanillin 73 (0.09 g, 0.56 mmol) in THF (0.5 mL) was added dropwise.  The solution was heated 
to 40 °C for 3 h.  The solution was then cooled to room temperature and stirred overnight.  The 
reaction was then quenched using NH4Cl (0.5 mL). The solvent was removed under reduced 
pressure, and the residual oil was purified by column chromatography (Hexanes/Acetone: 50/50) 
to give compound 54 (0.06 g, 31%) as a light yellow solid. 
1
H NMR (400 MHz, CDCl3) δ 8.03 
(s, 1H), 7.56 (d, J = 16.04 Hz, 1H), 7.23 (d, J = 8.80 Hz, 1H), 7.09 (dd, J = 8.28 Hz, 1.84 Hz, 
1H), 7.04-6.99 (m, 3H), 6.93 (d, J = 8.20 Hz, 1H), 6.85 (dd, J = 8.80 Hz, 2.4 Hz, 1H), 6.59 (d, J 
= 16.04 Hz, 1H), 3.92 (s, 3H), 3.86 (s, 3H), 3.63 (q, J = 5.76 Hz, 2H), 3.58 (s, 2H), 2.96 (t, J = 
6.88 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 195.31, 165.96, 154.09, 149.00, 147.00, 145.68, 
131.56, 127.73, 126.48, 124.18, 123.30, 122.89, 115.00, 112.62, 112.43, 111.95, 109.83, 100.54, 
56.03, 55.96, 47.30, 39.79, 25.24.  
N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-5-(3-methoxyphenyl)-3-oxopent-4-enamide (55). 
3-Methoxybenzaldehyde (0.076 g, 0.56 mmol) was reacted with 72 (0.25 g, 0.47 mmol) 
following Procedure F to give compound 55 (0.06 g, 33%). 
1
H NMR (400 MHz, CDCl3) δ 7.95 
(br. s., 1H), 7.71 (d, J = 7.53 Hz, 1H), 7.60 (d, J = 12.80 Hz, 1H), 7.37 (t, J = 8.03 Hz, 1H), 7.32 
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(t, J = 8.00 Hz, 1H), 7.24 (d, J = 8.78 Hz, 1H), 7.14 (d, J = 8.28 Hz, 1H), 7.04 (s, 1H), 7.03 (br. 
s., 1H), 6.98 (d, J = 1.76 Hz, 1H), 6.85 (dd, J = 2.51, 8.78 Hz, 1H), 6.72 (d, J = 16.31 Hz, 1H), 
3.86 (s, 6H), 3.60 - 3.67 (m, 4H), 2.97 (t, J = 7.03 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 
195.5, 166.1, 159.9, 159.6, 154.0, 145.3, 135.3, 131.5, 130.0, 129.4, 127.7, 125.8, 122.9, 121.4, 
120.1, 117.1, 113.4, 112.3, 111.9, 100.5, 55.9, 55.4, 55.3, 47.1, 39.8, 25.1.  
Procedure G. 5-(4-hydroxyphenyl)-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-3-oxopent-4-
enamide (56). 4-Hydroxybenzaldehyde (0.035 g, 0.29 mmol) and 72 (0.25 g, 0.47 mmol) were 
added together in a DMSO/H2O (5 mL/1 mL) solution, and then heated to 100 °C for 24 h. The 
reaction was cooled to room temperature, and the product was extracted into EtOAc. The EtOAc 
layer was washed extensively H2O and then concentrated under reduced pressure. The residual 
was purified by column chromatography (1. MeOH/DCM: 5/95; 2. Hexanes/Acetone: 50/50) to 
give compound 56 (0.045 g, 41%). 
1
H NMR (400 MHz, CDCl3) δ 9.01 (br. s., 1H), 8.21 (br. s., 
1H), 7.41 (d, J = 16.06 Hz, 1H), 7.24 (d, J = 8.53 Hz, 2H), 7.09 - 7.16 (m, 2H), 6.91 (dd, J = 
2.26, 5.52 Hz, 2H), 6.74 (d, J = 8.78 Hz, 2H), 6.69 - 6.73 (m, 1H), 6.43 (d, J = 16.06 Hz, 1H), 
3.73 (s, 3H), 3.49 (q, J = 6.78 Hz, 2H), 3.45 (s, 2H), 2.84 (t, J = 6.78 Hz, 2H); 
13
C NMR (100 
MHz, CD3COCD3) δ 194.7, 173.2, 168.2, 154.8, 154.8, 144.5, 135.0, 132.9, 131.3, 129.8, 128.5, 
124.1, 121.1, 116.6, 113.1, 112.5, 101.2, 55.9, 55.9, 49.3, 40.3, 26.3.  
N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-3-oxo-5-phenylpent-4-enamide (57). 
Benzaldehyde (0.060 g, 0.56 mmol) was reacted with 72 (0.25 g, 0.47 mmol) following 
Procedure F to give compound 57 (0.05 g, 29%). 
1
H NMR (400 MHz, CDCl3) δ 8.15 (br. s., 1H), 
7.59 (d, J = 16.06 Hz, 1H), 7.51 (dd, J = 1.80, 7.60 Hz, 2H), 7.29 - 7.45 (m, 3H), 7.21 (d, J = 
8.78 Hz, 1H), 7.08 (br. s., 1H), 7.02 - 7.04 (m, 1H), 7.00 (d, J = 2.01 Hz, 1H), 6.84 (dd, J = 2.51, 
8.78 Hz, 1H), 6.71 (d, J = 16.06 Hz, 1H), 3.84 (s, 3H), 3.61 (q, J = 6.80 Hz, 2H), 3.57 (s, 2H), 
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2.94 (t, J = 6.80 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 195.5, 165.6, 154.1, 145.3, 134.0, 
131.5, 131.2, 129.1, 128.8, 128.7, 127.7, 127.4, 125.7, 122.9, 112.7, 112.5, 112.0, 100.5, 56.0, 
47.4, 39.8, 25.2.  
N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-5-(4-methoxyphenyl)-3-oxopent-4-enamide (58). 
4-Methoxybenzaldehyde (0.076 g, 0.56 mmol) was reacted with 72 (0.25 g, 0.47 mmol) 
following Procedure F to give compound 58 (0.07 g, 39%). 
1
H NMR (400 MHz, CDCl3) δ 7.96 
(br. s., 1H), 7.59 (d, J = 16.06 Hz, 1H), 7.50 (d, J = 8.80 Hz, 2H), 7.24 (d, J = 9.03 Hz, 1H), 7.13 
(br. s., 1H), 7.04 (s, 2H), 6.92 (d, J = 8.80 Hz, 2H), 6.85 (dd, J = 2.38, 8.91 Hz, 1H), 6.62 (d, J = 
16.06 Hz, 1H), 3.86 (s, 3H), 3.85 (s, 3H), 3.59 - 3.65 (m, 4H), 2.96 (t, J = 6.90 Hz, 2H); 
13
C 
NMR (100 MHz, CDCl3) δ 195.4, 165.8, 162.2, 154.1, 145.2, 131.5, 130.5, 127.7, 126.6, 123.4, 
122.8, 114.6, 112.7, 112.5, 111.9, 100.5, 55.9, 55.4, 47.2, 39.7, 25.3.  
5-(2H-1,3-benzodioxol-5-yl)-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-3-oxopent-4-
enamide (59). 1,3-Benzodioxole-5-carbaldehyde (0.070 g, 0.47 mmol) was reacted with 72 (0.25 
g, 0.47 mmol) following Procedure F to give compound 59 (0.05 g, 26%). 
1
H NMR (400 MHz, 
CDCl3) δ 8.13 (br. s., 1H), 7.51 (d, J = 16.06 Hz, 1H), 7.22 (d, J = 8.78 Hz, 1H), 7.12 (br. s., 1H), 
6.99 - 7.04 (m, 4H), 6.84 (dd, J = 2.51, 8.78 Hz, 1H), 6.81 (d, J = 8.53 Hz, 1H), 6.54 (d, J = 
15.81 Hz, 1H), 6.01 (s, 2H), 3.85 (s, 3H), 3.61 (q, J = 6.78 Hz, 2H), 3.55 (s, 2H), 2.95 (t, J = 6.80 
Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 195.2, 165.8, 154.0, 150.4, 148.5, 145.1, 131.5, 127.7, 
125.6, 123.7, 122.9, 112.6, 112.4, 111.9, 108.7, 106.7, 101.7, 100.5, 55.9, 47.3, 39.7, 25.2.  
5-(3,4-dimethoxyphenyl)-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-3-oxopent-4-enamide 
(60). 3,4-Dimethoxybenzaldehyde (0.093 g, 0.56 mmol) was reacted with 72 (0.25 g, 0.47 mmol) 
following Procedure F to give compound 60 (0.075 g, 38%). 
1
H NMR (400 MHz, CDCl3) δ 8.15 
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(br. s., 1H), 7.58 (d, J = 13.55 Hz, 1H), 7.22 (d, J = 8.78 Hz, 1H), 7.14 (d, J = 8.28 Hz, 1H), 7.01 
- 7.09 (m, 4H), 6.88 (d, J = 8.53 Hz, 1H), 6.84 (dd, J = 1.51, 8.78 Hz, 1H), 6.62 (d, J = 16.06 Hz, 
1H), 3.92 (s, 3H), 3.91 (s, 3H), 3.86 (s, 3H), 3.58 - 3.65 (m, 4H), 2.96 (t, J = 6.90 Hz, 2H); 
13
C 
NMR (100 MHz, CDCl3) δ 195.3, 165.8, 154.0, 152.0, 149.3, 145.4, 131.5, 127.7, 126.9, 123.7, 
123.6, 122.9, 112.5, 112.3, 111.9, 111.1, 110.0, 100.5, 55.9, 47.3, 39.7, 25.2.  
5-(3,4-dihydroxyphenyl)-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-3-oxopent-4-enamide 
(61). 3,4-Dihydroxybenzaldehyde (0.077 g, 0.56 mmol) was reacted with 72 (0.25 g, 0.47 mmol) 
following Procedure G to give compound 61 (0.035 g, 19%). 
1
H NMR (400 MHz, CDCl3) δ 7.53 
(d, J = 16.06 Hz, 1H), 7.20 (d, J = 8.78 Hz, 1H), 7.07 - 7.10 (m, 1H), 7.03 - 7.07 (m, 2H), 6.96 
(d, J = 7.53 Hz, 1H), 6.78 (d, J = 8.03 Hz, 1H), 6.74 (dd, J = 2.26, 8.78 Hz, 1H), 6.60 (d, J = 
15.81 Hz, 1H), 3.78 - 3.83 (m, 3H), 3.49 - 3.55 (m, 2H), 3.31 (s, 2H), 2.93 (t, J = 7.03 Hz, 2H); 
13
C NMR (100 MHz, CD3OD) δ 196.3, 169.7, 155.1, 150.7, 147.2, 147.1, 133.6, 129.2, 127.6, 
124.5, 124.0, 123.5, 116.8, 115.6, 113.0, 112.7, 101.6, 56.6, 41.6, 31.0, 26.3.  
5-(4-hydroxy-3,5-dimethoxyphenyl)-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-3-oxopent-4-
enamide (62). 4-Hydroxy-3,5-dimethoxybenzaldehyde (0.129 g, 0.71 mmol) was reacted with 72 
(0.25 g, 0.47 mmol) following Procedure G to give compound 62 (0.068 g, 33%). 
1
H NMR (400 
MHz, CDCl3) δ 8.20 (br. s., 1H), 7.54 (d, J = 16.06 Hz, 1H), 7.23 (d, J = 8.53 Hz, 1H), 7.11 (t, J 
= 5.40 Hz, 1H), 7.03 (dd, J = 2.26, 6.53 Hz, 2H), 6.84 (dd, J = 2.51, 8.78 Hz, 1H), 6.78 (s, 2H), 
6.61 (d, J = 16.06 Hz, 1H), 3.90 (s, 6H), 3.85 (s, 3H), 3.73 (s, 1H), 3.58 - 3.65 (m, 4H), 2.96 (t, J 
= 7.00 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 195.1, 165.9, 154.0, 147.3, 145.9, 138.1, 131.5, 
127.7, 125.3, 123.5, 122.9, 112.4, 112.3, 111.9, 105.8, 100.5, 56.4, 55.9, 47.4, 43.4, 39.8, 25.2.  
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5-[4-(dimethylamino)phenyl]-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-3-oxopent-4-
enamide (63). 4-(Dimethylamino)benzaldehyde (0.084 g, 0.56 mmol) was reacted with 72 (0.25 
g, 0.47 mmol) following Procedure F to give compound 63 (0.047 g, 25%). 
1
H NMR (400 MHz, 
CDCl3) δ 8.15 (br. s., 1H), 7.59 (d, J = 15.81 Hz, 1H), 7.44 (d, J = 9.03 Hz, 2H), 7.32 (t, J = 5.77 
Hz, 1H), 7.24 (d, J = 8.78 Hz, 1H), 7.05 (dd, J = 2.26, 9.54 Hz, 2H), 6.86 (dd, J = 2.51, 8.78 Hz, 
1H), 6.63 - 6.69 (m, 2H), 6.55 (d, J = 15.81 Hz, 1H), 3.87 (s, 3H), 3.63 (q, J = 6.78 Hz, 2H), 3.58 
(s, 2H), 3.04 (s, 6H), 2.97 (t, J = 6.90 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 195.2, 166.3, 
154.0, 152.4, 146.2, 131.5, 130.7, 127.7, 122.9, 121.5, 120.4, 112.6, 112.3, 111.9, 111.8, 100.5, 
55.9, 46.9, 40.0, 39.7, 25.2.  
N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-3-oxo-5-(pyridin-3-yl)pent-4-enamide (64). 
Nicotinaldehyde (0.055 g, 0.51 mmol) was reacted with 72 (0.25 g, 0.47 mmol) following 
Procedure F to give compound 64 (0.055 g, 32%). 
1
H NMR (400 MHz, CDCl3) δ 13.59 (s, 1H), 
8.65 (s, 1H), 8.55 (d, J = 4.52 Hz, 1H), 8.13 (br. s., 1H), 7.76 (d, J = 8.03 Hz, 1H), 7.50 (d, J = 
16.06 Hz, 1H), 7.23 - 7.27 (m, 1H), 7.15 (d, J = 8.80 Hz, 1H), 6.94 (s, 1H), 6.86 (br. s., 1H), 6.77 
(dd, J = 2.50, 8.80 Hz, 1H), 6.71 (d, J = 16.31 Hz, 1H), 3.78 (s, 3H), 3.50 - 3.57 (m, 4H), 2.89 (t, 
J = 6.90 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 194.8, 154.1, 151.6, 150.3, 143.8, 141.3, 134.6, 
133.7, 131.5, 127.3, 122.8, 112.6, 112.5, 111.9, 100.5, 94.4, 55.9, 39.8, 25.2.  
N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-3-oxo-5-(pyridin-4-yl)pent-4-enamide (65). 
Isonicotinaldehyde (0.060 g, 0.56 mmol) was reacted with 72 (0.25 g, 0.47 mmol) following 
Procedure F to give compound 65 (0.065 g, 38%). 
1
H NMR (400 MHz, CDCl3) δ 13.64 (br. s., 
1H), 8.63 (d, J = 6.02 Hz, 1H), 8.54 (d, J = 5.77 Hz, 2H), 8.46 (br. s., 1H), 7.46 (d, J = 16.06 Hz, 
1H), 7.32 (d, J = 6.02 Hz, 1H), 7.23 (s, 1H), 6.99 (d, J = 2.00 Hz, 1H), 6.92 (br. s., 1H), 6.86 (dd, 
J = 2.26, 8.53 Hz, 1H), 6.46 (d, J = 15.81 Hz, 1H), 3.83 (s, 3H), 3.55 - 3.65 (m, 4H), 2.97 (t, J = 
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7.00 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 194.8, 171.4, 165.9, 154.3, 150.4, 142.0, 132.4, 
129.3, 127.0, 122.1, 121.4, 112.7, 112.5, 112.0, 100.5, 95.3, 56.0, 48.1, 39.5, 25.2.  
5-(furan-2-yl)-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-3-oxopent-4-enamide (66). 2-
Furaldehyde (0.054 g, 0.56 mmol) was reacted with 72 (0.25 g, 0.47 mmol) following Procedure 
F to give compound 66 (0.025 g, 15%). 
1
H NMR (400 MHz, CDCl3) δ 8.01 (br. s., 1H), 7.52 (d, 
J = 1.51 Hz, 1H), 7.37 (d, J = 15.81 Hz, 1H), 7.21 - 7.25 (m, 1H), 7.12 (br. s, 1H), 7.04 (d, J = 
2.51 Hz, 2H), 6.85 (dd, J = 2.38, 8.66 Hz, 1H), 6.72 (d, J = 3.51 Hz, 1H), 6.62 (d, J = 15.81 Hz, 
1H), 6.50 (dd, J = 1.88, 3.39 Hz, 1H), 3.86 (s, 1H), 3.58 - 3.65 (m, 2H), 3.55 (s, 2H), 2.96 (t, J = 
7.03 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 195.0, 165.8, 154.1, 150.7, 145.7, 131.5, 130.9, 
127.7, 122.9, 122.8, 117.2, 112.8, 112.7, 112.4, 111.9, 100.6, 55.9, 47.6, 39.7, 25.2.  
5-(furan-3-yl)-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-3-oxopent-4-enamide (67). 3-
Furaldehyde (0.054 g, 0.56 mmol) was reacted with 72 (0.25 g, 0.47 mmol) following Procedure 
F to give compound 67 (0.020 g, 12%). 
1
H NMR (400 MHz, CDCl3) δ 7.99 (br. s., 1H), 7.73 (s, 
1H), 7.55 (d, J = 15.81 Hz, 1H), 7.46 (t, J = 1.38 Hz, 1H), 7.26 (d, J = 8.78 Hz, 1H), 7.12 (br. s., 
1H), 7.05 (d, J = 2.26 Hz, 2H), 6.87 (dd, J = 2.26, 8.78 Hz, 1H), 6.61 (d, J = 1.76 Hz, 1H), 6.47 
(d, J = 16.06 Hz, 1H), 3.87 (s, 3H), 3.60 - 3.66 (m, 2H), 3.57 (s, 2H), 2.97 (t, J = 6.90 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ 165.8, 154.1, 146.0, 144.8, 135.4, 131.5, 125.6, 122.8, 122.6, 
112.6, 112.5, 111.9, 107.3, 100.5, 55.9, 47.1, 39.8, 25.2.  
5-(4-hydroxyphenyl)-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-3-oxopentanamide (68). 
Compound 56 (0.50 g, 1.32 mmol) was dissolved in MeOH (30 mL) under N2. To this, Pd/C 
(0.050 g) was added. The solution was then stirred under H2 at normal pressure overnight. The 
solution was then filtered to remove Pd/C, and the filtrate was concentrated under reduced 
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pressure. The residue was purified by column chromatography (MeOH/DCM: 2/98) to give 
compound 68 (0.360 g, 72%). 
1
H NMR (400 MHz, CDCl3) δ 8.37 (br. s., 1H), 7.75 (br. s., 1H), 
7.22 (d, J = 8.78 Hz, 1H), 7.01 (d, J = 2.26 Hz, 1H), 6.91 - 6.98 (m, 4H), 6.83 (dd, J = 2.26, 8.78 
Hz, 1H), 6.74 (d, J = 8.28 Hz, 2H), 3.83 (s, 0H), 3.55 (q, J = 6.61 Hz, 2H), 3.25 (s, 2H), 2.90 (t, J 
= 6.78 Hz, 2H), 2.67 - 2.78 (m, 4H); 
13
C NMR (100 MHz, CDCl3) δ 205.8, 165.8, 155.0, 153.9, 
131.5, 131.3, 129.2, 127.6, 123.0, 115.5, 112.2, 112.0, 100.5, 55.9, 49.3, 45.2, 39.7, 28.5, 25.0.   
 
5.1.3 NLRP3 Inhibitors 
 5-chloro-2-methoxy-N-phenethylbenzamide (87). 5-Chloro-2-methoxybenzoic acid 90 
(2.0 g, 10.7 mmol) and 2-phenylethanamine 91 (1.3 g, 10.7 mmol) were reacted following 
Procedure B to give compound 87 (1.95 g, 63%) as a viscous oil. 
1
H NMR (400 MHz, CDCl3) δ 
8.19 (d, J = 3.01 Hz, 1H), 7.82 (br. s., 1H), 7.36 (dd, J = 3.00, 8.80 Hz, 1H), 7.34 (d, J = 6.78 Hz, 
2H), 7.27 (d, J = 7.03 Hz, 2H), 7.26 - 7.28 (m, 1H), 6.85 (d, J = 8.78 Hz, 1H), 3.77 (q, J = 6.20 
Hz, 2H), 3.74 (s, 3H), 2.93 (t, J = 6.78 Hz, 2H); 
13
C NMR (100 MHz, DMSO-d6) δ 163.4, 155.7, 
139.4, 131.5, 129.6, 128.7, 128.3, 126.1, 124.7, 124.3, 114.1, 56.2, 40.7, 34.9. 
 4-(2-[(5-chloro-2-methoxyphenyl)formamido]ethyl)benzene-1-sulfonyl chloride (71). 
Compound 87 (0.50 g, 1.73 mmol) was dissolved in DCM (2 mL).  To this, excess 
chlorosulfonic acid (1 mL) was added, and the solution stirred at 70 °C for 2 h.  The reaction was 
cooled to room temperature, and then poured over crushed ice.  The product was extracted into 
DCM, and then concentrated under reduced pressure.  The product was purified by column 
chromatography (EtOAc/Hexanes: 20/80 to 50/50) yielding compound 71 (0.35 g, 52%) as a 
white solid. 
1
H NMR (400 MHz, CDCl3) δ 8.17 (d, J = 3.01 Hz, 1H), 8.00 (d, J = 8.28 Hz, 2H), 
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7.81 (br. s., 1H), 7.50 (d, J = 8.53 Hz, 2H), 7.39 (dd, J = 2.76, 8.78 Hz, 1H), 6.89 (d, J = 8.78 Hz, 
1H), 3.81 (s, 3H), 3.77 (q, J = 6.50 Hz, 2H), 3.08 (t, J = 6.90 Hz, 2H); 
13
C NMR (100 MHz, 
DMSO-d6) δ 163.5, 155.7, 146.1, 139.8, 131.5, 129.5, 128.0, 125.6, 124.7, 124.3, 114.2, 56.2, 
40.6, 34.6. 
 4-(2-[(5-chloro-2-methoxyphenyl)formamido]ethyl)benzene-1-sulfonic acid (73). 
Compound 71 (61 mg, 0.16 mmol) was added to H2O (5 mL) and refluxed overnight.  The water 
layer was washed with DCM, and the product was collected by distillation affording 73 (17.0 
mg, 29%). 
1
H NMR (400 MHz, DMSO-d6) δ 8.21 (t, J = 5.65 Hz, 1H), 7.67 (d, J = 2.76 Hz, 1H), 
7.53 - 7.57 (m, J = 8.28 Hz, 2H), 7.49 (dd, J = 2.76, 8.78 Hz, 1H), 7.19 - 7.23 (m, J = 8.03 Hz, 
2H), 7.15 (d, J = 8.78 Hz, 1H), 4.61 (br. s., 1H), 3.80 (s, 3H), 3.50 (q, J = 6.50 Hz, 2H), 2.83 (t, J 
= 7.03 Hz, 2H); 
13
C NMR (100 MHz, DMSO-d6) δ 163.5, 155.7, 146.1, 139.8, 131.5, 129.5, 
128.0, 125.6, 124.7, 124.3, 114.2, 56.2, 40.6, 34.6. 
 5-chloro-2-methoxy-N-[2-(4-sulfamoylphenyl)ethyl]benzamide (72). Compound 71 (500 
mg, 1.29 mmol) was added to aqueous NH4OH (10 mL) and stirred at room temperature for 1 h.  
The solid precipitate was collected, filtered, and washed extensively with H2O.  The remaining 
solid was purified by recrystallization in EtOH affording compound 72 (324 mg, 68%) as a white 
solid. 
1
H NMR (400 MHz, DMSO-d6) δ 8.25 (t, J = 5.52 Hz, 1H), 7.77 (d, J = 8.28 Hz, 2H), 7.65 
(d, J = 3.01 Hz, 1H), 7.50 (dd, J = 2.89, 8.91 Hz, 1H), 7.45 (d, J = 8.28 Hz, 2H), 7.28 (s, 2H), 
7.15 (d, J = 8.78 Hz, 1H), 3.81 (s, 3H), 3.54 (q, J = 6.30 Hz, 2H), 2.92 (t, J = 7.15 Hz, 2H); 
13
C 
NMR (100 MHz, DMSO-d6) δ 163.6, 155.7, 143.6, 142.1, 131.5, 129.5, 129.2, 125.7, 124.8, 
124.3, 114.1, 56.3, 40.3, 34.6. 
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 N-(2-(4-[bis(propan-2-yl)sulfamoyl]phenyl)ethyl)-5-chloro-2-methoxybenzamide (74). 
Compound 71 (220 mg, 0.76 mmol) was added to excess diisopropylamine (2 mL) in DCM (5 
mL) and stirred overnight.  The solution was then washed with H2O and concentrated under 
reduced pressure.  The product was purified by column chromatography (DCM/MeOH: 100/0 to 
97/3) yielding compound 74 (100 mg, 29%) as a white solid. 
1
H NMR (400 MHz, CDCl3) δ 8.13 
(d, J = 2.76 Hz, 1H), 7.81 (d, J = 8.28 Hz, 2H), 7.32 - 7.38 (m, 3H), 6.87 (d, J = 9.03 Hz, 1H), 
3.78 (s, 3H), 3.67 - 3.75 (m, 4H), 2.99 (t, J = 6.78 Hz, 2H), 1.27 (s, 6H), 1.25 (s, 6H); 
13
C NMR 
(100 MHz, DMSO-d6) δ 163.6, 155.6, 144.1, 140.1, 131.4, 129.4, 126.7, 124.8, 124.3, 114.1, 
56.2, 47.9, 40.1, 34.6, 21.5.  
 5-chloro-2-methoxy-N-(2-[4-(piperidine-1-sulfonyl)phenyl]ethyl)benzamide (75). 
Compound 71 (206 mg, 0.711 mmol) was added to excess piperidine (2 mL) in DCM (5 mL) and 
stirred overnight.  The solution was then washed with H2O and concentrated under reduced 
pressure.  The product was purified by column chromatography (DCM/MeOH: 100/0 to 97/3) 
yielding compound 75 (126 mg, 41%) as a white solid. 
1
H NMR (400 MHz, CDCl3) δ 8.16 (d, J 
= 2.76 Hz, 1H), 7.78 (br. s., 1H), 7.71 (d, J = 8.28 Hz, 2H), 7.40 (d, J = 8.30 Hz, 1H), 7.38 (dd, J 
= 2.80, 8.80 Hz, 2H), 6.88 (d, J = 8.78 Hz, 1H), 3.79 (s, 3H), 3.76 (q, J = 6.78 Hz, 2H), 2.99 (t, J 
= 5.50 Hz, 2H), 3.01 (t, J = 6.80 Hz, 4H), 1.64 (quin, J = 5.71 Hz, 4H), 1.42 (quin, J = 5.96 Hz, 
2H); 
13
C NMR (100 MHz, DMSO-d6) δ 163.6, 155.6, 145.0, 133.3, 131.4, 129.6, 129.4, 127.4, 
124.9, 124.3, 114.1, 56.2, 46.5, 40.1, 34.7, 24.6, 22.8. 
 5-chloro-N-(2-[4-(dimethylsulfamoyl)phenyl]ethyl)-2-methoxybenzamide (76). 
Dimethylamine HCl (105 mg, 1.29 mmol) and N-methylmorpholine (0.5 mL) were added to H2O 
(3 mL). Compound 71 (400 mg, 1.03 mmol) was dissolved in DCM (2 mL) and then added to 
the reaction, and the solution was stirred overnight at room temperature. The product was 
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extracted into DCM, concentrated, and purified by column chromatography (EtOAc/Hexanes: 
20/80 to 75/25) to give compound 76 (250 mg, 60%) as a white solid. 
1
H NMR (400 MHz, 
DMSO-d6) δ 8.26 (br. s., 1H), 7.68 (d, J = 7.78 Hz, 2H), 7.59 (br. s., 1H), 7.53 (d, J = 7.78 Hz, 
2H), 7.49 (d, J = 9.03 Hz, 1H), 7.15 (d, J = 9.29 Hz, 1H), 3.82 (s, 3H), 3.56 (q, J = 6.50 Hz, 2H), 
2.95 (t, J = 6.65 Hz, 2H), 2.59 (s, 6H); 
13
C NMR (100 MHz, DMSO-d6) δ 163.6, 155.6, 145.1, 
132.6, 131.4, 129.6, 129.4, 127.6, 124.9, 124.3, 114.1, 56.2, 40.1, 37.5, 34.7. 
 5-chloro-2-methoxy-N-(2-[4-(methylsulfamoyl)phenyl]ethyl)benzamide (77). 
Methylamine HCl (44 mg, 0.644 mmol) and N-methylmorpholine (0.1 mL) were added to 
MeOH (1 mL). Compound 71 (50 mg, 0.129 mmol) was dissolved in DCM (2 mL) and then 
added to the reaction, and the solution was stirred overnight at room temperature. The reaction 
was concentrated, and then dissolved in DCM and H2O. The product was extracted into DCM, 
concentrated, and purified by column chromatography (DCM/MeOH: 100/0 to 95/5) to give 
compound 77 (42 mg, 85%) as a white solid. 
1
H NMR (400 MHz, CDCl3) δ 8.17 (d, J = 2.76 Hz, 
1H), 7.82 (d, J = 8.28 Hz, 2H), 7.41 (d, J = 8.53 Hz, 2H), 7.39 (dd, J = 2.89, 8.91 Hz, 1H), 6.88 
(d, J = 8.78 Hz, 1H), 4.26 (q, J = 5.19 Hz, 1H), 3.80 (s, 3H), 3.75 (q, J = 6.70 Hz, 2H), 3.02 (t, J 
= 6.78 Hz, 2H), 2.68 (d, J = 5.52 Hz, 3H); 
13
C NMR (100 MHz, DMSO-d6) δ 163.6, 155.7, 
144.3, 137.2, 131.4, 129.5, 129.4, 126.7, 124.9, 124.3, 114.2, 56.2, 40.1, 34.6, 28.6.  
 5-chloro-N-(2-[4-(acetamidosulfonyl)phenyl]ethyl)-2-methoxybenzamide (78). 
Compound 72 (450 mg, 1.22 mmol) was added to excess acetic anhydride (1 mL) in DCM (5 
mL) and stirred at 75 °C overnight.  The solid precipitate was filtered off and washed with H2O 
and DCM affording compound 78 (400 mg, 80%) as a white solid. 
1
H NMR (400 MHz, DMSO-
d6) δ 12.01 (s, 1H), 8.25 (t, J = 5.65 Hz, 1H), 7.85 (d, J = 8.53 Hz, 2H), 7.63 (d, J = 2.76 Hz, 
1H), 7.47 - 7.53 (m, 3H), 7.15 (d, J = 8.78 Hz, 1H), 3.79 (s, 3H), 3.55 (q, J = 6.70 Hz, 2H), 2.94 
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(t, J = 7.03 Hz, 2H), 1.92 (s, 3H); 
13
C NMR (100 MHz, DMSO-d6) δ 168.7, 163.6, 155.7, 145.8, 
137.3, 131.5, 129.5, 129.4, 127.5, 124.9, 124.3, 114.1, 56.2, 40.1, 34.7, 23.2. 
 5-chloro-N-(2-[4-(hydrazinesulfonyl)phenyl]ethyl)-2-methoxybenzamide (79). Excess 
hydrazine (0.2 mL) was dissolved in DCM (8 mL) and cooled to 0 °C.  To this, compound 71 
(50 mg, 0.129 mmol) dissolved in DCM (2 mL) was added dropwise, slowly.  The reaction was 
allowed to warm to room temperature and stirred overnight.  The organic layer was washed with 
H2O and concentrated to give compound 79 (41 mg, 85%) as a white solid. 
1
H NMR (400 MHz, 
DMSO-d6) δ 8.32 (s, 1H), 8.28 (t, J = 5.65 Hz, 1H), 7.75 (d, J = 8.28 Hz, 2H), 7.64 (d, J = 2.76 
Hz, 1H), 7.50 (dd, J = 2.80, 8.80 Hz, 0H), 7.48 (d, J = 8.30 Hz, 2H), 7.16 (d, J = 9.03 Hz, 1H), 
4.06 (d, J = 3.01 Hz, 2H), 3.82 (s, 3H), 3.54 (q, J = 6.53 Hz, 2H), 2.93 (t, J = 6.90 Hz, 2H); 
13
C 
NMR (100 MHz, DMSO-d6) δ 163.6, 155.7, 144.6, 136.0, 131.5, 129.5, 129.3, 127.7, 124.8, 
124.3, 114.2, 56.3, 40.3, 34.7. 
 5-chloro-N-(2-[4-(hydroxysulfamoyl)phenyl]ethyl)-2-methoxybenzamide (80). 
Hydroxylamine HCl (441 mg, 6.44 mmol) and N-methylmorpholine (0.2 mL) were dissolved in 
MeOH (2 mL). To this, compound 71 (500 mg, 1.29 mmol) was added, and the solution was 
stirred for 4 h.  H2O was added, and the product was extracted into DCM and concentrated.  The 
product was purified by column chromatography (DCM/MeOH: 100/0 to 94/6) to give 
compound 80 (90 mg, 18%) as a white solid. 
1
H NMR (400 MHz, DMSO-d6) δ 9.56 (d, J = 3.26 
Hz, 1H), 9.52 (d, J = 3.26 Hz, 1H), 8.27 (t, J = 5.40 Hz, 1H), 7.78 (d, J = 8.28 Hz, 2H), 7.64 (d, J 
= 2.76 Hz, 1H), 7.48 - 7.53 (m, 3H), 7.15 (d, J = 8.78 Hz, 1H), 3.81 (s, 3H), 3.55 (q, J = 6.70 Hz, 
2H), 2.94 (t, J = 6.90 Hz, 2H); 
13
C NMR (100 MHz, DMSO-d6) δ 163.6, 155.7, 145.2, 135.3, 
131.5, 129.5, 129.2, 128.2, 124.8, 124.3, 114.2, 56.2, 40.2, 34.7.  
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 3-chloro-N-[2-(4-sulfamoylphenyl)ethyl]benzamide (81). 3-Chlorobenzoic acid (1.0 g, 
6.39 mmol) was added to thionyl chloride (20 mL) and 1 drop DMF.  The solution was refluxed 
for 3 h, cooled to room temperature, and concentrated.  The remaining residue was dissolved in 
ACN (40 mL).  To this, a solution of 4-(2-aminoethyl)benzenesulfonamide 92 (1.60 g, 7.98 
mmol) and N-methylmorpholine (1 mL) in ACN (9 mL) was added dropwise over 15 minutes.  
The reaction was stirred at room temperature overnight.  The solution was concentrated, and cold 
H2O was added.  The resulting precipitate was collected, filtered, and washed with H2O.  The 
product was purified by recrystallization in EtOH to give compound 81 (1.4 g, 65%) as a white 
solid. 
1
H NMR (400 MHz, DMSO-d6) δ 8.70 (br. s., 1H), 7.85 (s, 1H), 7.75 (d, J = 8.00 Hz, 2H), 
7.72 - 7.79 (m, 1H), 7.59 (d, J = 7.53 Hz, 1H), 7.50 (t, J = 7.53 Hz, 1H), 7.43 (d, J = 8.03 Hz, 
2H), 7.28 (s, 2H), 3.52 (q, J = 6.80 Hz, 2H), 2.93 (t, J = 7.15 Hz, 2H); 
13
C NMR (100 MHz, 
DMSO-d6) δ 164.8, 143.6, 142.1, 136.4, 133.2, 131.0, 130.3, 129.1, 126.9, 125.9, 125.7, 40.5, 
34.6.  
 2-methoxy-N-[2-(4-sulfamoylphenyl)ethyl]benzamide (82). 2-Methoxybenzoic acid (1.0 
g, 6.57 mmol) was added to thionyl chloride (20 mL) and 1 drop DMF.  The solution was 
refluxed for 3 h, cooled to room temperature, and concentrated.  The remaining residue was 
dissolved in ACN (40 mL).  To this, a solution of compound 92 (1.32 g, 6.57 mmol) and N-
methylmorpholine (1 mL) in ACN (9 mL) was added dropwise over 15 minutes.  The reaction 
was stirred at room temperature overnight.  The solution was concentrated, and cold H2O was 
added.  The resulting precipitate was collected, filtered, and washed with H2O.  The product was 
purified by recrystallization in EtOH to give compound 82 (1.4 g, 62%) as a white solid. 
1
H 
NMR (400 MHz, DMSO-d6) δ 8.17 (br. s., 1H), 7.77 (d, J = 7.03 Hz, 2H), 7.72 (d, J = 7.53 Hz, 
1H), 7.46 (d, J = 7.53 Hz, 2H), 7.41 - 7.48 (m, 0H), 7.28 (s, 2H), 7.11 (d, J = 8.78 Hz, 1H), 7.02 
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(t, J = 7.40 Hz, 1H), 3.81 (s, 3H), 3.55 (q, J = 6.80 Hz, 2H), 2.92 (t, J = 6.65 Hz, 2H); 
13
C NMR 
(100 MHz, DMSO-d6) δ 164.9, 156.9, 143.8, 142.1, 132.2, 130.4, 129.2, 125.7, 122.9, 120.5, 
112.0, 55.8, 40.2, 34.7. 
 N-[2-(4-sulfamoylphenyl)ethyl]benzamide (83). Benzoic acid (0.61 g, 5.0 mmol) was 
added to thionyl chloride (20 mL) and 1 drop DMF.  The solution was refluxed for 3 h, cooled to 
room temperature, and concentrated.  The remaining residue was dissolved in ACN (40 mL).  To 
this, a solution of compound 92 (1.0 g, 5.0 mmol) and N-methylmorpholine (1 mL) in ACN (9 
mL) was added dropwise over 15 minutes.  The reaction was stirred at room temperature 
overnight.  The solution was concentrated, and cold H2O was added.  The resulting precipitate 
was collected, filtered, and washed with H2O.  The product was purified by recrystallization in 
EtOH to give compound 83 (0.83 g, 55%) as a white solid. 
1
H NMR (400 MHz, DMSO-d6) δ 
8.57 (br. s., 1H), 7.81 (d, J = 7.03 Hz, 2H), 7.75 (d, J = 7.78 Hz, 2H), 7.52 (t, J = 7.00 Hz, 1H), 
7.41 - 7.48 (m, 4H), 7.29 (s, 2H), 3.52 (q, J = 6.20 Hz, 2H), 2.93 (t, J = 6.90 Hz, 2H); 
13
C NMR 
(100 MHz, DMSO-d6) δ 166.3, 143.8, 142.0, 134.5, 131.1, 129.1, 128.2, 127.1, 125.7, 40.4, 
34.8. 
 5-chloro-2-hydroxy-N-[2-(4-sulfamoylphenyl)ethyl]benzamide (84). 5-Chloro-2-
hydroxybenzoic acid (1.0 g, 5.79 mmol) was dissolved in DMF (40 mL) and cooled to 0 °C.  
EDC (1.39 g, 7.24 mmol) and HOBt (0.78 g, 5.79 mmol) were added, and the solution was 
stirred for 1 h.  Compound 92 (1.16 g, 5.79 mmol) and N-methylmorpholine (1.28 mL) were 
then added, and the solution was stirred overnight.  The solution was then concentrated under 
reduced pressure.  DCM was then added, and the resulting precipitate was filtered off and 
collected.  The precipitate was purified by recrystallization in EtOH to yield compound 84 (165 
mg, 8%) as a white solid. 
1
H NMR (400 MHz, DMSO-d6) δ 12.47 (s, 1H), 8.93 (t, J = 5.52 Hz, 
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1H), 7.90 (d, J = 2.51 Hz, 1H), 7.75 (d, J = 8.53 Hz, 2H), 7.44 (d, J = 8.28 Hz, 2H), 7.43 (dd, J = 
2.50, 8.80 Hz, 1H), 7.27 (s, 2H), 6.93 (d, J = 8.78 Hz, 1H), 3.56 (q, J = 6.80 Hz, 2H), 2.94 (t, J = 
7.28 Hz, 2H); 
13
C NMR (100 MHz, DMSO-d6) δ 167.3, 158.4, 143.4, 142.2, 133.2, 129.1, 
127.3, 125.7, 122.3, 119.3, 116.9, 40.2, 34.4. 
 5-chloro-2-methoxy-N-[2-(4-sulfamoylphenyl)ethyl]pyridine-3-carboxamide (85). 5-
Chloro-2-methoxypyridine-3-carboxylic acid (150 mg, 0.800 mmol) was added to thionyl 
chloride (5 mL) and 1 drop DMF.  The solution was refluxed for 3 h, cooled to room 
temperature, and concentrated.  The remaining residue was dissolved in ACN (5 mL).  To this, a 
solution of compound 92 (121 mg, 0.60 mmol) and N-methylmorpholine (0.5 mL) in ACN (5 
mL) was added dropwise over 15 minutes.  The reaction was stirred at room temperature 
overnight.  The solution was concentrated, and cold H2O was added.  The resulting precipitate 
was collected, filtered, and washed with H2O.  The product was purified by recrystallization in 
EtOH to give compound 85 (210 mg, 95%) as a white solid. 
1
H NMR (400 MHz, DMSO-d6) δ 
8.35 (d, J = 2.76 Hz, 1H), 8.35 (s, 0H), 8.06 (d, J = 2.76 Hz, 1H), 7.77 (d, J = 8.28 Hz, 2H), 7.45 
(d, J = 8.03 Hz, 2H), 7.28 (s, 2H), 3.92 (s, 3H), 3.54 (q, J = 6.70 Hz, 2H), 2.92 (t, J = 7.03 Hz, 
2H); 
13
C NMR (100 MHz, DMSO-d6) δ 162.4, 158.8, 146.8, 143.5, 142.2, 138.9, 129.2, 125.7, 
123.5, 118.9, 54.2, 40.4, 34.5.  
 5-chloro-2-(methylamino)-N-[2-(4-sulfamoylphenyl)ethyl]benzamide (86). 2-[(tert-
butoxycarbonyl)(methyl)amino]-5-chlorobenzoic acid (125 mg, 0.44 mmol) was dissolved in 
DCM (5 mL) and DMF (0.25 mL), and cooled to 0 °C.  EDC (150 mg, 0.78 mmol) and HOBt 
(105 mg, 0.78 mmol) were added, and the solution was stirred for 1 h.  Compound 92 (75 mg, 
0.374 mmol) and Et3N (0.1 mL) were then added, and the reaction was stirred overnight.  The 
solution was washed with acidic H2O. The organic layer was then concentrated under reduced 
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pressure.  The product was purified by column chromatography (DCM/MeOH: 100/0 to 95/5) to 
give compound 86 (79 mg, 49%) as a white solid. 
1
H NMR (400 MHz, DMSO-d6) δ 8.53 (t, J = 
5.27 Hz, 1H), 7.72 - 7.77 (m, 2H), 7.62 (q, J = 5.19 Hz, 1H), 7.53 (d, J = 2.51 Hz, 1H), 7.39 - 
7.44 (m, J = 8.28 Hz, 2H), 7.28 (s, 2H), 7.30 (dd, J = 2.50, 8.80 Hz, 1H), 6.63 (d, J = 8.78 Hz, 
1H), 3.46 (q, J = 6.80 Hz, 2H), 2.90 (t, J = 7.28 Hz, 2H), 2.76 (d, J = 5.02 Hz, 3H); 
13
C NMR 
(100 MHz, DMSO-d6) δ 167.8, 148.8, 143.7, 142.1, 131.8, 129.1, 127.4, 125.7, 117.4, 116.0, 
112.3, 40.1, 34.6, 29.3. 
 4-(2-([(5-chloro-2-methoxyphenyl)methyl]amino)ethyl)benzene-1-sulfonamide (88). 
Compound 92 (66 mg, 0.328 mmol) and 5-chloro-2-methoxybenzaldehyde 93 (50 mg, 0.293 
mmol) were added together in DCE (9 mL) and stirred at room temperature for 30 min.  Glacial 
acetic acid (16.4 mg, 0.328 mmol) in DCE (1 mL) was then added, and the reaction was stirred at 
room temperature for 1 h.  The solution was cooled to 0 °C, and then NaCNBH3 (25.5 mg, 0.39 
mmol) in MeOH (3 mL) was added dropwise.  The reaction was stirred at room temperature 
overnight.  The solution was then concentrated under reduced pressure, and then DCM was 
added.  The organic layer was washed with H2O, and then concentrated again.  The product was 
purified by column chromatography (DCM/MeOH/Et3N: 100/0/0 to 90/8/2) to afford compound 
88 (58 mg, 51%) as a white solid. 
1
H NMR (400 MHz, CDCl3) δ 7.84 (d, J = 8.53 Hz, 2H), 7.34 
(d, J = 8.28 Hz, 2H), 7.15 - 7.22 (m, 2H), 6.72 - 6.77 (m, 1H), 4.72 (br. s., 2H), 3.75 (s, 2H), 3.74 
(s, 3H), 2.87 - 2.90 (m, 4H); 
13
C NMR (100 MHz, DMSO-d6) δ 155.7, 144.8, 141.8, 129.0, 
128.1, 127.0, 125.6, 123.9, 112.1, 55.6, 49.9, 46.7, 35.5. 
 4-([(5-chloro-2-methoxyphenyl)formohydrazido]methyl)benzene-1-sulfonamide (89). 5-
chloro-2-methoxybenzohydrazide 95 (200 mg, 1.00 mmol) and 4-formylbenzene-1-sulfonamide 
94 (185 mg, 1.00 mmol) were added together in EtOH (5 mL).  AcOH (0.1 mL) was then added 
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and the reaction was refluxed overnight.  The solution was then cooled to room temperature, and 
the precipitate was filtered off and washed with EtOH.  The solid precipitate was added to a 
THF/MeOH (50/50) solution (20 mL).  To this, NaCNBH3 (63 mg, 1.00 mmol) was added, and 
the suspension was stirred at room temperature overnight.  Concentrated HCl (2 mL) was added 
to the suspension.  When no more bubbles were formed, the solution was basified with a 
saturated NaHCO3 solution.  The solid precipitate was filtered off, washed with H2O, and dried 
to give compound 89 (234 mg, 63%) as a white solid. 
1
H NMR (400 MHz, DMSO-d6) δ 9.50 (d, 
J = 6.27 Hz, 1H), 7.76 - 7.80 (m, 2H), 7.54 - 7.58 (m, J = 8.28 Hz, 2H), 7.53 (d, J = 2.76 Hz, 
1H), 7.48 (dd, J = 2.89, 8.91 Hz, 1H), 7.30 (s, 2H), 7.12 (d, J = 8.78 Hz, 1H), 5.69 (q, J = 5.50 
Hz, 1H), 4.06 (d, J = 5.27 Hz, 2H), 3.77 (s, 3H); 
13
C NMR (100 MHz, DMSO-d6) δ 163.3, 
155.6, 142.8, 142.7, 131.4, 129.1, 128.8, 125.4, 124.4, 124.2, 114.0, 56.2, 53.8. 
 
5.2 Biological Methods  
5.2.1 In Vitro Assays 
5.2.1.1 MC65 Cell Culture 
MC65 cells (kindly provided by Dr. George M. Martin at the University of Washington, 
Seattle) were cultured in Dulbecco‟s Modified Eagle‟s Medium (DMEM) (Life Technologies, 
Inc., Grand Island, NY) supplemented with 10% of heat-inactivated fetal bovine serum (FBS) 
(Hyclone, Logan, UT), 1% Penicillin/Streptomycin (P/S) (Invitrogen), 1 μg/mL Tetracycline 
(TC) (Sigma Aldrich, St. Louis, MO), and 0.2 mg/mL G418 (Invitrogen).  All assays were 
carried out in Opti-MEM Reduced Serum Medium (Life Technologies, Inc., Grand Island, NY).  
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Cells were maintained at 37 °C in a fully humidified atmosphere containing 5% CO2.  Cell 
controls were prepared in Opti-MEM with or without TC (+TC or -TC). 
 
5.2.1.2 MC65 Viability Assay  
MC65 cells were cells were washed twice with PBS, resuspended in Opti-MEM, and 
seeded in 96-well plates (4×10
4
 cells/well).  Indicated compounds were then added, and cells 
were incubated at 37 °C under +TC or -TC conditions for 72 h.  MTT (5 mg/mL in PBS) were 
then added and the cells were incubated for another 4 h.  Cell medium was then removed, and the 
remaining formazan crystals produced by the cellular reduction of MTT were dissolved in 
DMSO.  Absorbance at 570 nm was immediately recorded using a FlexStation 3 plate reader 
(Molecular Devices, CA).  Values are expressed as a percentage relative to those obtained in the 
+TC controls. 
 
5.2.1.3 ROS Production Assay  
MC65 cells were washed twice with PBS, resuspended in Opti-MEM, and seeded in 6-
well plates (2×10
6
 cells/well).  Indicated compounds were then added, and cells were incubated 
at 37 °C under +TC and -TC conditions for 48 h.  Cells were harvested, washed with cold PBS, 
then suspended in PBS and incubated with DCFH-DA (25 µM) in dark for 1 h.  Fluorescence 
was analyzed by flow cytometry using a Millipore Guava easyCyte flow cytometer.  Values are 
expressed as a percentage relative to those obtained in -TC controls.  
 
  
126 
 
5.2.1.4 Rotenone-Induced Toxicity Assay   
MC65 cells were seeded in 96-well plates (4×10
4
 cells/well) in growth medium and 
incubated at 37 °C for 24 h.  Medium was then removed and compounds were added in fresh 
growth medium at the indicated concentrations, and the cells were incubated for another 2 h.  
Rotenone was then added at a final concentration of 10 µM, and the plates were then incubated 
for 48 h. Cell viability was assessed by MTT assay as previously described. Values are expressed 
as a percentage relative to the negative (rotenone-free) control. 
 
5.2.1.5 Aß Western Blot  
MC65 cells were washed twice with PBS, re-suspended in Opti-MEM, and seeded in 6-
well plates (2×10
6
 cells/well).  Indicated compounds were then added, and cells were incubated 
at 37 °C under +TC and -TC conditions for 48 h.  Cells were harvested, washed with cold PBS, 
then lysed by sonication in a Tricine buffer solution. Protein samples were collected from the 
supernatant after centrifugation at 12,800×g for 5 min, and then quantified using the Bradford 
method. Equal amounts of protein (20.0 μg) were separated by SDS-PAGE on a Tris-Tricine gel 
(Bio-Rad) and transferred onto a PVDF membrane (Bio-Rad). Blots were blocked with a 5% 
milk in TBS-Tween 20 (0.1%) solution at room temperature for 1 h, and then probed with the 
6E10 antibody (Signet, Dedham, MA) overnight at 4 °C. Blots were washed twice in TBS-
Tween 20 for 15 min, and then incubated with a 1:1000 dilution of horseradish peroxidase-
conjugated secondary antibody in a 5% milk/PBS-Tween 20 solution at room temperature for 1 
h. After washing twice in TBS-Tween 20 for 15 min, the proteins were visualized by a Western 
Blot Chemiluminescence Reagent following the manufacturer‟s instructions (Thermo Fischer 
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Scientific, Waltham, MA). Blots were also probed with antibodies against α-tubulin to ensure 
equal loading of proteins. 
 
5.2.1.6 Aß40 and Aß42 ELISA 
MC65 cells were cells were washed twice with PBS, re-suspended in Opti-MEM, and 
seeded in 96-well plates (4×10
4
 cells/well).  Indicated compounds were then added, and cells 
were incubated at 37 °C under +TC or -TC conditions for 48 h.  The conditioned media was then 
added to ELISA plates precoated with BNT77 antibody (Wako, Richmond, VA) and incubated 
overnight at 4 °C.  Plates were then washed 5 times and HRP-conjugated secondary antibodies 
were added, BA27 for Aß40 or BC05 for Aß42, and plates were incubated at room temperature for 
1 h.  Plates were washed once more.  TMB was added to initiate the HRP reaction, and plates 
incubated in dark at room temperature for 30 min.  Stop solution was then added to terminate the 
reaction.  Absorbance at 450 nm was immediately recorded using a FlexStation 3 plate reader 
(Molecular Devices, CA).  Values are expressed in pM and were calculated using calibration 
curves generated with Aß standard proteins.  
 
 
5.2.1.7 Thioflavin T Binding Assay 
A thioflavin T (ThT)-binding assay, used to measure Aß42 aggregation, was conducted 
following published methods.
10
  Aß42 was obtained from American Peptide, Inc. (Sunnyvale, 
CA).  Briefly, 1 µL of each compound solution in DMSO (0.01 µM to 100 µM) was added to 
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corresponding wells in a 96-well plate.  Each concentration was prepared as independent 
triplicates, and a solvent control was included.  To each well, 9 µL of 25 µM Aß42 in PBS (pH 
7.4) was added, and plates were then incubated in dark at room temperature for 48 h.  Next, 200 
µL of a 5 µM ThT in 50 mM glycine solution (pH 8.0) was added to each well.  Fluorescence 
was immediately recorded using a FlexStation 3 plate reader (Molecular Devices, CA) at an 
excitation wavelength of 446 nm and an emission wavelength of 490 nm.  
 
5.2.1.8 AFM Analysis of Aß42 Fibril and Oligomer Formation 
Aß42 oligomers and fibrils were prepared based on reported procedures.
230
  Indicated 
compounds were incubated with Aß42 at a 1:1 ratio for 24 h.  Samples were loaded on mica, 
washed extensively with water, and dried overnight at room temperature before AFM analysis.  
The morphology of the Aß42 aggregates was assessed using an atomic force microscope 
(Dimension Icon, Bruker) operating in tapping mode in air.  The scan rate was varied between 1 
Hz and 0.5 Hz, depending on the tracking quality.  The silicon tips (Bruker mpp2100-100) have 
a sharpness of less than 5 nm and a force constant between 3 and 5 N/m along with a resonant 
frequency rated between 60-90 Hz.  All images were taken with 512 points per line, with a 1:1 
ratio.  Images were processed using Nanoscope analysis software v1.20 and Image-J (from the 
National Institutes of Health).  
 
5.2.1.9 Biometal Chelation Assay  
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Compounds (50 µM) and CuSO4, FeCl2, or ZnCl2 (50 µM) in water were incubated at 
room temperature for 10 min, and then UV absorption was recorded from 200 nm to 600 nm on a 
Flexstation 3 plate reader (Molecular Devices, CA). 
 
5.2.1.10 HT22 Cell Culture  
HT22 mouse hippocampal cells (graciously provided by Dr. Dave R. Schubert at the Salk 
Institute, La Jolla, CA) were cultured in DMEM supplemented with 10% FBS and 1% P/S.  Cells 
were maintained at 37 °C in a fully humidified atmosphere containing 5% CO2.  
 
5.2.1.11 H2O2-Induced Toxicity Assay  
HT22 cells were seeded in 96-well plates (4×10
3
 cells/well) in growth medium and 
incubated at 37 °C for 24 h.  Medium was then removed and compounds were added in fresh 
growth medium at the indicated concentrations, and the cells were incubated for another 1 h.  
H2O2 was then added at a final concentration of 500 µM, and the plates were then incubated for 
24 h.  Cell viability was assessed by MTT assay as previously described.  Values were expressed 
as a percentage relative to the negative (H2O2-free) control. 
 
 
5.2.1.12 J774.A1 Cell Culture  
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J774.A1 murine macrophage cells (ATCC, Manassas, VA) were cultured in DMEM 
supplemented with 10% FBS and 1% P/S, and filtered through a 0.2 micron membrane.  Cells 
were maintained at 37 °C in a fully humidified atmosphere containing 5% CO2.  
 
5.2.1.13 HL-1 Cell Culture  
HL-1 immortalized adult murine cardiomyocytes (a gift from Dr. Claycomb  at Louisiana 
State University, New Orleans, LA) were cultured in Claycomb medium (Sigma-Aldrich) as 
suggested.
231
  Cells were maintained at 37 °C in a fully humidified atmosphere containing 5% 
CO2. 
 
5.2.1.14 NLRP3 Inflammasome Activation and IL-1ß ELISA 
J774.A1 cells were plated in (5x10
4
 cells/well) 96-well plates for 24 h in growth medium.  
The cells were primed with Escherichia coli 0111:B4 lipopolysaccharide (LPS) (25 ng/mL; 
Sigma-Aldrich) (1 µg/mL) for 4 h.  Next, compounds were added at the indicated concentrations 
for 30 min.  Then, ATP (5 mM) was added to induce NLRP3 inflammasome formation, and cells 
were incubated another 30 min.  The supernatants were collected and levels of IL-1ß were 
measured with a mouse IL-1ß ELISA kit (Thermo Fisher Scientific, Princeton, NJ) following the 
manufacturer‟s instructions.  Values are expressed as a percentage relative to the positive 
(+LPS/ATP) control.    
In separate experiments, HL-1 cells were plated and primed with LPS (25 ng/mL) for 2 h 
and then treated with ATP (5 mM) for 1 h.  Cells were treated with compounds at the indicated 
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concentrations during the LPS priming phase, 30 min before ATP addition.  The supernatants 
were collected and levels of IL-1ß were measured as previously described.  Values are expressed 
as a percentage relative to the positive (+LPS/ATP) control.   
 
5.2.1.15 ASC Aggregation Staining 
HL-1 cells were plated on 24×24 mm glass covers pretreated with gelatin/plasma human-
fibronectin (0.02–0.5%) at 2.5 × 105 in 35-mm dishes 24 h before the experiment.  ASC 
expression was detected as circumscribed cytoplasmic perinuclear aggregates and expressed as 
ASC-positive cells over the total cells per field.  ASC aggregates were quantified blindly by two 
different investigators. 
 
5.2.1.16 Caspase-1 Activity 
 HL-1 cells (2 × 10
6
 cells) were plated in 90-mm dishes and NLRP3 inflammasome 
formation was induced as described above.  After treatment, cells were washed, harvested, and 
frozen.  The pellet was then homogenized using RIPA buffer (Sigma-Aldrich) containing a 
mixture of protease inhibitors (Sigma-Aldrich) and centrifuged at 16,200×g for 20 min.  The 
supernatants were collected and the protein contents were quantified using the Bradford method.  
The caspase-1 activity was determined by cleavage of CaspACE, a fluorogenic substrate 
(Promega, Madison, WI).  The fluorescence was measured at an excitation wavelength of 360 
nm and an absorbance wavelength of 460 nm.  Data is reported as arbitrary fluorescence units 
produced by 1 μg of sample per min (fluorescence/μg/min). 
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5.2.1.17 Trypan Exclusion Method 
HL-1 cells were treated as described above and also with LPS (25 ng/mL) and nigericin 
(20 µM) (Enzo Life Sciences Inc, Farmingdale, NY).  Cells were then harvested, and re-
suspended in 1 mL of Claycomb medium.  Cells were treated with 100 μL of 0.4% Trypan blue 
stain (Gibco) and incubated at room temperature for 5 min.  Trypan blue positive cells were 
deemed nonviable, and the percentage of cell death was measured as the ratio of trypan blue 
positive cells over total cell number per field.  
 
5.2.1.18 NLRC4 and AIM2 Inflammasome Activation 
HL-1 cells (1x10
6
) were plated in 35 mm dishes and treated with flagellin or Poly-
deoxyadenylic-deoxythymidylic acid sodium salt (Poly(dA:dT)) to induce NLRC4 and AIM2 
inflammasome formation, respectively.  Flagellin (0.7 µg/mL) (Enzo Life Sciences, 
Farmingdale, NY), isolated from Salmonella typhimurium strain 14028, was added to Claycomb 
medium without FBS.  In order to induce the NLRC4 inflammasome, cells were first treated with 
flagellin for 4 h and then treated with LPS (25 ng/mL) for 1 h.  In order to induce the AIM2 
inflammasome, HL-1 cells were cultured in DMEM (Invitrogen) without FBS, treated with 
Poly(dA:dT) (4 µg/mL) for 6 h and then treated with LPS (25 ng/mL) for 1 h.  Compounds were 
added at indicated concentrations at the same time as flagellin or Poly(dA:dT).  Formation of the 
AIM2 and NLRC4 inflammasomes was determined and quantified by caspase-1 activity and cell 
death, as described above. 
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5.2.2 In Vivo Assays 
5.2.2.1 BBB Penetration Assay 
Ten week old CD1 male mice were purchased from Harlan Laboratories (Frederich, 
MD).  Compound 68 was diluted to a concentration of 15 mg/mL in a solution with 2% DMSO 
and 10% Cremophor in PBS, and was administered via oral gavage at a final dosage of 50 
mg/kg.  Two groups of mice (n = 6/group) were used to determine the plasma and brain 
concentrations of the compound at various time points.  Following administration of anesthetic 
(sodium pentobarbital 150 mg/kg, Sigma-Aldrich, Saint Louis, MO), blood samples were 
collected from the inferior vena cava to prepare the plasma.  Afterward, the right atrium was 
removed to allow exsanguination, and the left ventricular apex was cannulated with a 24 G 
needle and perfused with 30 mL of warm (37 °C) heparinized normal saline solution to enable 
perfusion of all the organs and complete blood washout.  The perfused brains were then 
collected, rapidly washed in normal saline, blot-dried, and frozen in liquid nitrogen.  For brain 
samples, half a brain was weighed and diluted with 1.0 mL of acetonitrile and then homogenized 
well.  For plasma samples, 0.01 mL of plasma was diluted with 0.99 mL of acetonitrile and then 
mixed well.  After mixing, samples were centrifuged at 15,000 rpm, and the supernatant was 
transferred to a new tube and evaporated to dryness using a spin vacuum.  The samples were then 
reconstituted with an 80:20 solution of 1% acetic acid in acetonitrile: 1% acetic acid in water, 
and a volume of 0.025 mL was then injected into a LC-MS/MS.  The LC/MS/MS method 
employed positive electrospray ionization (ESI) with a selected reaction monitoring (SRM) 
mode.  Compound 68 was monitored using the following SRM transitions: 381→174, 130, and 
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159.  Chromatographic separation was achieved under gradient conditions using a Waters 
Acquity® UPLC, with a reversed phase column (Gemini 5 µm C18 110Å, 100 mm x 2.0 mm; 5 
µm, Phenomenex Inc., Torrance, CA) with a mobile phase composition of 1% acetic acid in 
water (mobile phase A) and 1% acetic acid in acetonitrile (mobile phase B).  The initial gradient 
consisted of 30% B for 1 min, 30% to 95% B from 1 to 3 min, hold for 1 min at 95% B, and then 
equilibrate at 30% B for 2.5 min.  The total run time was 6.5 min.  Results were processed using 
Analyst 1.5.2 software.  Absolute recovery, precision and accuracy, and matrix effects 
experiments produced an efficient method to continue sample analysis.  Calibration curves were 
made with freshly prepared samples and calculated using peak area versus concentration with a 
linear or quadratic regression.  
 
5.2.2.2 Administration of Compound 72 in the Mouse 
Compound 72 was dissolved in DMSO (0.05-0.1 mL). In order to determine whether 
treatment with 72 had any toxic effects in vivo, weight, appetite, and behavior were measured 
after single and repeated administrations intraperitoneally in healthy control mice.  Adult male 
(12-16 weeks old) out-bred Institute of Cancer Research (CD1) mice were supplied by Harlan 
Laboratories (Charles River, MA).  Capillary glucose levels were measured through prick stick 
of the tail and a point-of-care-testing glucometer.  Transthoracic echocardiography (to measure 
cardiac function) was used after single and repeated injections, over a range of concentrations 
between 20 to 500 mg/kg (N=4-6 per group).  All the experiments were conducted under the 
guidelines of the “Guide for the care and use of laboratory animals” published by National 
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Institutes of Health (revised 2011).  The study protocol was approved by the Virginia 
Commonwealth University Institutional Animal Care and Use Committee.  
 
5.2.2.3 Experimental Model of Acute Myocardial Infarction  
Experimental acute myocardial infarction (AMI) was induced by transient myocardial 
ischemia for 30 min followed by reperfusion as described.
232
  Briefly, mice were orotracheally 
intubated under anesthesia (pentobarbital 50 to 70 mg/kg), placed in the right lateral decubitus 
position, then subjected to left thoracotomy, pericardiectomy, and ligation of the proximal left 
coronary artery.  The ligated coronary artery was released after 30 min before closure of the 
thorax.  Sham operations were performed wherein animals underwent the same surgical 
procedure without coronary artery ligation (N=6-12 per group).  To evaluate the effect of 
compound 72, a group of mice were given 72 (100 mg/kg in 0.1 mL), DMSO solution (0.1 mL, 
vehicle), NaCl 0.9% solution (0.1 mL, control) 30 min prior to surgery, then repeated at time of 
reperfusion and every 6 h for 3 additional doses.  Mice were then sacrificed at 24 h.  The hearts 
were removed and processed for the assessment of caspase-1 in the tissue or infarct size 
measurement.  Caspase-1 activity was measured on frozen hearts as previously described.
  
 
5.2.2.4 Infarct Size Measurement 
Infarct size was measured using two different methods: using triphenyl tetrazolium 
chloride (TTC) (Sigma Aldrich) staining of viable myocardium,
232
 and measuring serum 
troponin I levels (Life Diagnostic Inc., West Chester, PA), 24 h after surgery.  Briefly, blood was 
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drawn from the heart and processed for troponin I levels determined by ELISA in the supernatant 
(following the manufacturer‟s protocol).  The heart was quickly removed after sacrifice and 
mounted on a Langendorff apparatus.  The coronary arteries were perfused with 0.9% NaCl 
containing 2.5 mM CaCl2.  After the blood was washed out, the coronary artery was again 
ligated, and approximately 2 mL of 1% Evans blue dye (Sigma Aldrich) was injected as a bolus 
into the aorta until the heart „not-at-risk‟ turned blue.  The heart was then removed, frozen, and 
cut into 5 to 7 transverse slices from apex to base of equal thickness (approximately 1 mm).  The 
slices were then incubated in a 1% TTC isotonic phosphate buffer (pH 7.4) at room temperature 
for 30 min.  The infarcted tissue (appearing white), the risk zone (red), and the non-risk zone 
(blue) were measured by computer morphometry using Image Pro Plus 6.0 software (Media 
Cybernetics, Silver Spring, MD). 
 
5.2.2.5 Experimental Model of Acute Peritonitis in the Mouse 
To determine the effects of 72 in the NLRP3 inflammasome in vivo, independent of other 
potential effects on heart viability or function, mice were injected with 1 mg (0.1 mL) of 
zymosan A (Sigma-Aldrich) freshly prepared in sterile saline solution (0.9% NaCl) into the 
peritoneum.  After 6 h mice were sacrificed by anesthesia overdose.  The peritoneal cavity was 
immediately washed with 7 mL of cold PBS to recover peritoneal cells.  Treatment with 72 or an 
equal volume of DMSO (vehicle) was administered at different doses (5, 20, and 100 mg/kg in 
0.1 mL) 30 min before stimulation with zymosan A to determine the inhibitory effects on 
leukocyte recruitment in the cavity (N=4-12 per group).  In addition to 72, glyburide (132.5 
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mg/kg) was used as a positive control.  The total number of leukocytes in the peritoneal cavity 
was measured using a cell-counting Thoma chamber (Thermo Fisher Scientific). 
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6 Conclusion 
 Alzheimer‟s disease is a devastating neurodegenerative disorder and the leading cause of 
dementia.  As of yet, there is no cure, and currently approved treatments only offer symptomatic 
relief.  Utilizing a bivalent design strategy, a series of ligands based on curcumin and diosgenin 
were synthesized and evaluated for their neuroprotective abilities in MC65 cells.  From this 
series, compounds 8 and 18 were discovered to have neuroprotective ability, antioxidative 
function, and anti-Aß oligomerization properties, all in the nM range.  Interestingly, linker 
lengths of 17 and 21 atoms imparted the most potent protection, in agreement with previous 
publications.  A hybridization strategy was also followed for the design of a second series of 
compounds.  These ligands combined pharmacophoric features from two natural products known 
to have neuroprotective properties, curcumin and melatonin.  From this series, representative 
compound 54 and analogs 56 and 68 all conferred neuroprotection to MC65 cells.  Lead 
compound 68 was also shown to have antioxidative function, but interestingly, no strong effects 
on Aß oligomerization.  Mechanistic studies suggest 68 works by disrupting interactions between 
AßOs and partner proteins in the mitochondria.  Compound 68 was also shown to be able to pass 
the BBB, supporting its further investigation.  Lastly, a series of NLRP3 inhibitors were 
designed based on glyburide, an anti-diabetic medication shown to have some anti-inflammatory 
activity.  Synthesis of this series yielded compound 72, which was able to successfully inhibit the 
NLRP3 inflammasome and reduce IL-1ß express without affecting blood glucose.  Further 
studies demonstrated 72‟s ability to reduce adverse inflammation-related outcomes in in vivo 
models of peritonitis and acute myocardial infarction.  Compounds 76 and 80 were also shown to 
prevent IL-1ß release at concentrations similar to 72.  Together, these results warrant further 
investigations of these analogs in other NLRP3-related pathologies, specifically AD. 
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